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A B S T R A C T
Background
Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation.
Objectives
To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment
or other antipsychotic medication.
To critically appraise and summarise current evidence on the resource use, cost and cost-effectiveness of risperidone (depot) for
schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group’s Register (December 2002, 2012, and October 28, 2015). We also checked the
references of all included studies, and contacted industry and authors of included studies.
Selection criteria
Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia-like
psychoses.
Data collection and analysis
Two review authors independently selected trials, assessed trial quality and extracted data. For dichotomous data, we calculated the risk
ratio (RR), with 95% confidence interval (CI). For continuous data, we calculated mean differences (MD). We assessed risk of bias for
included studies and created ’Summary of findings’ tables using GRADE.
Main results
Twelve studies, with a total of 5723 participants were randomised to the following comparison treatments:
Risperidone depot versus placebo
Outcomes of relapse and improvement in mental state were neither measured or reported. In terms of other primary outcomes, more
people receiving placebo left the study early by 12 weeks (1 RCT, n=400, RR 0.74 95% CI 0.63 to 0.88, very low quality evidence),
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experienced severe adverse events in short term (1 RCT, n=400, RR 0.59 95% CI 0.38 to 0.93, very low quality evidence). There was
however, no difference in levels of weight gain between groups (1 RCT, n=400, RR 2.11 95% CI 0.48 to 9.18, very low quality evidence).
Risperidone depot versus general oral antipsychotics
The outcome of improvement in mental state was not presented due to high levels of attrition, nor were levels of severe adverse events
explicitly reported.Most primary outcomes of interest showed no difference between treatment groups. However, more people receiving
depot risperidone experienced nervous system disorders (long-term:1 RCT, n=369, RR 1.34 95% CI 1.13 to 1.58, very-low quality
evidence).
Risperidone depot versus oral risperidone
Data for relapse and severe adverse events were not reported. All outcomes of interest were rated as moderate quality evidence. Main
results showed no differences between treatment groups with equivocal data for change in mental state, numbers leaving the study early,
any extrapyramidal symptoms, weight increase and prolactin-related adverse events.
Risperidone depot versus oral quetiapine
Relapse rates and improvement in mental state were not reported. Fewer people receiving risperidone depot left the study early (long-
term: 1 RCT, n=666, RR 0.84 95% CI 0.74 to 0.95,moderate quality evidence). Experience of serious adverse events was similar between
groups (low quality evidence), but more people receiving depot risperidone experienced EPS (1 RCT, n=666, RR 1.83 95% CI 1.07
to 3.15, low quality evidence), had greater weight gain (1 RCT, n=666, RR 1.25 95% CI 0.25 to 2.25, low quality evidence) and more
prolactin-related adverse events (1 RCT, n=666, RR 3.07 95% CI 1.13 to 8.36, very low quality evidence).
Risperidone depot versus oral aripiprazole
Relapse rates, mental state using PANSS, leaving the study early, serious adverse events and weight increase were similar between
groups. However more people receiving depot risperidone experienced prolactin-related adverse events compared to those receiving
oral aripiprazole (2 RCTs, n=729, RR 9.91 95% CI 2.78 to 35.29, very low quality of evidence).
Risperidone depot versus oral olanzapine
Relapse rates were not reported in any of the included studies for this comparison. Improvement in mental state using PANSS and
instances of severe adverse events were similar between groups. More people receiving depot risperidone left the study early than those
receiving oral olanzapine (1 RCT, n=618, RR 1.32 95% CI 1.10 to 1.58, low quality evidence) with those receiving risperidone depot
also experiencing more extrapyramidal symptoms (1 RCT, n=547, RR 1.67 95% CI 1.19 to 2.36, low quality evidence). However, more
people receiving oral olanzapine experienced weight increase (1 RCT, n=547, RR 0.56 95% CI 0.42 to 0.75, low quality evidence).
Risperidone depot versus atypical depot antipsychotics (specifically paliperidone palmitate)
Relapse rates were not reported and rates of response using PANSS, weight increase, prolactin-related adverse events and glucose-related
adverse events were similar between groups. Fewer people left the study early due to lack of efficacy from the risperidone depot group
(long term: 1 RCT, n=749, RR 0.60 95% CI 0.45 to 0.81, low quality evidence), but more people receiving depot risperidone required
use of EPS-medication (2 RCTs, n=1666, RR 1.46 95% CI 1.18 to 1.8, moderate quality evidence).
Risperidone depot versus typical depot antipsychotics
Outcomes of relapse, severe adverse events or movement disorders were not reported. Outcomes relating to improvement in mental
state demonstrated no difference between groups (low quality evidence). However, more people receiving depot risperidone compared
to other typical depots left the study early (long-term:1 RCT, n=62, RR 3.05 95% CI 1.12 to 8.31, low quality evidence).
Authors’ conclusions
Depot risperidone may be more acceptable than placebo injection but it is hard to know if it is any more effective in controlling the
symptoms of schizophrenia. The active drug, especially higher doses, may be associated with more movement disorders than placebo.
People already stabilised on oral risperidone may continue to maintain benefit if treated with depot risperidone and avoid the need to
take tablets, at least in the short term. In people who are happy to take oral medication the depot risperidone is approximately equal to
oral risperidone. It is possible that the depot formulation, however, can bring a second-generation antipsychotic to people who do not
reliably adhere to treatment. People with schizophrenia who have difficulty adhering to treatment, however, are unlikely to volunteer
for a clinical trial. Such people may gain benefit from the depot risperidone with no increased risk of extrapyramidal side effects.
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P L A I N L A N G U A G E S U M M A R Y
Long-acting preparation of risperidone for schizophrenia
Review question
Risperidone is a newer antipsychotic drug that was the first available as a long-lasting injection (a depot injection). The review examines
the clinical effects of depot risperidone for people with schizophrenia.
Background
People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). People can also become
withdrawn, socially isolated, tired and apathetic. The main treatment for these symptoms of schizophrenia is antipsychotic drugs.
However, these drugs can have serious side effects, such as weight gain, uncontrollable shaking, tremors, spasms and tiredness. These
side effects often mean that people stop taking their medication (non- compliance), which may lead to relapse.
Study characteristics
The review was updated in 2015 and includes 12 studies with 5723 people who received risperidone depot or a range of other
treatments (placebo, general oral antipsychotics, oral risperidone, oral quetiapine, oral aripiprazole, oral olanzapine, atypical/newer
depot antipsychotics, older depot antipsychotics).
Key results
It is difficult to know from the results of this review if depot risperidone is any more effective in treating the symptoms of schizophrenia
than placebo or other treatments. For people who are happy to take oral medication, depot risperidone is about equal to oral risperidone.
People on oral risperidone may continue to benefit if treated with depot risperidone, without the need to take tablets. However, in high
doses, depot risperidone can have serious side effects, particularly movement disorders, uncontrollable shaking, spasms and tremors.
Depot risperidone may bring this new antipsychotic to people who stop taking their tablets, so helping reduce relapse and with little
increased risk of side effects.
Quality of the evidence
The quality of evidence presented is, in the main, low and at best moderate. There is the need for large, long-term and well reported
trials on depot risperidone for people with schizophrenia. Depot injections are often used on people who refuse treatment. Such people
are difficult to include in studies.
Written by a consumer, Ben Gray, Senior Peer Researcher, McPin Foundation. http://mcpin.org/
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
RISPERIDONE DEPOT compared with PLACEBO for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: PLACEBO
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
PLACEBO RISPERIDONE DEPOT
Global state: Relapse -
long term - not mea-
sured
See comment See comment Not est imable - See comment No study reported this
outcome.
M ental state: clini-
cally significant im-
provement in mental
state - long term1 - not
reported
See comment See comment Not est imable1 - See comment Study reported PANSS
responder rate, but un-
usable due to high attri-
t ion
Leaving the study
early: Any reason - all
doses risperidone de-
pot - short term
694 per 1000 513 per 1000
(437 to 611)
RR 0.74
(0.63 to 0.88)
400
(1 study)
⊕©©©
very low2,3
Adverse events: Gen-
eral: Severe adverse
event - any dose
risperidone depot -
short term
Spontaneous report ing
by study part icipants
235 per 10004 138 per 1000
(89 to 218)
RR 0.59
(0.38 to 0.93)
400
(1 study)
⊕©©©
very low2,5
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Adverse events: Spe-
cific: Weight gain - all
doses of depot risperi-
done - short term
Spontaneous report ing
by study part icipants
20 per 1000 43 per 1000
(10 to 187)
RR 2.11
(0.48 to 9.18)
400
(1 study)
⊕©©©
very low2,6
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Not reported: only included study (Kane 2002* ) reported PANSS responder rate, but these data were unusable due to high
levels of attrit ion.
2 Risk of bias: ’very serious’ - high attrit ion in one included study (Kane 2002* ) of greater than 50% overall. Research supported
by Johnson and Johnson/ Janssen, producers of depot risperidone.
3 Imprecision: ’serious’ - only one small study reported data for this comparison.
4 Control risk: mean baseline presented for one individual study.
5 Imprecision: ’serious’ - adverse events were reported spontaneously by part icipants, rather than systematically assessed
by the researchers. This could ef fect the precision of the results as there is only one study (Kane 2002* ) addressing this
comparison.
6 Imprecision: ’serious’- the method of measuring weight gain and threshold for report ing it were not described. This could
ef fect the precision of the results as there is only one study (Kane 2002* ) addressing this comparison.
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B A C K G R O U N D
Description of the condition
Schizophrenia is a major, often chronic, psychiatric disease that
close to seven people in every 1000 will be affected by at some
point during their lifetime (McGrath 2008). Antipsychotic drugs
are effective for treating acute episodes and for preventing relapse
(Davis 1977; Davis 1986). These drugs are usually given orally,
but compliance is poor and ranges from 20% to 89% with an
average of 50% (Fenton 1997; Young 1986). This means that, on
average, half the patients treated with these drugs will not comply
with prescribedmedication. This is probably due to a combination
of various factors such as the erosion of insight that accompanies
psychotic illnesses, adverse effects and human nature.
Description of the intervention
Long-acting depot antipsychotics, given by injection into themus-
cle, should be helpful in increasing compliance with medication.
In studies comparing one depot with another, attrition rates are
markedly lower than in studies comparing oral preparations, but
in trials comparing an oral with a depot preparation, there are no
differences in the attrition rates between groups (Adams 2001).
This is likely to be due to a limitation in the design of the relevant
studies, as people participating in randomised trials are more likely
to be compliant. This is an area where ’real world’ or ’pragmatic’
randomised trials are indicated.
The newer generation of antipsychotics, often called atypical, seem
to cause less of the movement disorders associated with older
drugs. This group of compoundsmay be equally clinically effective
(Small 1997), and be more acceptable to people with schizophre-
nia, than older drugs such as haloperidol (Leucht 1999; Marder
1994; Tollefson 1997) although this is disputed (Geddes 2000).
Atypical drugs have gained popularity amongst clinicians but,
along with their cost, a lack of a depot preparation has been cited
as a significant obstacle to their frequent use (Sarfati 1999).
Risperidone is an atypical antipsychotic, firstmade available for the
care of those with schizophrenia in 1986. Since then clinical trials
have been conducted to evaluate its efficacy and safety and studies
have indicated that it may be superior to older drugs (Marder
1994). When oral risperidone is compared with haloperidol, it
appears to havemarginal benefits in terms of clinical improvement
and is less likely to cause movement disorders (Hunter 2003).
Risperidone is the first newer drug to be available in a long-acting
injection formulation.
How the intervention might work
Risperidone is one of the new or second-generation “atypical”
antipsychotics, developed in the late 1980s. It is known to block
dopamine D2 and 5HT2 (serotonin) receptors in the brain, with
a high ratio of 5HT2 to D2 blockade. It also blocks alpha1 and
alpha2 adrenoceptors, H1 receptors and has no effect on beta
adrenoceptors, muscarinic cholinoceptors or peptidergic receptors
(Janssen 1988).
The depot formulation of risperidone has unmodified risperidone
encapsulated in biodegradable polymer microspheres, which are
then suspended in an aqueous solution. Once the microspheres
are injected into the muscle, the polymers begin to degrade and
the drug is released at a set rate. This takes place over the course
of several weeks, with the highest plasma concentration occurring
approximately one month after injection (Ramstack 2003).
Why it is important to do this review
In terms of the costs of schizophrenia, this was estimated at about
£6.7 billion in England in 2004/05, of which the direct costs
were £2 million while the indirect costs accounted for the rest
(Mangalore 2007). The cost of risperidone (depot) itself is expen-
sive compared to other typical antipsychotics, at £142.76 for a 50
mg vial. The maximum monthly dose of risperidone (depot) is
100 mg per month, which costs £285.52 per month (BNF 2012).
These newer, atypical antipsychotics in comparison are more ex-
pensive than typical antipsychotics, with olanzapine available at
£13.11 for 28 x 5 mg tablets, and clozapine (Clozaril) at £21.56
for 28 x 100 mg tablets.
It is important to complement the clinical effectiveness of risperi-
done (depot) with its cost-effectiveness. Davies et al. (Davies 2007)
conducted a study on cost-effectiveness of first-generation an-
tipsychotics (i.e. flupentixol, trifluoperazine, chlorpromazine) and
the second-generation antipsychotics (i.e. risperidone, olanzapine,
amisulpiride). The study findings argue that there is no evidence to
suggest that atypical (second-generation) antipsychotics are more
cost-effective than typical (first-generation) antipsychotics.
O B J E C T I V E S
To examine the effects of depot risperidone for treatment of
schizophrenia or related psychoses in comparison with placebo,
no treatment or other antipsychotic medication.
If possible, to critically appraise and summarise current evidence
on the resource use, cost and cost-effectiveness of risperidone (de-
pot) for schizophrenia.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
All relevant randomised controlled trials (RCTs).Where a trial was
described as ’double-blind’ but it was implied that the study was
randomised, these trials were included in a sensitivity analysis. If
there was no substantive difference within primary outcomes (see
Types of outcome measures) when these ’implied randomisation’
studies were added, then they were included in the final analysis.
If there was a substantive difference, only clearly randomised trials
were utilised and the results of the sensitivity analysis described
in the text. We excluded quasi-randomised studies, such as those
allocating by using alternate days of the week.
Types of participants
People with schizophrenia and schizophrenia-like disorders such as
schizophreniform disorder, delusional disorder or schizoaffective
disorder, diagnosed by any criteria. People with ’serious/chronic
mental illness’ or ’psychotic illness’ were also included. Where
possible, peoplewith dementia, depression andproblemsprimarily
associated with substance misuse were excluded.
Types of interventions
1. Risperidone
Administered by long-acting intramuscular injection, any dose.
2. Placebo or no treatment
3. Other antipsychotic drugs (depot)
Any dose, administered in depot form.
4. Other antipsychotic drugs (oral)
Any dose, administered in oral form. Oral drugs were divided
into two subgroups; typical and atypical. For the purposes of this
review atypicals were amisulpiride, aripiprazole, clozapine, cloth-
iapine, loxapine, molindone, risperidone, olanzapine, quetiapine,
sulpiride, zotepine, ziprasidone.
Types of outcome measures
All outcomes were reported for the short term (up to 12 weeks),
medium term (13-26weeks), and long term (more than 26weeks).
Primary outcomes
1. Global state
1.1 Relapse
2. Mental state
2.1 Clinically important change in general mental state
Secondary outcomes
1. Death - suicide and natural causes
2. Global state
2.1 Time to relapse
2.2 Clinically important change in global state
2.3 Any change in global state
2.4 Average endpoint global state score
2.5 Average change in global state scores
3. Service outcomes
3.1 Hospitalisation
3.2 Time to hospitalisation
3.3 Duration of stay in hospital
4. Mental state
4.1 Change in general mental state
4.2 Average endpoint general mental state score
4.3 Average change in general mental state scores
4.4 Clinically important change in specific symptoms
4.5 Change in specific symptoms
4.6 Average endpoint specific symptom score
4.7 Average change in specific symptom scores
5. Leaving the study early
5.1 For specific reasons
5.2 For general reasons
6. General functioning
6.1 Clinically important change in general functioning
6.2 Any change in general functioning
6.3 Average endpoint general functioning score
6.4 Average change in general functioning scores
6.5 Clinically important change in specific aspects of functioning,
such as social or life skills
6.6 Any change in specific aspects of functioning, such as social
or life skills
6.7 Average endpoint specific aspects of functioning, such as social
or life skills
6.8 Average change in specific aspects of functioning, such as social
or life skills
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7. Behaviour
7.1 Clinically important change in general behaviour
7.2 Any change in general behaviour
7.3 Average endpoint general behaviour score
7.4 Average change in general behaviour scores
7.5 Clinically important change in specific aspects of behaviour
7.6 Any change in specific aspects of behaviour
7.7 Average endpoint specific aspects of behaviour
7.8 Average change in specific aspects of behaviour
8. Adverse effects
8.1 Clinically important general adverse effects
8.2 Any general adverse effects
8.3 Average endpoint general adverse effect score
8.4 Average change in general adverse effect scores
8.5 Clinically important change in specific adverse effects
8.6 Any change in specific adverse effects
8.7 Average endpoint specific adverse effects
8.8 Average change in specific adverse effects
9. Engagement with services
9.1 Clinically important engagement
9.2 Any engagement
9.3 Average endpoint engagement score
9.4 Average change in engagement scores
10. Satisfaction with treatment
10.1 Recipient of care not satisfied with treatment
10.2 Recipient of care average satisfaction score
10.3 Recipient of care average change in satisfaction scores
10.4 Carer not satisfied with treatment
10.5 Carer average satisfaction score
10.6 Carer average change in satisfaction scores
11. Quality of life
11.1 Clinically important change in quality of life
11.2 Any change in quality of life
11.3 Average endpoint quality of life score
11.4 Average change in quality of life scores
11.5 Clinically important change in specific aspects of quality of
life
11.6 Any change in specific aspects of quality of life
11.7 Average endpoint specific aspects of quality of life
11.8 Average change in specific aspects of quality of life
12. Economic outcomes
12.1 Average change in total cost of medical and mental health
care
12.2 Total indirect and direct costs
12.3 Direct resource use:
12.3.1Outpatients - number of contacts (GP consultation, psychi-
atrist, psychologists, psychiatric nurse, counsellor, social worker)
12.3.2 Hospitalisation (taking battery of tests, patients’ physical,
psychiatric andpsychological profile andpsychological assessment,
number of days, relapse)
12.3.3 Medication (different types of antipsychotics to include
dose and frequency, treatment of side effects)
12.3.4 Psychological therapies (different types of psychological
therapies to include session numbers and frequency)
12.3.5 Other resources (day centres, night shelter) and transporta-
tion for medical care visits
12.4 Indirect resource use:
12.4.1 Family, relatives’ and friends’ resources
12.4.2 Police, criminal justice system
12.4.3 Benefits paid, social security payments
12.4.4 Employment agency workers, absence from work, loss of
productivity
12.5 Cost-effectiveness ratios represented by incremental cost-ef-
fectiveness (ICER)
12.6 Cost-utilities represented by incremental costs per quality-
adjusted life year (QALY) or disability-adjusted life year (DALY)
12.7 Cost benefit represented by net Benefit Ratio, others.
13. ’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2008) and used GRADE profiler (GRADEPRO) to import data
fromRevMan5 (Review Manager) to create ’Summary of findings’
tables. These tables provide outcome-specific information con-
cerning the overall quality of evidence from each included study
in the comparison, the magnitude of effect of the interventions
examined, and the sum of available data on all outcomes we rated
as important to patient-care and decision making. We selected the
following main outcomes for inclusion in the ’Summary of find-
ings’ table.
1. Relapse - long term.
2. Clinically significant improvement in mental state - long term.
3. Leaving the study early for any reason - medium/long term.
4. Severe adverse effects - medium/long term.
5. Adverse events related to movement disorder, weight gain, pro-
lactin levels and glucose metabolism - medium/long term.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Trials Register
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On October 28, 2015, the Trials Search Co-ordinator (TSC)
searched the Cochrane Schizophrenia Group’s Study-Based Reg-
ister of Trials using the following search strategy:
(*Risperidone* AND *Injection*) in Intervention Field of
STUDY
In such a study-based register, searching the major concept re-
trieves all the synonym keywords and relevant studies because all
the studies have already been organised based on their interven-
tions and linked to the relevant topics.
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE,MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group’s
Module). There is no language, date, document type, or publica-
tion status limitations for inclusion of records into the register.
For previous searches, please see Appendix 1.
Searching other resources
1. Reference searching
The review authors inspected references of all identified studies
for more studies.
2. Personal contact
The review authors attempted to contact the first author of each
study considered for inclusion in the review for more information
regarding unpublished trials or any available data.
3. Drug companies
The review authors contacted Janssen-Cilag Limited for further
data.
Data collection and analysis
For details of previous data collection and analysis methods see
Appendix 2.
Selection of studies
For this update, review author PH and TN (see
Acknowledgements) independently inspected citations from the
searches and identified relevant abstracts. A random 20% sample
was independently re-inspected by SS to ensure reliability. Where
disputes arose, the full-text report was acquired for more detailed
scrutiny. If citations met inclusion criteria, we obtained full-text
reports for more detailed inspection. Again, a random 20% of re-
ports were re-inspected by SS in order to ensure reliable selection.
Where it was not possible to resolve disagreement by discussion,
we attempted to contact the authors of the study for clarification
and added these studies to the list awaiting classification.
With regards to selecting studies for economic evaluations, review
authors (SS and VF) categorised studies as per the following:
Type A - Full economic evaluation (within the framework of
RCT): studies that focus on cost-effectiveness analysis, cost-utility
analysis and cost-benefit analysis.
Type B - Partial economic evaluation (within the framework of
RCT): studies that focus on cost-analysis and cost-minimisation
studies of Risperidone (depot).
Type C - Randomised trials that reported limited information,
such as estimates of resources use or costs associated with Risperi-
done (depot).
Data extraction and management
1. Extraction
For this update PH, and TN extracted data from all included stud-
ies. In addition, to ensure reliability, SS independently extracted
data from a random sample of these studies, comprising 10% of
the total. Again, any disagreement was discussed, decisions doc-
umented and, if necessary, authors of studies contacted for clar-
ification. With any remaining problems, we contacted editorial
team (CEA) to help clarify issues and these final decisions were
documented. Data presented only in graphs and figures were ex-
tracted whenever possible, but included only if two review authors
independently had the same result. We attempted to contact au-
thors through an open-ended request in order to obtain missing
information or for clarification whenever necessary.
For the economic analysis hadVFandSS foundTypeA andB stud-
ies (see Types of studies), they would have investigated whether
appraisal had already been undertaken by NHS EED using their
search tool derived for this purpose. If appraisal had not been
undertaken, VF and SS would have applied the NHS EED tool
to the data. In this current review, should there only be Type C
studies available, we would extract outcome data directly from the
already-included effectiveness studies. We recognise that much in-
formation would be lacking to get results that are both valid and
reliable.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
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2.2 Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument has not been written or modified by
one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly, and we
noted in Description of studies whether or not this was the case.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint), which can be difficult in
unstable and difficult tomeasure conditions such as schizophrenia.
We decided primarily to use endpoint data, and only use change
data if the former were not available. We combined endpoint and
change data in the analysis as we used mean differences (MD)
rather than standardised mean differences (SMD) throughout (
Higgins 2011, Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we aimed to apply the following
standards to relevant data before inclusion:
a) standard deviations (SDs) and means are reported in the paper
or obtainable from the authors;
b) when a scale starts from the finite number zero, the SD, when
multiplied by two, is less than the mean, as otherwise the mean is
unlikely to be an appropriate measure of the centre of the distri-
bution, (Altman 1996);
c) if a scale started from a positive value (such as the Positive
and Negative Syndrome Scale (PANSS) (Kay 1986), which can
have values from 30 to 210), the calculation described above was
modified to take the scale starting point into account. In these
cases skew is present if 2 SD > (S-S min), where S is the mean
score and S min is the minimum score.
Endpoint scores on scales oftenhave a finite start and endpoint and
these rules can be applied. We entered skewed endpoint data from
studies of less than 200 participants in additional tables rather than
into an analysis. However, skewed data pose less of a problemwhen
looking at mean if the sample size is large, we therefore, entered
skewed endpoint data from studies with over 200 participants
into syntheses.When continuous data are presented on a scale that
includes a possibility of negative values (such as change data), it
is difficult to tell whether data are skewed or not and we entered
skewed change data into analysis.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962)
or the Positive and Negative Syndrome Scale (PANSS, Kay 1986),
this could be considered as a clinically significant response (Leucht
2005; Leucht 2005a). If data based on these thresholds were not
available, we used the primary cut-off presented by the original
authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicated a favourable outcome for
risperidone depot. Where keeping to this made it impossible to
avoid outcome titles with clumsy double-negatives (e.g. ’Not un-
improved’), we reported data where the left of the line indicates
an unfavourable outcome. This was noted in the relevant graphs.
Assessment of risk of bias in included studies
For this update, PH and TN worked independently by using cri-
teria described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011) to assess trial quality. This new set of
criteria is based on evidence of associations between overestimate
of effect and high risk of bias of the article such as sequence gener-
ation, allocation concealment, blinding, incomplete outcome data
and selective reporting.
Where inadequate details of randomisation and other characteris-
tics of trials were provided, we contacted authors of the studies in
order to obtain additional information.
We have noted the level of risk of bias in both the text of the review
and in the Summary of findings for the main comparison.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI)*. It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios
(ORs) and that ORs tend to be interpreted as RR by clinicians
(Deeks 2000). We did not calculate the Number Needed to Treat/
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Harm (NNT/H). The NNT/H statistic with its CIs is intuitively
attractive to clinicians but is problematic both in its accurate cal-
culation in meta-analyses and interpretation (Hutton 2009). For
binary data presented in the ’Summary of findings’ tables, where
possible, we calculated illustrative comparative risks.
2. Continuous data
For continuous outcomes, we estimated mean difference (MD)
between groups. We prefer not to calculate effect size measures
(standardised mean difference SMD). However, if scales of very
considerable similarity were used, we presumed there was a small
difference in measurement, and we would have calculated effect
size and transformed the effect back to the units of one or more
of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992), whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
Where clustering was not accounted for in primary studies, we
presented data in a table, with a (*) symbol to indicate the pres-
ence of a probable unit of analysis error. In subsequent versions
of this review, we will seek to contact first authors of studies to
obtain intra-class correlation coefficients (ICCs) for their clustered
data and to adjust for this by using accepted methods (Gulliford
1999). Where clustering has been incorporated into the analysis
of primary studies, we presented these data as if from a non-cluster
randomised study, but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (
Donner 2002). If the ICC was not reported it was assumed to be
0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed taking into ac-
count ICCs and relevant data documented in the report, synthe-
sis with other studies would have been possible using the generic
inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase the
participants can differ systematically from their initial state despite
a wash-out phase. For the same reason cross-over trials are not ap-
propriate if the condition of interest is unstable (Elbourne 2002).
As both effects are very likely in severe mental illness, if we had
included cross-over trials, we planned only to use the data from
the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if rele-
vant, the additional treatment arms were presented in compar-
isons. Where the additional treatment arms were not relevant, we
did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility
(Xia 2009). We chose that, for any particular outcome, should
more than 50% of data be unaccounted for, we did not reproduce
these data or use them within analyses, except for the outcomes of
leaving the study early and adverse events. If, however, more than
50% of those in one arm of a study were lost, but the total loss
was less than 50%, we marked such data with (*) to indicate that
such a result may well be prone to bias. This was the case for three
studies (Gaebel 2010*; Kane 2002* Quinn 2012*).
2. Binary
In the case where attrition for a binary outcome was between 0%
and 50%, and where these data were not clearly described, we
presented data on a ’once-randomised-always-analyse’ basis (an
intention-to-treat analysis). Those leaving the study early were
all assumed to have the same rates of negative outcome as those
who completed, with the exception of the outcome of death and
adverse effects. For these outcomes, the rate of those who stayed
in the study - in that particular arm of the trial - were used for
those who did not. We undertook a sensitivity analysis to test how
prone the primary outcomes were to change when data only from
people who completed the study to that point were compared to
the intention-to-treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50%, and data only from people who completed the study
to that point were reported, we presented and used these data.
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3.2 Standard deviations
If standard deviations (SDs) were not reported, we first tried to
obtain the missing values from the authors. If not available, where
there are missing measures of variance for continuous data, but
an exact standard error (SE) and confidence intervals available for
group means, and either a P value or T value available for differ-
ences in mean, we can calculate them according to the rules de-
scribed in theCochraneHandbook for Systematic reviews of Interven-
tions (Higgins 2011): When only the SE is reported, SDs are cal-
culated by the formula SD = SE * square root (n). Chapters 7.7.3
and 16.1.3 of the Cochrane Handbook for Systematic reviews of In-
terventions (Higgins 2011) present detailed formulae for estimat-
ing SDs from P values, T or F values, confidence intervals, ranges
or other statistics. If these formulae do not apply, we can calcu-
late the SDs according to a validated imputation method which is
based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would be to exclude a given study’s outcome and
thus to lose information. However, we did not impute any data in
this review.
3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results (Leucht 2007). Therefore, where LOCFdata had been used
in the trial, if less than 50% of the data had been assumed, we
reproduced these data and indicated that they are the product of
LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations which we had
not predicted would arise. When such situations or participant
groups arose, these were fully discussed.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlyingmethodswhichwe had not
predicted would arise. When such methodological outliers arise
these were fully discussed.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
Heterogeneity between studies was investigated by considering
the I2 method alongside the Chi2 ’P’ value. The I2 provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of
an I2 depends on i. magnitude and direction of effects and ii.
strength of evidence for heterogeneity (e.g. ’P’ value from Chi2
test, or a confidence interval for I2). An I2 estimate greater than
or equal to around 70% accompanied by a statistically significant
Chi2 statistic, was interpreted as evidence of substantial levels of
heterogeneity (Section 9.5.2 - Higgins 2011). When substantial
levels of heterogeneity were found in the primary outcome, we
explored reasons for the heterogeneity (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We planned
not to use funnel plots for outcomes where there were less than
10studies in each analysis, or where all studies were of similar sizes.
If funnel plots had been possible, we planned to seek statistical
advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model. It puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect these studies can either inflate or deflate the effect size.
We chose the random-effects model for all analyses.
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Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses - only primary outcomes
1.1 Clinical state, stage or problem
We proposed to undertake this review and provide an overview of
the effects of risperidone depot for people with schizophrenia in
general. In addition, however, we tried to report data on subgroups
of people in the same clinical state, stage andwith similar problems.
2. Investigation of heterogeneity
If inconsistency was high, this was reported. First, we investigated
whether data had been entered correctly. Second, if data were cor-
rect, we visually inspected the graph and removed outlying studies
to see if heterogeneity was restored. For this review, we decided
that should this occur with data contributing to the summary
finding of no more than around 10% of the total weighting, data
were presented. If not, data were not pooled and issues discussed.
We know of no supporting research for this 10% cut-off but are
investigating use of prediction intervals as an alternative to this
unsatisfactory state.
When unanticipated clinical or methodological heterogeneity
were obvious, we simply stated hypotheses regarding these for fu-
ture reviews or versions of this review. We did not anticipate un-
dertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the primary
outcomes, we included these studies and if therewas no substantive
difference when the implied randomised studies were added to
those with a better description of randomisation, then all data were
used from these studies.
2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up (see Dealing with missing data), we compared the findings of
the primary outcomes when we used our assumption compared
with completer data only. If there was a substantial difference, we
reported results and discussed them, but continued to employ our
assumption.
Where assumptions had to be made regarding missing SDs data
(see Dealing with missing data), we compared the findings on
primary outcomes when we used our assumption compared with
complete data only. A sensitivity analysis was undertaken to test
how prone results were to change when ’completer’ data only were
compared to the imputed data using the above assumption. If
there was a substantial difference, we reported results and discussed
them, but continued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be
at high risk of bias across one or more of the domains of randomi-
sation (implied as randomised with no further details available)
allocation concealment, blinding and outcome reporting for the
meta-analysis of the primary outcome. If the exclusion of trials at
high risk of bias did not substantially alter the direction of effect
or the precision of the effect estimates, thenwe included data from
these trials in the analysis
4. Imputed values
Had we included cluster-randomised trials, we planned to under-
take a sensitivity analysis to assess the effects of including data
from trials where we used imputed values for ICC in calculating
the design effect in such trials.
If substantial differences were noted in the direction or precision
of effect estimates in any of the sensitivity analyses listed above,
we did not pool data from the excluded trials with the other trials
contributing to the outcome, but presented them separately.
5. Fixed-effect and random-effects
All data were synthesised using a random-effects , however, we
also synthesised data for the primary outcome using a fixed-effect
model to evaluate whether the greater weights assigned to larger
trials with greater event rates, altered the significance of the results
compared to themore evenly distributedweights in the fixed-effect
model.
R E S U L T S
Description of studies
Salient features of the included and excluded studies are given in
the tables (Characteristics of included studies; Characteristics of
excluded studies).
Results of the search
1. Overall
The original published version of this review (Hosalli 2003) in-
cluded two studies and excluded 11, with two studies awaiting
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classification. The search updates in 2010, 2012 and 2015 identi-
fied 181 references with no additional records identified through
other sources. No duplicates were found.We screened 181 records.
Twenty-eight potentially relevant full-text reports were obtained
and scrutinised, and 17 of these reports did not meet the inclusion
criteria (see Characteristics of excluded studies), and were added
to the excluded studies. Ten studies were added to included studies
and one study was added to awaiting classification (Figure 1).
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Figure 1. Study flow diagram: 2010 and 2012, 2015 updated search
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Included studies
Twelve studies, reported as 15 conference presentations and 13
full-text papers met the selection criteria and are included in this
update.
1. Study design
All 12 included studies were randomised and eight featured some
form of blinding - ranging from blinding of raters in other-
wise open-label studies to blinding of all participants and in-
vestigators; four studies were expressly or implied as ’open-label’
but employed blinded raters (Bai 2006; Covell 2012; Li 2011;
MacFadden 2010). Study duration also varied considerably; three
studies were short term at 12 to 13 weeks (Bai 2006; Chue 2002;
Pandina 2011); Covell 2012 was medium term, while seven fol-
lowed up participants for two years (Fleischhacker 2011; Gaebel
2010*; Kane 2002*; Li 2011; MacFadden 2010; Quinn 2012*;
Rosenheck 2011). One study (Keks 2007), combined short- and
medium-term outcomes, with analyses at 12 weeks and one-year
of follow-up. Themajority of studies took place in the community,
and were well-represented internationally, with studies conducted
in Taiwan (Bai 2006) and the remaining as multi-centre studies,
conducted within the USA (Covell 2012; Kane 2002*; Rosenheck
2011), Canada (Quinn 2012*), China (Li 2011), Europe (Gaebel
2010*; Keks 2007); and international multi-centre studies (Chue
2002; Fleischhacker 2011; MacFadden 2010; Pandina 2011).
2. Participants
A total of n = 5723 participants who received the interventionwere
included, with the majority of studies providing data as to male
and female participants; a total of n = 3140 male and n = 2112
female participants were included, with a mean age of around 40
years. All studies used the Diagnostic and Statistical Mannual ver-
sion 1V (DSM-IV) (APA 2000) to define schizophrenia; so for at
least six continuous months a participant must have shown some
evidence of schizophrenia, and for at least one month must have
shown at least two symptoms of frank psychosis. These symptoms
would have included delusions, hallucinations, incoherent speech,
disorganised or catatonic behaviour, or flat affect. To meet DSM
IV criteria, the symptoms must be disabling in such a way that
social and occupational functioning is impaired; these symptoms
should not be the direct result of a physical disorder or of substance
misuse. Most studies randomised people who had been experienc-
ing schizophrenia for some years; often specifying that they need
to have had schizophrenia for at least one year before diagnosis.
Further criteria for selecting participants varied from study to
study, depending on exactly what was being investigated, but gen-
eral exclusion criteria were reasonably consistent; people with a
history of violence to themselves or others, or of recent suicide at-
tempts were not permitted to take part. Nor were those with active
DSM-IV diagnosed substance dependence or general ill health,
including serious psychiatric problems other than schizophrenia.
Tolerance to risperidone was an important factor that all studies
addressed; most potential participants underwent a screening pe-
riod at the start of their trial to establish that they could tolerate
risperidone; this was sometimes waived if they had already demon-
strated this (i.e. they were currently treated with the drug).
3. Interventions
The prescribing of depot risperidone was consistent across the
board; 25, 37.5 and 50 mg injections every two weeks were the
most common dosages, with participants typically initiated on 25
mg/two weeks, which was then stepped up in 12.5 mg increments
if their symptoms worsened. Three earlier studies (Chue 2002;
Kane 2002*; Keks 2007) included depot risperidone up to 75 mg,
but such high doses were not used by the most recent studies.
Because it can take several weeks for therapeutic plasma levels
of the drug to build-up, oral supplementation, either with oral
risperidone or the participant’s previous oral antipsychotic, was
typically used for the initial two to four weeks.
The trials involving oral antipsychotics either compared depot
risperidone versus another specific single antipsychotic or to more
than one antipsychotic. Only one study compared depot risperi-
done with placebo (Kane 2002*). Of the studies comparing de-
pot risperidone with another single antipsychotic, two used oral
risperidone at 2 mg to 6 mg per day (Bai 2006; Chue 2002); one
study investigated5 mg to 20mg/day oral olanzapine (Keks 2007),
and one compared depot risperidone against 5 mg to 30 mg/day
oral aripiprazole (MacFadden 2010). Covell 2012 compared ei-
ther haloperidol decanoate or fluphenazine (no doses prescribed,
but used at ’clinician’s judgement’; Gaebel 2010* was mainly con-
cerned with quetiapine at up to 750 mg/day, but also featured a
smaller aripiprazole arm of 10mg to 30mgper day. The remaining
three studies randomised patients to receive depot risperidone or
to remain on their current oral antipsychotic; in the case of Quinn
2012*, only second-generation “atypical” drugs were used, specif-
ically risperidone, olanzapine and quetiapine; Rosenheck 2011
provides no details of which drugs were used.
Paliperidone palmitate (PP) is the active metabolite of risperidone,
but features a different administration schedule and dosages to de-
pot risperidone; PP doses can be given either in milligrams (mg),
for the overall volume injected, or in milligram equivalents (mg
eq), which refers to the fraction of the drug that is actually phar-
macologically active. So 39 mg of PP is given as 25 mg eq, 78 mg
is 50 mg eq, etc. The injection schedule of this drug only requires
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monthly intra-muscular injections to maintain therapeutic levels
and oral supplementation is not needed, so in the non open-la-
bel PP studies (Fleischhacker 2011; Li 2011; Pandina 2011) oral
placebo and bi-weekly placebo injections were used.
4. Outcomes
4.1 Global state
The Clinical Global Impression (CGI) scale was utilised in some
manner by the majority of the included studies, with data pro-
vided either as mean (SD or SE) endpoint or change scores, or as
percentages of participants who were either not ill or mildly ill.
Much data were unusable due to the high level of attrition in some
studies and inconsistent reporting in others. Another rating scale
used to assess global state was the Schedule for Deficit Syndrome
(SDS) scale.
Other outcomes that give an impression of the general condition
of somebody with schizophrenia, such as levels of relapse and re-
mission, the proportion of participants who needed concomitant
benzodiazepine and how long they were able to stay on the study
drug are also included here.
Where relapse was included as an outcome, the investigators typi-
cally used the criteria for relapse in Csernansky 2002. Briefly, these
consist of worsening of psychiatric condition (i.e. requiring hos-
pitalisation or increased care), Positive and Negative Syndrome
Scale (PANSS) or CGI scores that are markedly higher than the
baseline, self-harm or suicidal/homicidal ideation, discontinuing
the study drug due to ineffectiveness, requiring additional antipsy-
chotic medications or non protocol doses of the study drugs.
4.2 Mental state
PANSS was the key mental state assessment scale; each study re-
ported changes in PANSS total scores, with some also including
the subscales and factor scores. Unfortunately, as with CGI, high
attrition prevented us from including PANSS scores from every
study in the analysis.
4.3 General functioning
The Global Assessment of Functioning (GAF) scale was used by
Bai 2006 and data for the Personal and Social Performance (PSP)
scale were available from Li 2011 and Pandina 2011.
4.4 Service utilisation
The primary outcomes for Rosenheck 2011 centred around the
use of medical and psychiatric health services; the data for these
outcomes were obtained through the VA health services, which
potentially side-steps the issue of low follow-up interview rates as
these data would be available for participants who missed inter-
views but nonetheless remained a part of the study. Data on in-
patient and out-patient care were available, and include rates of
hospitalisation and mean (SD) numbers of visits to individual or
group psychiatry sessions, as well as other psychiatric and general
healthcare services.
4.5 Quality of life
It is disappointing that more studies did not include measures to
assess quality of life (QoL) on the trial drugs. Several studies did
make use of various QoL questionnaires, but high attrition means
that the results could not be used. The one exception to this is in
Bai 2006, which made use of the Medical Outcome Study Short-
Form Health Survey (SF-36).
4.6 Economic outcomes
Very few studies involved any assessment of the economic out-
comes associated with treatment with depot risperidone. The two
exceptions areRosenheck 2011 andGaebel 2010* which presented
these outcomes in papers published separately to the main study
report. Lack of standard deviations and the format in which some
of these outcomes were presented makes it difficult to use them in
a quantitative analysis, but we have commented on the key find-
ings in a qualitative manner.
4.7 Satisfaction with treatment
Only one trial addressed this in a manner that did not fall foul
of the 50% attrition limit; Bai 2006 recorded patient satisfaction
with their current treatment using a five-point scale, very good to
poor. However, no evidence to validate this methodwas presented,
consequently we decided not to include the data.
4.8 Leaving the study early
All studies reported the number of participants leaving the study
early from both groups, and provided a breakdown of the main
reasons given for doing so.
4.9 Adverse effects
Adverse events were reported by all of the included studies. Chue
2002 reported overall rates of adverse events in both groups, and
the numbers withdrawing from the study as a result of side ef-
fects. No details were given regarding the nature of these adverse
events or how they were recorded. The abstracts available for this
review state that body weight was measured and laboratory tests
were undertaken. The reports state that there were no differences
between oral and depot groups, but present no numbers. Chue
2002 also used the Extrapyramidal SymptomRating Scale (ESRS),
but again, no numerical data were reported. Kane 2002* reported
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rates of individual adverse events spontaneously reported by par-
ticipants, and reported these for all people in the study, not just
those who completed the trial. Median ESRS scores were also re-
ported for each group at baseline and change at endpoint. Pain
and swelling at injection sites rated by investigators and patients
were also reported.
MacFadden 2010 gave rates of adverse events that occurred in
>10% of participants in either group, as well as serious, prolactin-
and glucose-related events. The results of laboratory tests for levels
of prolactin, glucose, cholesterol and triglycerides were also pro-
vided. Adverse events occurring in more than 5% of participants
were reported in Rosenheck 2011; there was no discussion of how
these events were identified or reported. They were also grouped
under quite general subheadings, so “nervous system disorders”
comprises all extrapyramidal symptoms (EPS), as well as the likes
of headache, somnolence and dizziness.
5. Outcome measures used in this review
5.1 Global state
5.1.1 Global functioning. Clinical Global Impression - CGI (Guy
1976)
A rating instrument commonly used in studies on schizophrenia
that enables clinicians to quantify severity of illness and overall
clinical improvement during therapy. A seven-point scoring system
is usually used with low scores indicating decreased severity and/
or greater recovery.
5.1.2 Global Assessement of Functioning - GAF (DSM-IV-TR, APA
2000)
The GAF rating scale is presented in DSM-IV as a quick method
for assessing psychological, social and occupational function to
give an impression of an individual’s overall level of functioning
relating to their mental health. Scoring is from zero to 100. Very
high scores indicate absent or minimal symptoms that have little
effect on functioning, very low scores (below 20) indicate a serious
danger that somebody will hurt themselves or others.
5.1.3 Schedule for Deficit Syndrome - SDS (Kirkpatrick 1989)
This tool is used to evaluate the presence of negative or deficit-
related symptoms, SDS regards these as flattened affect, poverty
of speech, diminished emotional range, curbing of interest and
diminished sense of purpose. If a person with schizophrenia has
had two or more of the listed symptoms for 12 months, and they
were not caused by other factors such as substance dependence or
depression, then they are diagnosedwith deficit syndrome. Severity
is rated from zero to four, higher scores are worse, for each criteria.
5.2 Mental state
5.2.1 Positive and Negative Symptom Scale - PANSS (Kay 1987)
This scale was developed to evaluate the positive, negative and
general symptoms in schizophrenia. The PANSS has 30 items,
and each item can be defined on a seven-point scoring system
varying from one (absent) to seven (extreme). This scale is di-
vided into three subscales formeasuring the severity of general psy-
chopathology, positive symptoms (PANSS-P) and negative symp-
toms (PANSS-N). A low score indicates lesser severity.
5.3 General functioning
5.3.1 Personal and Social Performance Scale - PSP (Nafees 2012)
The PSP scale measures an individual’s functioning within soci-
ety and is assessed through a 10 to 15 minute structured inter-
view looking at four domains (socially useful activities, personal
and social relationships, self-care and disturbing and aggressive be-
haviours). An overall score between zero and 100 is derived from
the individual factor scores; a higher score indicates better personal
and social functioning.
5.4 Quality of life
5.4.1 Medical Outcome Study Short-Form Health Survey - SF-36
(Ware 1992)
SF-36 rates health-related quality of life in eightmain components
(physical function, role limitations due to physical problems, bod-
ily pain, general health,mental health, role limitations due to emo-
tional problems, social function and vitality), each scored from
zero to 100, higher scores are better.
5.5 Adverse effects
The majority of the following scales were used by the study inves-
tigators to obtain dichotomised results relating to specific adverse
effects - the data and analysis section of this review presents pre-
dominantly dichotomised data relating to adverse effects.
5.5.1 Extrapyramidal Symptom Rating Scale - ESRS (Chouinard
1980)
This scale consists of a questionnaire relating to parkinsonian
symptoms (nine items), a physician’s examination for parkinson-
ism and dyskinetic movements (eight items) and a clinical global
impression of tardive dyskinesia. High scores indicate severe levels
of movement disorder.
5.5.2 Barnes Akathisia Scale - BARS (Barnes 1989)
This rating scale assesses drug-induced akathisia (restlessness or
the urge to move). Individuals are rated on their observable level
of restlessness while sitting (objective), their awareness of the urge
tomove and the distress, if any, that this causes (subjective) and on
a global assessment. Higher scores indicate more severe akathisia.
5.5.3 Abnormal Involuntary Movement Scale - AIMS (Munetz
1988)
This 12-item scale is used to assess the severity of dyskinesia in an
individual. Items such as movement of the jaw or the extremities
are rated on a scale from zero (none) to four (severe) and combined
to give a total score.
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5.5.4 The Udvalg for Kliniske Undersgelser side effects rating scale -
UKU (Lingjaerd 1987)
The UKU is a tool for recording side effects of neuroleptic treat-
ment in a standardised manner, items are scored from zero, absent
or normal, to three, severe.
5.5.5 Arizona Sexual Experiences Scale - ASEX (McGahuey 2000)
The ASEX scale is a five-item rating scale that quantifies sexual
experiences (including drive/ arousal/ satisfaction from or ability
to reach orgasm) with total scores ranging from five to 30, with
higher scores indicating greater sexual dysfunction
Excluded studies
We have excluded a total of 28 studies (see Characteristics of
excluded studies).
Studies awaiting assessment
Three studies await further clarification; Turner 2000 seemed to
be an eligible study for the first edition of this review (Hosalli
2003), but while preparing the updated review we were unable to
find any further details. Nasrallah 2002, both conference abstracts,
reports QoL data with depot risperidone but it may be part of
one of the included studies (Kane 2002*). Again, the authors have
been contacted for more details. Segarra 2010 also appeared to be
eligible, but we were unable to extract any usable data from the
published conference poster and abstract. We have contacted Dr
Segarra for more details of this study.
Ongoing studies
We contacted Janssen-Cilag Limited for further information re-
garding ongoing studies and were told that such studies existed
and the data would be forwarded to us. We are still awaiting these
studies and data.
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 3.
Allocation
All studies were randomised, but there was extreme inconsistency
in how well the methods used were reported. Most studies also
did not describe how allocation concealment was achieved. At
one end of the spectrum, it is simply stated that participants were
randomised (Bai 2006; MacFadden 2010; Quinn 2012*) with no
further details, with other studies giving more details on the strat-
ification factors used, e.g. site, PANSS score, previous antipsy-
chotic medication (Chue 2002; Gaebel 2010*; Rosenheck 2011).
While the implication is that all studies used computer-generated
schemes to randomise participants, this is only explicitly stated
in a handful of cases. Descriptions of allocation concealment are
neglected by most of the included studies, but methods were simi-
lar amongst studies that provide them. Interactive Voice Response
Systems (IVRS) were used by Fleischhacker 2011, Keks 2007 and
Pandina 2011; this is a system whereby the investigator phones a
number, enters the patient details and receives a medication allo-
cation based on the randomisation algorithm. Keks 2007 set the
benchmark for minimising the risk of allocation bias, with a de-
scription of the randomisation algorithm and the use of an IVRS.
Blinding
The included studies utilised a number of types of blinding, each
resulting in different amounts of risk for performance and detec-
tion bias.
The studies with the least risk were often described as “double
blind”; they took measures to ensure that neither the participants
nor the investigators monitoring them and rating outcomes would
know which treatment a person was actually taking. The study of
depot risperidone versus placebo (Kane 2002*) and one of those
involving oral antipsychotics (Chue 2002) used placebo injections
that were the same volume as those containing the study drug. Two
of the paliperidone palmitate (PP) studies (Fleischhacker 2011;
Pandina 2011) utilised placebos in the PP group so that both
groups took the same number of tablets and had the same number
of injections. Participants were also precluded from seeing the
syringe when they received the injection, as the two drugs were
different in appearance. The techniques used for blinding in these
studies were of very high quality and present little risk of the blind
being broken.
All other studies have a significantly higher risk of performance
bias as the allocation of interventions was not blinded; this was
somewhat mitigated against in Bai 2006, Li 2011, MacFadden
2010, and Rosenheck 2011, all of which used blinded raters to
perform outcome assessments, often via video conference.
Incomplete outcome data
There is little risk of attrition bias emerging from incomplete out-
come data in most studies. Drop-out rates are uniformly reported
and are normally accompanied by a breakdown of the main rea-
sons for leaving the study early. Overall attrition is greater than
50% in some studies; where this is the case we have not used the
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data from affected outcomes. In Rosenheck 2011, the attrition
rate was not simply explained; it was stated that 69.8% of the
oral treatment group and 63.6% of the depot risperidone group
completed the study, but what this actually means is never made
explicitly clear. Indeed, the overall completion rate does not tally
with the follow-up interview rates, which are given as 60% at 12
months, 46% at 18 months and only 29% of participants com-
pleting the full two years of follow-up interviews, with there being
no difference between follow-up rates across the two intervention
groups. The implication is that patients could remain in the study
and have their health service use available for analysis despite no
longer taking part in the follow-up interviews to assess secondary
outcome measures. Generally, across studies, attrition was high,
and therefore rated at a ’high’ risk of bias - three studies in par-
ticular reported losses of greater than 50% (Gaebel 2010*; Kane
2002*; Quinn 2012*).
Selective reporting
Gaebel 2010* stated in the methods section of the main study
report that CGI-S was used as an outcome measure, but this out-
come is not reported in the results section. As CGI-S is a very
commonly used measure, we have contacted the study authors to
try to obtain any unpublished data that may pertain to this, but
at the time of writing have had no response.
Other potential sources of bias
Author conflicts of interest are reported for all studies, as are fund-
ing sources.
Most studies included in this review were either partially or fully
funded and supported by Jassen-Cilag/Johnson & Johnson Co. In
addition to this, a significant number of authors and investigators
are or were employees of Jassen. While it is understandable that
a pharmaceutical company has an interest in research regarding
their own products, it is perhaps alarming that the only studies
that address the questions posed by this review are supported by a
party with a vested interest in depot risperidone.
Effects of interventions
See: Summary of findings for the main comparison
RISPERIDONE DEPOT compared with PLACEBO for
schizophrenia; Summary of findings 2RISPERIDONEDEPOT
compared with GENERAL ORAL ANTIPSYCHOTICS for
schizophrenia; Summary of findings 3RISPERIDONEDEPOT
compared with ORAL RISPERIDONE for schizophrenia;
Summary of findings 4 RISPERIDONE DEPOT compared
with ORAL QUETIAPINE for schizophrenia; Summary
of findings 5 RISPERIDONE DEPOT compared with
ORAL ARIPIPRAZOLE for schizophrenia; Summary of
findings 6 RISPERIDONE DEPOT compared with ORAL
OLANZAPINE for schizophrenia; Summary of findings 7
RISPERIDONE DEPOT compared with ATYPICAL DEPOT
ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for
schizophrenia; Summary of findings 8RISPERIDONEDEPOT
compared with TYPICAL DEPOT ANTIPSYCHOTICS for
schizophrenia
COMPARISON 1: RISPERIDONE DEPOT versus
PLACEBO
For this comparison, we found only one relevant study (Kane
2002*, n = 400); apart fromone outcome (leaving the study early),
all data for this comparison from this 12-week study, are ’short
term’.
1.1 Mental state: 1. Change (exacerbation) in specific
symptoms
Mental state data were presented as change in specific symptoms.
For the outcomes of anxiety, hallucination and nervousness, no
differences between groups were found; however, there was sta-
tistically significant difference in favour of depot risperidone for
levels of agitation (risk ratio (RR) 0.60 95% confidence interval
(CI) 0.39 to 0.92) and psychosis (RR 0.52 95% CI 0.33 to 0.83,
Analysis 1.1).
1.2 Leaving the study early: 1. Any reason (by time period)
The number of participants leaving the study early ’very early on’
were similar between treatment groups, however data at 12 weeks
showed more people left the placebo group early compared to
those receiving risperidone depot (RR 0.74 95% CI 0.63 to 0.88,
Analysis 1.2).
1.3 Leaving the study early: 2. Any reason (by doses)
More participants left the study early for any reason from the
placebo group compared to those receiving either ’all doses’ risperi-
done depot (RR 0.74 95% CI 0.63 to 0.88), 25 mg risperidone
depot (RR 0.74 95% CI 0.59 to 0.94), 50 mg risperidone depot
(RR 0.74 95% CI 0.59 to 0.93) or 75 mg risperidone depot (RR
0.75 95% CI 0.60 to 0.94, Analysis 1.3).
1.4 Leaving the study early: 3. Due to insufficient response
(by doses)
For leaving the study early due to insufficient response, there was
no statistically significant difference between groups for those re-
ceiving 25 mg depot risperidone. However fewer participants left
early from the risperidone depot groups for those receiving either
all three doses combined (RR 0.53 CI 0.36 to 0.79), 50 mg (RR
0.48 CI 0.27 to 0.83) or 75mg (RR 0.39 CI 0.21 to 0.72, Analysis
1.4).
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1.5 Adverse events: 1. General: a. Death
Nodeaths were reported in the risperidone depot group, one death
was reported in the placebo group. This difference was not statis-
tically significant (RR 0.11 95% CI 0.00 to 2.65 Analysis 1.5).
1.6 Adverse events: 1. General: b. Severe adverse event (by
doses)
There were no statistically significant differences between groups
for severe adverse events by doses (25 mg, 50 mg or 75 mg) of
depot risperidone (n = 400, Kane 2002*); however, ’any dose’
of risperidone demonstrated a statistically significant difference,
favouring risperidone depot, between groups (RR 0.59 CI 0.38 to
0.93, Analysis 1.6).
1.7 Adverse events: 1. General: c. Adverse event
necessitating withdrawal from study (by doses)
There were no statistically significant difference between groups
for adverse events necessitation withdrawal from the study by any
dose, 25 mg, 50 mg or 75 mg (Analysis 1.7).
1.8 Adverse events: 2. Specific: a. Cardiovascular
There was no statistically significant difference between groups
for dizziness; however, there was a statistically significant differ-
ence between groups for tachycardia, with greater instances in the
placebo group (RR 0.32 95% CI 0.11 to 0.98, Analysis 1.8).
1.9 Adverse events: 2. Specific: b. Gastrointestinal
There were no statistically significant differences between groups
for constipation, diarrhoea, nausea or vomiting (Analysis 1.9)
1.10 Adverse events: 2. Specific: c. Movement disorders: a.
Extrapyramidal disorder - spontaneously reported (by doses)
There was no statistically significant difference between groups for
extrapyramidal disorder when receiving ’all doses’, 25 mg, 50 mg
or 75 mg depot risperidone (Analysis 1.10).
1.11 Adverse events: 2. Specific: d. Movement disorders: b.
Hyperkinesia (by doses)
There was no statistically significant difference between groups for
hyperkinesia when receiving ’all doses’, 25 mg, 50 mg or 75 mg
depot risperidone (Analysis 1.11).
1.12 Adverse events: 2. Specific: e. Movement disorders: c.
Hypertonia (by doses)
There was no statistically significant difference between groups
for hypertonia when receiving ’all doses’, 25 mg, 50 mg or 75 mg
depot risperidone (Analysis 1.12).
1.13 Adverse events: 2. Specific: f. Pain
There was no statistically significant difference between groups for
headache or other ’unspecified’ pain (Analysis 1.13).
1.14 Adverse events: 2. Specific: g. Salivation
There was no statistically significant difference between groups for
either increased or decreased levels of salivation (Analysis 1.14).
1.15 Adverse events: 2. Specific: h. Sleep disturbances
There was no statistically significant difference between groups for
either insomnia or somnolence (Analysis 1.15).
1.16 Adverse events: 2. Specific: i. Weight gain
There was no statistically significant difference between groups for
weight gain with any dose of depot risperidone (1 RCT, n = 400,
RR 2.11, 95% CI 0.48 to 9.18) (Analysis 1.16).
1.17 Adverse events: 2. Specific: j. Others
There was no statistically significant difference between groups for
coughing, fatigue, injury or rhinitis (Analysis 1.17).
COMPARISON 2: RISPERIDONE DEPOT versus
GENERAL ORAL ANTIPSYCHOTICS
Two studies provided data for this comparison (Quinn 2012*;
Rosenheck 2011, n = 467). Both studies were two years-long, and
are categorised as ’long term’.
2.1 Global state: 1. Relapse (any reason)
There was no statistically significant difference between groups for
relapse (n = 63, Quinn 2012*, Analysis 2.1).
2.2 Global state: 2. Needing use of benzodiazepine or
sedative drugs
There was no statistically significant difference between groups
for requiring use of benzodiazepines or sedative drugs (n = 369,
Rosenheck 2011, Analysis 2.2).
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2.3 Service utilisation: 1. Hospitalisation
There was no statistically significant difference between groups for
hospitalisation by long term (n = 369, Rosenheck 2011, Analysis
2.3).
2.4 Service utilisation: 2. Outpatient care - number of
outpatient visits (skewed data)
Data for this outcome are considerably skewed, and are best in-
spected by viewing (Analysis 2.4).
2.5 Not receiving allocated study medication
There was no statistically significant difference between risperi-
done depot and general oral antipsychotics (n = 382, Rosenheck
2011, Analysis 2.5).
2.6 Leaving the study early: 1. Any reason
There was no statistically significant difference between groups for
leaving the study early (n = 467, two randomised controlled trials
(RCTs), Analysis 2.6).
2.7 Leaving the study early: 2. Specific
There was no statistically significant difference between groups for
leaving the study early due to insufficient response or withdrawn
consent (n = 382, Rosenheck 2011, Analysis 2.7).
2.8 Adverse events: 1. General: a. Death
There was no statistically significant difference between groups for
instances of death (n = 467, Rosenheck 2011, Analysis 2.8).
2.9 Adverse events: 2. Specific
There was a statistically significant difference between groups for
general disorders and administration site conditions (n = 369,
Rosenheck 2011, RR 1.31 95%CI 1.02 to 1.69, Analysis 2.9) and
headache (n = 85, Quinn 2012*, RR 2.80 95% CI 1.12 to 7.00
Analysis 2.9), both favouring oral antipsychotics, with no statis-
tically significant difference between groups for other outcomes
of anxiety; dizziness; fatigue/somnolence; insomnia; nausea/vom-
iting; prolactin-related; weight increase (n = 85, Quinn 2012*;
Analysis 2.9), as well as diabetes mellitus and gastrointestinal ad-
verse events (n = 369, Rosenheck 2011, Analysis 2.9).
2.10 Adverse events: Nervous system disorders (including
extrapyramidal symptoms (EPS))
There was a statistically significant difference between groups for
nervous system disorders, favouring the unspecified oral antipsy-
chotics (as prescribed by study’s treating physician) (n = 369,
Rosenheck 2011, RR 1.34 CI 1.13 to 1.58, Analysis 2.10).
COMPARISON 3: RISPERIDONE DEPOT versus
ORAL RISPERIDONE
Two studies provided data for this comparison (Bai 2006; Chue
2002, n = 690); both studies were 12-weeks long and categorised
in the ’short term’ (note: Chue 2002 had an eight-week open-
label run-in period in which participants were stabilised on oral
risperidone).
3.1 Global state: 1. Moderate to severely ill at end of study
period (Clinical Global Impression (CGI) rating)
There was no statistically significant difference between groups for
being ’moderate to severely ill at the end of the study period’ (n =
640, Chue 2002, Analysis 3.1).
3.2 Global state: 2. Mean change from baseline (CGI-S,
greater change = better outcome)
There was no statistically significant difference between groups in
mean changes in CGI-S score from baseline (n = 50, Bai 2006,
Analysis 3.2).
3.3 Global state: 3. Mean (SD) Global Assessment of
Functioning (GAF) score change to endpoint
There was no statistically significant difference between risperi-
done depot and oral risperidone in mean endpoint scores using
the GAF (n = 50, Bai 2006), Analysis 3.3).
3.4 Global state: 4. Needing use of benzodiazepine or
sedative drugs
There was no statistically significant difference between risperi-
done depot and oral risperidone for needing benzodiazepines or
sedative drugs (n = 690, two RCTs, Analysis 3.4).
3.5 Mental state: 1. Average change/endpoint scores
(Positive and Negative Syndrome Scale (PANSS))
There were no statistically significant differences between for av-
erage endpoint scores using the PANSS for mean total scores (2
RCTs, n = 591, MD 1.05, CI -0.77 to 2.88); average change in
positive symptoms or negative symptoms; disorganised thoughts;
hostility/excitement; or anxiety/depression (Analysis 3.5).
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3.6 Leaving the study early: 1. Any reason
There was no statistically significant difference between risperi-
done depot and oral risperidone for leaving the study early for any
reason (n = 690, 2 RCTs, Analysis 3.6).
3.7 Leaving the study early: 2. Specific
There were no statistically significant differences between groups
for leaving the study early for adverse events; insufficient response;
or withdrawn consent (n = 640, Chue 2002, Analysis 3.7).
3.8 Quality of life: Mean (SD) SF-36 score change/endpoint
In one small study, there was a statistically significant difference
favouring depot risperidone for the social functioning component
of the SF-36 scale (n = 50, Bai 2006, mean difference (MD) 18.50
95% CI 3.98 to 33.02). There were no statistically significant dif-
ferences between groups for remaining physical and mental com-
ponents; vitality; general health; mental health; bodily pain; and
physical function (n = 50, Bai 2006, Analysis 3.8).
3.9 Adverse events: 1. General
There were no statistically significant differences between groups
for ’any’ adverse events or death (n = 640, Chue 2002, Analysis
3.9).
3.10 Adverse events: 1. General: Udvalg for Kliniske
Undersgelser (UKU) (average change score)
There was a statistically significant difference between groups,
favouring risperidone depot for adverse events using the UKU,
short term (n = 50, Bai 2006, MD -1.99, 95% CI -3.59 to -0.39,
Analysis 3.10).
3.11 Adverse events: 2. Specific
There were no statistically significant differences between groups
for specific adverse event outcomes of anxiety; psychosis; prolactin-
related; impotence/ejaculation failure; dysmenorrhoea; hyperpro-
lactinaemia galactorrhoea; headache; insomnia or sexual dysfunc-
tion (n = 640, Chue 2002, Analysis 3.11).
3.12 Adverse events: 2. Specific: Mean (SD) weight increase
There was no statistically significant difference between groups for
mean weight increase (kg) (n = 640, Chue 2002, Analysis 3.12).
3.13 Adverse events: 3. Movement disorder
There were no statistically significant differences between groups
for EPS or tardive dyskinesia (n = 640, Chue 2002); nor was
there any statistically significant difference between groups for
participants requiring anti-cholinergic drugs (n = 690, 2 RCTs,
Analysis 3.13).
3.14 Adverse events: Mean (SD) change in movement
disorder rating scales
There were no statistically significant differences between groups
for change in movement disorder rating scales using either Ab-
normal Involuntary Movement Scale (AIMS), Barnes Akathisia
Rating Scale (BARS) or Simpson and Angus Rating scale (SAS)
(n = 50, Bai 2006, Analysis 3.14).
COMPARISON 4: RISPERIDONE DEPOT versus
ORAL QUETIAPINE
One study provideddata for this outcome (n=666,Gaebel 2010*);
as a two-year study, results are labelled as ’long term’.
4.1 Leaving the study early: 1. Any reason
There was a statistically significant difference favouring risperi-
done depot for participants leaving the study early for any reason
(n = 666, Gaebel 2010*, RR 0.84 95% CI 0.74 to 0.95, Analysis
4.1).
4.2 Leaving the study early: 2. Specific
There was a statistically significant difference favouring risperi-
done depot for participants leaving the study early due to relapse
(n = 666, Gaebel 2010*, RR 0.54, CI 0.40 to 0.73, Analysis 4.2).
4.3 Adverse events: 1. General
There were no statistically significant differences between groups
for any general adverse events; serious adverse events or death (n
= 666, Gaebel 2010*, Analysis 4.3).
4.4 Adverse events: 2. Specifc
For specific adverse events, there were no statistically significant
differences between groups for psychiatric symptoms; serious psy-
chiatric symptoms; weight increase; or headache (n = 666, Gaebel
2010*). There was a statistically significant difference favouring
risperidone depot for fatigue/somnolence (n = 666, Gaebel 2010*,
RR 0.16 95% CI 0.07 to 0.38); however, there was a statistically
significant difference favouring quetiapine oral for prolactin-re-
lated adverse events (P = 0.03) (n = 666, Gaebel 2010*, RR 3.07
95% CI 1.13 to 8.36) and hyperprolactinaemia (n = 666, Gaebel
2010*, RR 8.81 95% CI 3.53 to 21.96, Analysis 4.4).
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4.5 Adverse events: 2. Specific: Mean (SD) weight increase in
kg
There was a statistically significant difference between groups
favouring oral quetiapine for weight increase (n = 666, Gaebel
2010*, MD 1.25 95% CI 0.25 to 2.25, Analysis 4.5).
4.6 Adverse events: 3. Movement disorder
There was a statistically significant difference between groups,
favouring oral quetiapine for any EPS (n = 666, Gaebel 2010*),
RR 1.83 95% CI 1.07 to 3.15); tremor (RR 5.12 95% CI 1.13 to
23.20), and parkinsonism (RR 2.56 95% CI 1.01 to 6.52). There
was no statistically significant difference between groups for fur-
ther outcomes of tardive dyskinesia; dystonia; and hyperkinesia (n
= 666, Gaebel 2010*, Analysis 4.6).
COMPARISON 5: RISPERIDONE DEPOT versus
ORAL ARIPIPRAZOLE
Two studies provided data for this comparison (n = 730, Gaebel
2010*; MacFadden 2010); both studies were two-years long, and
results are therefore listed as ’long term’.
5.1 Global state: 1. Relapse (any reason)
There was no statistically significant difference between risperi-
done depot and oral aripiprazole (n = 349, MacFadden 2010, RR
1.05 95% CI 0.83 to 1.33, Analysis 5.1).
5.2 Global state: 3. Mean time in remission (days)
There was no statistically significant difference between groups for
mean time in remission (n = 348, MacFadden 2010, Analysis 5.2).
5.3 Mental state: 1. Average change scores (PANSS, negative
change = good) 1. Total
There was no statistically significant difference between groups for
change in mental state using PANSS (n = 349, MacFadden 2010,
Analysis 5.3).
5.4 Leaving the study early: 1. Any reason
There was no significant difference between groups for leaving the
study early for any reason (2 RCTs n = 723, RR 0.83 95% CI
0.53 to 1.30, Analysis 5.4). This outcome had important levels of
heterogeneity (Chi2 = 5.67; df = 1; P = 0.02; I2 = 82%).
5.5 Leaving the study early: 2. Specific
There were no statistically significant differences between groups
for leaving the study early due to adverse events; withdrawn con-
sent (n = 723, 2 RCTs); insufficient response; lost to follow-up
(n = 349, MacFadden 2010); or due to relapse (n = 374, Gaebel
2010*, Analysis 5.5).
5.6 Adverse events: 1. General
There were no statistically significant differences between groups
for ’any’ adverse events; serious adverse events; or death (n = 729,
2 RCTs, Analysis 5.6)
5.7 Adverse events: 2. Specific
There was a statistically significant difference favouring oral arip-
iprazole for prolactin-related adverse events (n = 729, 2 RCTs, RR
9.91 CI 2.78 to 35.29); decreased appetite (1 RCT, n = 355, RR
1.78 CI 1.00 to 3.16), and dizziness (1 RCT, n = 355, RR 1.89
CI 1.00 to 3.58). Gaebel 2010* found a statistically significant
difference favouring risperidone depot, with higher instances of
gastrointestinal adverse effects (1 RCT, n = 374, RR 0.27 CI 0.14
to 0.55), andMacFadden 2010 had similar results for upper respi-
ratory track infection (1 RCT, n = 355, RR 0.38 CI 0.16 to 0.89,
Analysis 5.7).
There were no statistically significant differences between groups
for headache; anxiety; depression; psychosis; ’schizophrenia’; nau-
sea/vomiting; diarrhoea; insomnia; pyrexia; nasopharyngitis; glu-
cose-related; psychiatric symptoms; ’serious’ psychiatric symp-
toms; hyperprolactinaemia; or weight increase (Analysis 5.7).
5.8 Adverse events: 2. Specific 12. Mean (SD) weight
increase in kg
MacFadden 2010 found no significant difference between risperi-
done depot and oral aripiprazole for long-term mean weight in-
crease (1 RCT, n = 355, MD 1.00 95% CI -0.42 to 2.42, Analysis
5.8).
5.9 Adverse events: 3. Movement disorder
There were no statistically significant differences between groups
for any EPS, tremor or akathisia (Analysis 5.9).
COMPARISON 6: RISPERIDONE DEPOT versus
ORAL OLANZAPINE
One study provideddata for this comparison (n=361,Keks 2007),
which at 12 months is labelled as a ’long-term’ study.
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6.1 Mental state: 1. Average change scores (PANSS, negative
change = good)
There were no statistically significant differences between groups
in average change scores using the PANSS total on short-term or
long-term positive symptoms, negative symptoms, disorganised
thoughts, hostility/excitement or anxiety/depression components
(Analysis 6.1).
6.2 Leaving the study early: 1. Any reason
There were higher rates of leaving the study early in the risperidone
(depot) group (1 RCT, n = 618, RR 1.32 95% CI 1.10 to 1.58,
Analysis 6.2).
6.3 Leaving the study early: 2. Specific
There was no statistically significant difference between groups
when leaving the study early due to adverse events; insufficient
response; or due to weight gain. There was a statistically signifi-
cant difference between groups for leaving the study early due to
withdrawn consent, with higher losses in the risperidone depot
group (1 RCT, n = 547, RR 2.54 95% CI 1.56 to 4.16, Analysis
6.3).
6.4 Adverse events: 1. General
There were no statistically significant differences between groups
for serious adverse events or death (Analysis 6.4).
6.5 Adverse events: 2. Specific
There were no statistically significant differences between groups
for specific adverse events including anxiety, depression, psychosis,
headache, fatigue/somnolence, nasopharyngitis impotence/ejacu-
lation failure, galactorrhoea, serious psychiatric symptoms, serious
anxiety, suicide attempt, serious injury, diabetes mellitus, hypo-
glycaemia, and hyperglycaemia (Analysis 6.5).
There was a statistically significant difference favouring risperi-
done depot for weight increase (1 RCT, n = 547, RR 0.56 95% CI
0.42 to 0.75), however with significant favour of oral olanzapine
for agitation (1 RCT, n = 532, RR 1.98 95%CI 1.06 to 3.68), and
levels of insomnia ((1 RCT, n = 532, RR 4.59 CI 2.61 to 8.07,
Analysis 6.5).
6.6 Adverse events: 3. Movement disorder
There were no significant differences between groups for tardive
dyskinesia; hypertonia; or dystonia (n = 547, Keks 2007). There
was a statistically significant difference between groups, favouring
oral olanzapine for EPS (1RCT, n=547,RR1.67CI1.19 to 2.36),
tremor (RR 2.29 95% CI 1.04 to 5.06); hyperkinesia (1 RCT, n =
547, RR 2.02 CI 1.01 to 4.06); and requiring antiparkinson drugs
(1 RCT, n = 547, RR 1.26 CI 1.02 to 1.56, Analysis 6.6).
COMPARISON 7: RISPERIDONE DEPOT versus ALL
ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
We pooled all studies comparing risperidone depot with all oral
antipsychotics in order to more effectively present estimates of the
effects for our primary outcomes in a more concise format (n =
2840, 7 RCTs).
7.1 Global state: 1. Relapse (any reason)
Therewas no significant difference between groups for relapsewith
either risperidone depot versus aripiprazole (n = 349, MacFadden
2010), or versus ’general oral antipsychotics’ (n = 63, Quinn
2012*, Analysis 7.1).
7.2 Mental state: 1. Average scores (PANSS, greater change
= better outcome) 1. total
There was no statistically significant difference between groups in
PANSS scores when risperidone depot was compared with oral
risperidone (n = 591, 2 RCTs); oral olanzapine at short term (n
= 377, Keks 2007) and long term (n = 361, Keks 2007); or oral
aripiprazole (n = 349, MacFadden 2010, Analysis 7.2).
7.3 Leaving the study early: 1. Any reason
There was no difference between groups in numbers leaving the
study early when risperidone depot was compared with oral arip-
iprazole (n = 723, 2 RCTs); oral risperidone (n = 690, 2 RCTs); or
’any oral antipsychotic’ (n = 382, Rosenheck 2011). Gaebel 2010*
found a statistically significant difference between groups favour-
ing risperidone depot when compared with oral quetiapine (1
RCT, n = 666, RR0.84 95%CI 0.74 to 0.95),Quinn 2012* found
similar results for ’any new generation antipsychotic’ (1 RCT, n
= 77, RR 0.72 95% CI 0.55 to 0.95). Keks 2007 found there
was a statistically significant difference between groups favouring
oral olanzapine (1 RCT n = 618 RR 1.32 95% CI 1.10 to 1.58,
Analysis 7.3).
7.4 Adverse events: 1. Death
There were no statistically significant differences between groups
for the outcome of death with risperidone depot was compared
with oral olanzapine (n = 618, Keks 2007); oral risperidone (n =
640, Chue 2002); ’any oral antipsychotic’ (n = 382, Rosenheck
2011); oral aripiprazole (n = 729, 2 RCTs); or oral quetiapine (n
= 666, Gaebel 2010*, Analysis 7.4).
7.5 Adverse events: 1. General: a. any
There were no significant differences between groups for instances
of ’any adverse events’ when risperidone depot was compared with
either oral aripiprazole (n = 729, 2 RCTs); oral risperidone (n =
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640, Chue 2002); or oral quetiapine (n = 666, Gaebel 2010*,
Analysis 7.5).
7.6 Adverse events: 1. General: b. serious
There were no significant differences between groups for instances
of ’serious adverse events’ when risperidone depot was compared
with either oral quetiapine (n = 666, Gaebel 2010*); oral aripipra-
zole (n = 729, 2 RCTs); or oral olanzapine (n = 547, Keks 2007,
Analysis 7.6).
7.7 Adverse events: 2. Movement disorder: a. any
extrapyramidal symptoms (EPS)
There was no statistically significant difference between groups
for instances of ’any EPS’ when risperidone depot was compared
with oral aripiprazole (n = 729, 2 RCTs) or oral risperidone (n =
640, Chue 2002). There were significantly more instances of EPS
amongst participants receiving risperidone depot when compared
with oral quetiapine Gaebel 2010* (1 RCT, n = 666, RR 1.83
95% CI 1.07 to 3.15), or oral olanzapine, Keks 2007 (1 RCT, n
= 547, RR 1.67 95% CI 1.19 to 2.36, Analysis 7.7).
COMPARISON 8: RISPERIDONE DEPOT VERSUS
ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE)
Three studies compared risperidone depot with paliperidone
palmitate (Fleischhacker 2011; Li 2011; Pandina 2011), with a to-
tal of n = 2,421. Two of the included studies lasted for 12 months
(Fleischhacker 2011; Li 2011), as a long-term study; Pandina 2011
was categorised as a medium-term study lasting for 13 weeks.
8.1 Global State: 1. CGI-S mean change from baseline to
endpoint (intention-treat (ITT) data)
There was no statistically significant difference between groups at
medium term (2 RCTs, n = 1326, MD -0.07 95% CI - 0.26 to
0.11, Analysis 8.1). This outcome had important levels of hetero-
geneity (Chi2 = 2.23; df = 1; P = 0.135; I2 = 55%).
8.2 Global state: Schedule for Deficit Syndrome (SDS) scale
(mean change from baseline to endpoint, ITT data)
There was no statistically significant difference between groups at
medium term formean change scores using the SDS scale, Pandina
2011, (1 RCT, n = 913, MD 0.1 CI -0.29 to 0.49, Analysis 8.2).
8.3 Mental state: 1. PANSS scores - medium term
Medium term PANSS scores from two studies (n = 1326) demon-
strate no statistically significant differences inmental state between
groups using the PANSS. The majority of data relating to the sub-
scale scores demonstrated moderate to substantial levels of het-
erogeneity (P = 0.05; I2 = 73% for anxiety/depression score for
endpoint; P = 0.008; I2 = 86% for changes in positive symptom
scores, Analysis 8.3).
8.4 Mental state: Improved by 30% in total PANSS score
(ITT data)
There was no significant difference between risperidone depot and
atypical depot antipsychotics (paliperidone palmitate) at medium
term (n = 1326, 2 RCTs), Analysis 8.4. This outcome had impor-
tant levels of heterogeneity (Chi2 = 5.31; df = 1; P = 0.021; I2 =
81%).
8.5 General functioning: Personal and Social Performance
(PSP) scale (mean change from baseline to endpoint)
There was no significant difference between groups in general
functioning using the PSP scale at medium term (n = 1326, 2
RCTs, Analysis 8.5).
8.6 Leaving the study early: 1. Any reason
There were no significant differences between groups leaving the
study early due to death; adverse events; patient choice/withdrawn
consent; lost to follow-up; pregnancy; ’other’ or ’any reason’ at
medium term. Although there was no significant difference at
medium term, significantly more people receiving paliperidone
palmitate left the study early due to lack of efficacy in the long
term (1 RCT n = 749, RR 0.60 95% CI 0.45 to 0.81, Analysis
8.6).
8.7 Adverse events: 1. general
Fleischhacker 2011 found a statistically significant difference in
the long term for overall rates of adverse events (1 RCT, n = 747,
RR 0.74 95% CI 0.58, 0.95); however, there were no statistically
significant differences between groups for general adverse events in
the medium term for overall adverse events (n = 1666, 2 RCTs) or
medium or long term for; worsening of schizophrenia (n = 1666,
2 RCTs), worsening of psychiatric disorders (n = 1214, Pandina
2011), or death (n = 2415, 3 RCTs), Analysis 8.7.
8.8 Adverse events: 2. specific
There were no significant differences between groups for overall
rates of specific adverse effects in the medium or long term (n =
2413, 3 RCTs); insomnia in medium or long term (n = 1961, 2
RCTs), headache, psychotic disorder or ’worsening of schizophre-
nia’ (n = 747, Fleischhacker 2011), somnolence, weight gain (n =
452, Li 2011) or tachycardia (n = 1199, 2 RCTs).
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In the medium term, levels of anxiety were significantly greater in
participants receiving paliperidone palmitate (1 RCT, n = 1214,
RR 0.50 95% CI 0.26 to 0.96); however, at long term, levels of
anxiety were significantly greater in participants receiving risperi-
done depot (1 RCT, n = 747, RR 1.49 95%CI 1.01 to 2.20). Peo-
ple receiving risperidone depot also reported significantly higher
instances of constipation at medium term (1 RCT, n = 1214, RR
3.79 CI 1.42 to 10.08). Results were statistically significant for
greater pain in injection site at medium term for people receiving
paliperidone palmitate (n = 1666, 2 RCTs, RR 0.16 CI 0.07 to
0.38, Analysis 8.8).
8.9 Adverse events: 3. Prolactin-related
There were no statistically significant differences between groups
in prolactin-related adverse events, including amenorrhoea (n =
784, 2 RCTs); galactorrhoea or amenorrhoea-galactorrhoea syn-
drome (n = 271, Li 2011); hyperprolactinaemia or increase in
serum prolactin (n = 452, Li 2011); erectile dysfunction (n =
701, Li 2011); or ’any’ prolactin-related (n = 1666, 2 RCTs).
Fleischhacker 2011 found thatmoremen receiving risperidone de-
pot experienced a statistically significant abnormally high level of
prolactin (1RCTn=424, RR1.68 95%CI 1.32 to 2.14)„Analysis
8.9, with no difference between groups for women.
8.10 Adverse events: 4. Movement disorder
In themedium term, there were no significant differences between
groups with instances of tardive dyskinesia (n = 1214, Pandina
2011). There were also no significant differences between groups
for instances of akathisia and neuroleptic malignant syndrome at
medium term (n = 452, Li 2011). Remaining movement disor-
ders were more prevalent in people receiving risperidone depot
compared to paliperidone palmitate, with statistically significant
differences between groups for tremor (1 RCT, n = 452, RR 1.71
95% CI 1.07 to 2.74) and hyperkinesia (1 RCT, n = 747, RR 1.66
95%CI 1.0 to 2.73). There was a statistically significant difference
(P = 0.0004) favouring paliperidone palmitate for requiring use
of anti-EPS medication at medium term (n = 1666, 2 RCTs, RR
1.46 CI 1.18 to 1.80, Analysis 8.10).
8.11 Adverse events: 5. Body weight (mean increase)
For this outcome we found three relevant trials (n = 2350).
There was no statistically significant difference between groups at
medium term (n = 1666, 2 RCTs), however, Fleischhacker 2011
found a statistically significant difference in favour of paliperidone
palmitate at long term (1 RCT, n = 684, MD 1.00 95% CI 0.13
to 1.87, Analysis 8.11).
8.12 Adverse events: 6. Mean prolactin level increase
(ng/mL)
In this subgroup we found three relevant trials; there were no
significant differences between male (n = 1125) and female (n =
807) subgroups in mean prolactin level increase (Analysis 8.12).
8.13 Adverse events: 7. Glucose-related
There were no statistically significant differences between groups
for glucose-related adverse events, including increased blood glu-
cose; hyperglycaemia; diabetes mellitus; glycosuria; ketonuria;
urine ketone; hypoglycaemia (n = 747, Fleischhacker 2011); and
’any’ glucose-related adverse events at medium term (n = 1666, 2
RCTs) and long term (n = 747, 1 RCT, Analysis 8.13).
8.14 Adverse events: 8. Injection site pain (mean (SD) Visual
Analogue Scale score (0-100 mm))
In one study (Fleischhacker 2011), there were no significant dif-
ferences in mean scores for injection site pain between groups at
baseline and endpoint (n = 474, Analysis 8.14).
COMPARISON 9: RISPERIDONE DEPOT versus
TYPICAL DEPOT ANTIPSYCHOTICS
One study provided data for this outcome (Covell 2012, n = 62),
which, as a six-month study, is categorised as medium term.
9.1 Mental state: 1. Average scores (PANNS, high score =
worse) 1. total
There were no statistically significant differences between groups
in total average change score using PANSS at either short (n = 49),
medium (n = 46), or long term (n = 43, Analysis 9.1).
9.2 Leaving the study early
There were no significant differences between groups for leaving
the study early due to increased psychiatric symptoms; due to EPS
effects; due to weight gain and hypertension; or due to participant
preference (n = 62, Covell 2012). There was a statistically signifi-
cant difference between groups for leaving the study early before
beginning assigned treatment (RR 7.50 CI 1.00 to 56.44) and by
six months (RR 3.05 CI 1.12 to 8.31, Analysis 9.2).
9.3 Hospitalisation by six months
There was no significant difference between groups for hospitali-
sation by medium term (n = 62, Covell 2012, Analysis 9.3).
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9.4 Adverse events: 1. Continuous outcomes (skewed)
All continuous outcome data for change in bodymass index (BMI)
and prolactin endpoint levels are skewed and are best inspected by
viewing (Analysis 9.4).
9.5 Adverse events: 2. Sexual experiences (Arizona Sexual
Experiences Scale( ASEX), high score = worse)
There were no statistically significant differences between groups
in sexual experiences scores using ASEX at either short (n = 44),
medium (n = 41), or long term (n = 40, Analysis 9.5).
10. SENSITIVITY ANALYSIS
10.1 Implication of randomisation
10.1.1 Global state: relapse
Both included studies for this outcome were rated as an ’unclear’
risk of bias for randomisation and made mention that participants
were randomised; however methods of randomisation were not
fully described in either study (MacFadden 2010; Quinn 2012*).
10.1.2 Mental state: average scores (PANSS)
Two studies that implied randomisation were removed from data
and analysis (Bai 2006;MacFadden 2010); there was no significant
difference in the estimate of effect after the removal of these studies.
10.2 Assumptions for lost binary data
10.2.1 Global state: relapse
For our binary outcome of relapse, there was no significant dif-
ference in results when completer-only data were compared with
ITT data.
10.3 Risk of bias
All included studies were rated as a ’high’ risk of bias across at least
one domain; therefore there were no data left to compare for either
outcome of relapse, or no clinically important change in mental
state.
10.4 Imputed values
Wedid not include any cluster-randomised trials, and therefore no
values were imputed for intra-class correlation coefficients (ICC)
for either relapse, or no clinically important change inmental state.
10.5 Fixed-effect and random-effects
There was no difference in data when synthesised using a fixed-
effect model for both outcomes of relapse and no clinically im-
portant change in mental state.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: GENERAL ORAL ANTIPSYCHOTICS
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
GENERAL ORAL AN-
TIPSYCHOTICS
RISPERIDONE DEPOT
Global state: Relapse
(any reason) - long
term
Number of part icipants
relapsing in each treat-
ment arm.
M oderate RR 2.13
(0.84 to 5.43)
63
(1 study)
⊕©©©
very low2,3
Criteria for relapse
were derived f rom
Csernansky 2002.<BR/
>
161 per 10001 343 per 1000
(135 to 874)
M ental state: clini-
cally significant im-
provement in mental
state - long term
See comment See comment Not est imable 0
(0)
See comment Outcomes relat ing to
mental state were unus-
able due to high study
attrit ion
Leaving the study
early: Any reason - long
term
Study population RR 1.24
(0.98 to 1.57)
467
(2 studies)
⊕⊕⊕©
moderate
322 per 10004 399 per 1000
(315 to 505)
M oderate
387 per 10004 480 per 1000
(379 to 608)3
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Adverse events: Gen-
eral: Severe adverse
event - any dose
risperidone depot -
short term
See comment See comment Not est imable 0
(0)
See comment ‘‘Severe ad-
verse events’’ were not
explicit ly reported.
Adverse events: Spe-
cific - prolactin- related
- long term
It is unclear how ad-
verse events were re-
ported
Low RR 10.27
(0.59 to 180.05)
85
(1 study)
⊕©©©
very low2,6
10 per 10005 103 per 1000
(6 to 1000)
M oderate
100 per 10005 1000 per 1000
(59 to 1000)
High
200 per 10005 1000 per 1000
(118 to 1000)
Adverse events: Spe-
cific - weight increase
- long term
It is unclear how ad-
verse events were re-
ported
Study population RR 1.33
(0.56 to 3.17)
85
(1 study)
⊕©©©
very low2,6
171 per 10004 227 per 1000
(96 to 541)
M oderate
171 per 10004 227 per 1000
(96 to 542)
Adverse events: Ner-
vous system disorders
(inc. EPS) - long term
It is unclear how ad-
verse events were re-
ported
Study population RR 1.34
(1.13 to 1.58)
369
(1 study)
⊕©©©
very low2,6
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171 per 10004 227 per 1000
(96 to 541)
M oderate
171 per 10004 227 per 1000
(96 to 542)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Assumed risk: mean baseline presented for one individual study.
2 Risk of bias: ’very serious’ - a high level of attrit ion (> 50%), the open-label nature of this study and the fact that it was
supported by the manufacturers of depot risperidone result in a very serious risk of bias.
3 Imprecision: ’serious’ - the sample size for this outcome was small (n = 63).
4 Assumed risk: median control group risk f rom the studies.
5 Assumed risk: control risk relates to ’low’ (0%).
6 Serious risk of imprecision due to the small sample size of this study.
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RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: ORAL RISPERIDONE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ORAL RISPERIDONE RISPERIDONE DEPOT
Global state: Relapse -
long term
See comment See comment Not est imable 0
(0)
See comment Outcomes relat ing to
relapse were not avail-
able for this compari-
son
M ental state: aver-
age PANSS total score
at endpoint (non- ITT
data)
PANSS total scores (30
to 210) Higher scores
are worse.
The mean mental state:
average PANSS total
score at endpoint (non-
ITT data) in the inter-
vent ion groups was
1.05 higher
(0.77 lower to 2.88
higher)
591
(2 studies)
⊕⊕⊕©
moderate1
Leaving the study
early: Any reason -
short term
Study population RR 1.28
(0.92 to 1.79)
690
(2 studies)
⊕⊕⊕©
moderate1
145 per 10002 185 per 1000
(133 to 259)
M oderate
78 per 10002 100 per 1000
(72 to 140)3
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Adverse events: Gen-
eral: Severe adverse
event - any dose
risperidone depot -
short term
See comment See comment Not est imable 0
(0)
See comment ‘‘Severe adverse
events’’ were not explic-
it ly reported by these
studies
Adverse events: M ove-
ment disorder - any
extra pyramidal symp-
toms - short term
Study population RR 1.05
(0.59 to 1.88)
640
(1 study)
⊕⊕⊕©
moderate4
65 per 10003 69 per 1000
(39 to 123)
M oderate
65 per 10003 68 per 1000
(38 to 122)
Adverse events: Spe-
cific: M ean (SD) weight
increase in kg - short
term
The mean adverse
events: specif ic: mean
(SD) weight increase in
kg - short term in the
control groups was
0.2 points
The mean adverse
events: specif ic: mean
(SD) weight increase in
kg - short term in the in-
tervent ion groups was
0.2 higher
(0.35 lower to 0.75
higher)
640
(1 study)
⊕⊕⊕©
moderate4
Adverse events: Spe-
cific - prolactin- related
M oderate RR 0.5
(0.15 to 1.65)
640
(1 study)
⊕⊕⊕©
moderate4
25 per 10003 12 per 1000
(4 to 41)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: ’serious’ - both studies received funding support f rom the manufacturers of risperidone depot
2 Assumed risk: median control group risk f rom the studies.
3 Assumed risk: mean baseline presented for one individual study.
4 Risk of bias: ’serious’ - this research was supported by the manufacturers of risperidone depot.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: ORAL QUETIAPINE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ORAL QUETIAPINE RISPERIDONE DEPOT
Global state: Relapse -
long term
See comment See comment Not est imable 0
(0)
See comment Criteria for relapse
were derived f rom
Csernansky 2002. <BR/
> Outcomes relat ing to
relapse were reported,
but were unusable due
to study attrit ion
M ental state: clini-
cally significant im-
provement in mental
state - long term
See comment See comment Not est imable 0
(0)
See comment Outcomes relat ing to
mental state were unus-
able due to high study
attrit ion
Leaving the study
early: Any reason - long
term
M oderate RR 0.84
(0.74 to 0.95)
666
(1 study)
⊕⊕⊕©
moderate2,3
644 per 10001 541 per 1000
(477 to 612)
Adverse events: Gen-
eral - serious
Recorded at each fol-
low-up visit .
M oderate RR 0.84
(0.62 to 1.13)
666
(1 study)
⊕⊕©©
low2,3,4
3
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229 per 10001 192 per 1000
(142 to 259)
Adverse events: M ove-
ment disorder - any ex-
tra pyramidal symptom
M oderate RR 1.83
(1.07 to 3.15)
666
(1 study)
⊕⊕©©
low2,3,4
56 per 10001 102 per 1000
(60 to 176)
Adverse events: Spe-
cific: M ean (SD) weight
increase in kg - long
term
The mean adverse
events: specif ic: mean
(SD) weight increase in
kg - long term in the in-
tervent ion groups was
1.25 higher
(0.25 to 2.25 higher)
666
(1 study)
⊕⊕©©
low2,3,4
Adverse events: Spe-
cific - prolactin- related
Reported by part ici-
pants at follow-up vis-
its
Study population RR 3.07
(1.13 to 8.36)
666
(1 study)
⊕⊕©©
low2,3,4
15 per 10001 46 per 1000
(17 to 124)
M oderate
15 per 10001 46 per 1000
(17 to 125)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Assumed risk: mean baseline risk used for one included study.
2 Risk of bias: ’serious’ - this study was supported by the manufacturers of risperidone depot.
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3 Risk of bias: ’serious’ - this study was open-label in nature.
4 Risk of bias: ’very serious’ - study attrit ion was high (> 50%).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: ORAL ARIPIPRAZOLE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ORAL ARIPIPRAZOLE RISPERIDONE DEPOT
Global state: Relapse
(any reason) - long
term
Assessed by 5 blinded
raters in accordance
with study criteria (see
comment)
M oderate RR 1.05
(0.83 to 1.33)
349
(1 study)
⊕⊕©©
low2,3
Criteria for relapse
were derived f rom
Csernansky 2002.
436 per 10001 458 per 1000
(362 to 580)
M ental state: Average
change scores- long
term
PANSS total score (30
to 210), higher scores
are worse.
The mean mental state:
average change scores-
long term in the inter-
vent ion groups was
0.1 lower
(3.15 lower to 2.95
higher)
349
(1 study)
⊕⊕©©
low2,3
Leaving the study
early: Any reason - long
term
Study population RR 0.83
(0.53 to 1.3)
723
(2 studies)
⊕©©©
very low5,6
387 per 10004 321 per 1000
(205 to 503)
M oderate
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531 per 10004 441 per 1000
(281 to 690)
Adverse events: Gen-
eral - serious
Unclear how these
events were reported
Study population RR 0.96
(0.66 to 1.39)
729
(2 studies)
⊕©©©
very low5,6
190 per 10004 182 per 1000
(125 to 264)
M oderate
177 per 10004 170 per 1000
(117 to 246)
Adverse events: M ove-
ment disorder - any
extra pyramidal symp-
toms
Study population RR 1.19
(0.91 to 1.55)
729
(2 studies)
⊕©©©
very low5,6
285 per 10004 339 per 1000
(259 to 442)
M oderate
196 per 10004 233 per 1000
(178 to 304)
Adverse events: Spe-
cific - weight increase
M oderate RR 1.57
(0.38 to 6.45)
374
(1 study)
⊕⊕©©
low2,3
44 per 10001 69 per 1000
(17 to 284)
Adverse events: Spe-
cific - prolactin- related
Study population RR 9.91
(2.78 to 35.29)
729
(2 studies)
⊕©©©
very low5,6
9 per 10004 90 per 1000
(25 to 319)
M oderate
6 per 10004 59 per 1000
(17 to 212)
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Assumed risk: mean baseline risk presented for one individual study.
2 Risk of bias: ’very serious’ - a number of the study authors were employed by the manufacturers of risperidone depot at the
t ime of the study.
3 Risk of bias: ’serious’ - serious risk of bias due to the open nature label of the study.
4 Assumed risk: median control group risk f rom the studies.
5 Risk of bias: ’very serious’ - serious risk of bias as both studies were open-label and supported by the manufacturers of
risperidone depot.
6 Imprecision: ’serious’ - possibly serious risk of imprecision in Gaebel 2010* as the aripiprazole arm of this study was very
small (n = 45) compared to the risperidone depot (n = 329) arm.
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RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: ORAL OLANZAPINE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ORAL OLANZAPINE RISPERIDONE DEPOT
Global state: Relapse -
long term
See comment See comment Not est imable 0
(0)
See comment Outcomes relat ing to
relapse were not re-
ported for this compar-
ison
M ental state: Average
change scores - long
term
PANSS total score (30-
210), high scores are
worse.
The mean mental state:
average change scores
- long term in the inter-
vent ion groups was
0.1 higher
(3.96 lower to 4.16
higher)
361
(1 study)
⊕⊕©©
low1,2,3
Leaving the study
early: Any reason - long
term
Study population RR 1.32
(1.1 to 1.58)
618
(1 study)
⊕⊕©©
low1,2,3
377 per 10004 497 per 1000
(414 to 595)
M oderate
377 per 10004 498 per 1000
(415 to 596)
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Adverse events: Gen-
eral - serious
M oderate RR 1.1
(0.8 to 1.51)
547
(1 study)
⊕⊕©©
low1,2,3
210 per 10004 231 per 1000
(168 to 317)
Adverse events: M ove-
ment disorder - any
extra pyramidal symp-
toms
M oderate RR 1.67
(1.19 to 2.36)
547
(1 study)
⊕⊕©©
low1,2,3
150 per 10004 250 per 1000
(179 to 354)
Adverse events: Spe-
cific - weight increase
M oderate RR 0.56
(0.42 to 0.75)
547
(1 study)
⊕⊕©©
low1,2,3
360 per 10004 202 per 1000
(151 to 270)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: ’very serious’ - serious risk of bias due to study attrit ion in excess of 50%.
2 Risk of bias: ’serious’ - serious risk of bias as this study was supported by the manufacturers of risperidone depot, and some
of the authors are employed by the same.
3 Risk of bias: ’serious’ - serious risk of bias due to the open-label nature of the study.
4 Assumed risk: mean baseline risk f rom one included study.
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RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALM ITATE) for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ATYPICAL DEPOT AN-
TIPSY-
CHOTICS (PALIPERI-
DONE PALM ITATE)
RISPERIDONE DEPOT
Global state: Relapse -
long term
See comment See comment Not est imable 0
(0)
See comment Outcomes relat ing to
relapse were not re-
ported for this compar-
ison
M ental state: PANSS
responders (ITT data) -
medium term
PANSS responders-
part icipants achieving
a >30% improvement in
total score
Study population RR 1.01
(0.83 to 1.23)
1326
(2 studies)
⊕⊕⊕©
moderate2,3
585 per 10001 591 per 1000
(486 to 720)
M oderate
619 per 10001 625 per 1000
(514 to 761)
Leaving the study
early: lack of efficacy -
long term
Study population RR 0.60
(0.45 to 0.81)
749
(1 study)
⊕⊕©©
low2,3,4
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361 per 10001 307 per 1000
(275 to 340)
M oderate
280 per 10001 238 per 1000
(213 to 263)
Adverse events: M ove-
ment disorder requir-
ing the use of anti-EPS
medication - medium
term
Study population RR 1.46
(1.18 to 1.8)
1666
(2 studies)
⊕⊕⊕©
moderate2,3,5
122 per 10001 178 per 1000
(144 to 220)
M oderate
182 per 10001 266 per 1000
(215 to 328)
Adverse events: Body
weight (mean in-
crease) - medium/ long
term
The mean adverse
events: body weight
(mean increase) -
medium/ long term in
the intervent ion groups
was
0.18 higher
(0.36 lower to 0.72
higher)
2350
(3 studies)
⊕⊕©©
low2,3,4
Adverse events:
Any prolactin- related -
medium term
Study population RR 1.02
(0.61 to 1.71)
1666
(2 studies)
⊕⊕⊕©
moderate2,3
32 per 10001 33 per 1000
(20 to 55)
M oderate
48 per 10001 49 per 1000
(29 to 82)4
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Adverse events:
Any glucose- related -
medium/ long term
10 per 10001 18 per 1000
(9 to 36)
RR 1.79
(0.89 to 3.61)
2413
(3 studies)
⊕⊕©©
low2,3,4
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Assumed risk: median control group risk f rom the studies.
2 Risk of bias: ’serious’ - Li 2011 was open-label and supported by the manufacturer of risperidone depot.
3 Risk of bias: ’serious’ - Pandina 2011 was supported by the manufacturer of risperidone depot.
4 Risk of bias: ’serious’ - as the attrit ion rate of Fleischhacker 2011 was in excess of 50%, and the study was supported by the
manufacturer of risperidone depot.
5 Possible imprecision: the rate of movement disorder requiring ant i-EPS medicat ion may not be a ref lect ion of the true rate
of movement disorders.
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RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia
Patient or population: pat ients with schizophrenia
Settings:
Intervention: RISPERIDONE DEPOT
Comparison: TYPICAL DEPOT ANTIPSYCHOTICS
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
TYPICAL DEPOT AN-
TIPSYCHOTICS
RISPERIDONE DEPOT
Global state: Relapse -
long term
See comment See comment Not est imable 0
(0)
See comment Outcomes relat ing to
relapse were not re-
ported for this compar-
ison
M ental state: Total av-
erage scores (PANSS,
high score = worse) -
long term
The mean mental state:
total average scores
(PANSS, high score =
worse) - long term in
the intervent ion groups
was
1.8 higher
(10.04 lower to 13.64
higher)
43
(1 study)
⊕⊕©©
low1,2
Leaving the study early
for any reason - long
term
Study population RR 3.05
(1.12 to 8.31)
62
(1 study)
⊕⊕©©
low1,2
133 per 10003 407 per 1000
(149 to 1000)
M oderate
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133 per 10003 406 per 1000
(149 to 1000)
Adverse events: Gen-
eral: Severe adverse
event
See comment See comment Not est imable 0
(0)
See comment ‘‘Severe ad-
verse events’’ were not
explicit ly reported for
this comparison
Adverse events: re-
lated to movement dis-
order, weight gain,
prolactin levels and
glucose metabolism -
medium/ long term - not
reported
See comment See comment Not est imable - See comment Outcomes relat ing to
specif ic adverse events
were not reported in
such as way as to be
useable
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: ’serious’ - due to the open-label nature of this study.
2 Imprecision: ’serious’ - due to the small size of the single study.
3 Assumed risk: median control group risk f rom the studies.
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D I S C U S S I O N
Summary of main results
1. Risperidone depot versus placebo
1.1 Relapse
No direct evidence exists regarding the risk of relapse for risperi-
done depot versus placebo. The closest available data relate to
change in mental state, which is discussed below.
1.2 Clinically significant improvement in mental state
Clinically significant improvement in the context of Kane 2002*
was defined as being a 20% improvement in total Positive and
Negative Syndrome Scale (PANSS) score, but evidence pertaining
to this cannot be used in this analysis as more than half of the
data were assumed by the authors.To indirectly assess clinically
significant changes in mental state, it may possible to look at the
incidence of related adverse events; depot risperidone did result
in significantly decreased reports of agitation and psychosis, the
latter especially could be indicative of a clinical differences. Using
adverse events from this study in this way is hampered by the fact
that they were only recorded when spontaneously reported by a
participant.
1.3 Leaving the study early for any reason
Four hundred people were randomised and 370 participants had
at least one injection and one post-baseline assessment. There was
no difference between depot risperidone and placebo group for the
outcome of leaving the study before one injection (n = 400, RR
1.30CI 0.55 to 3.08). Fifty-six per cent of people did not complete
the three-month study (68% in the placebo group, 52% in the
depot groups). The attrition rate was higher for those allocated
placebo compared with people allocated risperidone depot. There
did not seem to be any dose-related effects, although when the
reason for leaving was lack of efficacy, there seemed to be some
differences. Higher doses of risperidone depot resulted in slightly
less attrition. People randomised to the placeboweremore likely to
leave the study early than those in the depot risperidone group, and
the level of attrition for any reason did not differ between the three
doses of risperidone depot. The numbers of people leaving early
due to lack of efficacy may be dose-related; half as many people
gave it as their reason in the 75 mg group compared to the 25
mg group. This suggests that there were people for whom higher
doses of depot risperidone are required to produce a therapeutic
effect.
1.4 Severe adverse effects
Severe adverse events were common in Kane 2002*, occurring in
13% to 23% of participants and significantly more often in the
placebo group. The authors define a severe adverse event as any-
thing that resulted in death or was life-threatening, required hos-
pitalisation or prolongation of hospitalisation, resulted in persis-
tent or significant disability or incapacity, or resulted in congen-
ital anomaly or birth defect. No details are given about specific
severe adverse events that were reported in each group; this raises
the serious possibility that very different events have been bundled
together. This in turn could conceal evidence regarding important
effects of using depot risperidone, but there is no way to tell with
the data reported as they are.
1.5 Adverse events related to movement disorder, weight
gain, prolactin levels and glucose metabolism
Rates of movement disorder did not differ between depot risperi-
done and the placebo; the data did show a trend towards more
extrapyramidal symptoms (EPS) with increasing doses of depot
risperidone, but even at the 75 mg dose of risperidone, this fell
short of statistical significance (Analysis 1.10). More studies, with
larger sample sizes, would probably produce a significant result,
but it is unlikely that such studies will ever be conducted.
The number of participants experiencingweight gain did not differ
between the interventions.
2. Risperidone depot versus general oral
antipsychotics
2.1 Relapse
Quinn 2012* found no significant difference in relapse rates be-
tween risperidone depot and general oral antipsychotics.
2.2 Clinically significant improvement in mental state
Data relating directly to mental state (such as PANSS scores) are
not useable due to the high levels of attrition in both Quinn
2012* and Rosenheck 2011. Alternative outcomes that may give
some indirect indication of themental state of participants include
the need for benzodiazapine or sedative drugs and the rate of
hospitalisation. Neither of these outcomes differed significantly
between the treatment groups.
2.3 Leaving the study early for any reason
There was no significant difference in the overall rates of study
attrition when comparing risperidone depot with general oral an-
tipsychotics, however the general trend was towards risperidone
depot group participants being more likely to leave, with the lower
limit of the 95% confidence interval only just falling to the left of
the line of no effect (Analysis 2.6).
50Risperidone (depot) for schizophrenia (Review)
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2.4 Severe adverse effects
Outcomes relating to severe adverse events were not available.
2.5 Adverse events related to movement disorder, weight
gain, prolactin levels and glucose metabolism
There was no difference between risperidone depot and general
oral antipsychotics for adverse events related to weight gain, pro-
lactin or glucose metabolism. “Nervous system disorders” were
more likely to occur in those taking risperidone depot than those
on oral treatment; it is unclear precisely what proportion of these
events involved movement disorder.
3. Risperidone depot versus oral risperidone
3.1 Relapse
Relapse was not an outcome addressed by any usable outcomes
from these studies.
3.2 Clinically significant improvement in mental state
3.3 Leaving the study early for any reason
Leaving the study early did not occur any more in one treatment
arm over the other. The attrition rate in Bai 2006 was very low,
with only one participant from the risperidone depot group and
none from the oral group leaving early; this is probably due to
its setting being an inpatient psychiatric unit, where the constant
presence of various healthcare professionals would ensure that pa-
tients adhered to their prescribed medication. Attrition in Chue
2002, a study taking place in the community, was predictably
higher.
3.4 Severe adverse effects
No distinction was made between serious and general adverse
events in either study.
3.5 Adverse events related to movement disorder, weight
gain, prolactin levels and glucose metabolism
There was no difference between depot and oral risperidone re-
garding the number experiencing any EPS, which occurred in
6.5% to 6.8% of all participants in Chue 2002. Tardive dyskinesia
was reported four times in the depot group of Chue 2002 and not
at all in the oral group, but this was not quite enough to establish
a statistical difference between the two.
Prolactin-related adverse events were rare, occurring in 1.2% to
2.5% of participants; with between zero and two people in each
group experiencing each of: sexual dysfunction and impotence,
galactorrhoea and dysmenorrhoea. The number of participants
who experienced a significant amount of weight gain is not known,
but there was a small mean increase of 0.5 kg in the depot group
and 0.3 kg in the oral group.
4. Risperidone depot versus oral quetiapine
4.1 Relapse
Time to relapse was measured as a primary outcome by Gaebel
2010*, but the high level of attrition in the study made most of
the data unsuitable for inclusion in our analysis. One outcome
that can be included is the number of participants leaving the
study early for the specific reason of relapse; individuals in the oral
quetiapine group were 46% more likely to leave the study due to
relapse than the risperidone depot group.
4.2 Clinically significant improvement in mental state
Outcomes relating to mental state suffer from the same high at-
trition rates that affect so many of the included studies.
4.3 Leaving the study early for any reason
Participants in the oral quetiapine group were significantly more
likely to leave the study early for any reason,
4.4 Severe adverse effects
There was no difference between the two interventions for the rate
at which severe adverse events were reported, and the overall rate of
severe adverse events in Gaebel 2010* appears broadly congruent
with the other included studies.
4.5 Adverse events related to movement disorder, weight
gain, prolactin levels and glucose metabolism
Risperidone depot caused more EPS than oral quetiapine among
the study population, with ~10% of the risperidone group report-
ing any EPS symptom compared to 5.6% of the quetiapine group.
The specific symptoms of tremor and “parkinsonism” were more
common with risperidone depot.
Similar numbers of people in both groups experienced weight gain
through the study period, but the mean (SD) increase in weight
appears to be greater for risperidone depot.
Significantly more prolactin-related problems occurred in those
taking depot risperidone. The rate of hyperprolactinaemia was al-
most nine times greater than the quetiapine group, and risperi-
done group members were three times more likely to experience
side effects related to prolactin.
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5. Risperidone depot versus oral aripiprazole
5.1 Relapse
MacFadden 2010 showed no difference between the two inter-
ventions, with just under half of each group relapsing during the
study period. These data cannot be compared directly to the re-
lapse data from Gaebel 2010* due to the attrition level of that
study, but the number of individuals leaving the study early due to
relapse in Gaebel 2010* did trend towards favouring risperidone
depot for relapse prevention, the very small size of the aripiprazole
arm in this study prevents this outcome from reaching statistical
significance.
5.2 Clinically significant improvement in mental state
Data relating to PANSS responder rates were not available or us-
able for either study, but MacFadden 2010 reported that the over-
all change in PANSS total score through the study period was vir-
tually the same for both groups, with a mean reduction of around
11 points.
5.3 Leaving the study early for any reason
There was substantial heterogeneity relating to this outcome.
Meta-analysis shows no difference between risperidone depot and
oral aripiprazole when leaving the study early for any reason, but
the participants in each study differedmarkedly. Drop-out rates in
MacFadden 2010were very similar (n =349RR1.03 [0.74, 1.43]),
with around 30% attrition overall, whereas in Gaebel 2010*, those
in the aripiprazole group were significantly more likely to leave
(n = 384 RR 0.70 [0.58, 0.84]), with 78% dropping out of that
group. It is unclear what has contributed to this disparity.
5.4 Severe adverse effects
Rates of serious adverse events were the same for both interven-
tions.
5.5 Adverse events related to movement disorder, weight
gain, prolactin levels and glucose metabolism
Rates of movement disorder did not differ significantly overall
between the risperidone depot and oral aripiprazole groups, but
this probably does not tell the whole story. Risperidone depot was
associated with movement disorder in a greater proportion of par-
ticipants than aripiprazole in Gaebel 2010*, but the substantial
disparity in the size of the two analysis sets prevents those results
from achieving statistical significance (n = 384 RR 2.33 [0.58,
9.35]). There were also differences between the studies, with sub-
stantially more participants in both groups reporting movement
disorder inMacFadden 2010. It is not clear why this is so; whether
it is due to methodological differences in the way such events were
defined and the data collected, differences in the make up of the
study population and their susceptibility to EPS effects or some
other factors.
Glucose-related events were reported by 9% to 10% of those in
MacFadden 2010, with no difference between the groups. Weight
gain was also broadly similar for both interventions, but prolactin-
related adverse events were much more common with risperidone
depot and there were no incidences of hyperprolactinaemia with
aripiprazole
6. Risperidone depot versus oral olanzapine
6.1 Relapse
The only study comparing risperidone depot to oral olanzapine
(Keks 2007) did not include relapse as an outcome.
6.2 Clinically significant improvement in mental state
There is some discrepancy between the stated levels of study at-
trition (i.e. the completion rate) and the number of participants
for whom outcome data are available up to the end of the study
period. For depot risperidone, average endpoint PANSS scores are
provided for 155 participants, with last observation carried for-
wards (LOCF) analysis used. However, the number of participants
for whom the mean PANSS score change at 12 months (the end
of the study) is given was only 116. We are not certain how the
difference between the number of participants who completed the
study from this group (n = 160) and the number for whom data
are available at 12 months (n = 116) can be so great.
6.3 Leaving the study early for any reason
Participants taking risperidone depot had a significantly increased
risk of leaving the study early; about half of the risperidone depot
group compared to a third of the olanzapine arm. Much of this
difference can be explained by the decision of the investigators to
alter the protocol and exclude the 75 mg risperidone depot group
after randomisation had taken place, resulting in 66 participants
being excluded from themain analysis. If this is taken into account,
the rates of participants leaving the study for other reasons, such
as insufficient response, are similar for each intervention.
6.4 Severe adverse effects
Severe adverse events were reported at similar rates for both in-
terventions, but what made a particular adverse event “severe” is
not explained. Adverse events such as anxiety are reported as both
general and severe adverse events Presumably the investigators in
Keks 2007 had some criteria to differentiate severe adverse events,
but these are not explained.
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6.5 Adverse events related to movement disorder, weight
gain, prolactin levels and glucose metabolism
Movement disorder was a common adverse event in both groups,
but was significantly more common in those receiving risperidone
depot, with around 25% experiencing it to some degree, com-
pared to 15% of the olanzapine group. Perhaps unsurprisingly, the
usage of anti-parkinsonian medications was greater in the depot
risperidone group as well. Reporting of EPS was not clear in this
study; the overall percentage of participants experiencing EPS was
given, but it is difficult to see how these data correspond to those
in a table which breaks down EPS into separate symptoms, e.g.
hyperkinesia, tardive dyskinesia, tremor, etc. In particular, “Ex-
trapyramidal disorder” is listed as a specific outcome in this table,
but was apparently only reported by 8% of the risperidone depot
group and 4% of the olanzapine group. There is no way to discern
precisely what this item encompasses, nor what differentiates it
from the overall rate of EPS. We have contacted the study authors
for clarification on this point, but have yet to receive a response.
Olanzapine caused significantlymore weight gain than risperidone
depot in the study population;more than1/3of participants taking
olanzapine are reported to have experienced weight gain greater
than 7% of their bodyweight (mean weight gain overall of 4.0 kg),
compared to a 1/5 of the risperidone group (mean increase of 1.7
kg overall).
Prolactin-related adverse events were rare and did not differ be-
tween the interventions; there were two instances of impotence or
ejaculation failure in each arm, and similarly low levels of galact-
orrhoea. One new diagnosis of diabetes mellitus was made in each
group during the study period.
7. Risperidone depot versus all oral
antipsychotics (primary outcomes)
7.1 Relapse
Data from the three trials (Gaebel 2010*, MacFadden 2010,
Quinn 2012*) that measured relapse directly suggest that it occurs
at the same rate when depot risperidone treatment is compared
to aripiprazole or a variety of second-generation antipsychotics.
When compared to quetiapine, however, depot risperidone treat-
ment leads to only half as many cases of relapse. The precise meth-
ods used to define this outcome vary between Gaebel 2010* and
MacFadden 2010, but they are similar enough in appearance (fac-
tors such as hospitalisation, PANSS and CGI change being com-
mon between the two) that we can be confident they are measur-
ing the same thing. Quinn 2012* is more problematic, as no defi-
nition of relapse is given; such methodological details are probably
too much to be asking of a single poster and an abstract, but if a
full report becomes available it will be important to confirm this.
The quality of some of this evidence is also questionable; Gaebel
2010* andQuinn 2012* in particular had a high risk of bias due to
their nature as open-label studies with no evidence of rater blind-
ing. One perhaps very serious methodological weakness of Gaebel
2010* that may have had an impact on the effect size reported
was that follow-upmethods differed between intervention groups.
Depot risperidone participants attended physical appointments to
receive their medication and undergo assessment of certain out-
comes every two weeks, whereas those in the oral quetiapine and
aripiprazole groups received phone calls for the same purpose. The
depot group participants therefore spent more time with health-
care professionals during the course of the study; even if the exact
same questions were asked at in-person and telephone check-ups,
seeing a patient in the flesh may have made it easier to detect clini-
cal deterioration and adjust doses of concomitant medications and
the study drug before a slight deterioration has time to snowball
into a full relapse.
The regular attention that comes with being prescribed depot
rather than oral antipsychotics may be an important aspect of the
intervention, but in a randomised clinical trial (RCT) of two drugs
there is a case for limiting potential confounders so that the only
effect measured is that of the drugs, not that of the drugs plus the
intensity of care provided. More studies are needed that address
the issue of relapse directly; a RCT comparing relapse and hospi-
talisation rates between depot and oral risperidone is of particular
importance. Using only the currently available evidence compar-
ing depot risperidone with oral quetiapine, it is not possible to tell
whether the significant difference in relapse rates is due mainly to
the difference in administration methods or due to the different
pharmacological properties of risperidone and quetiapine. If oral
risperidone is as effective as the depot preparation at preventing
relapse, then economic considerations may take on greater impor-
tance in prescribing decisions.
7.2 Clinically significant improvement in mental state
No comparisons with usable data from these studies give any di-
rect indication as to howmany participants achieved clinically sig-
nificant improvements in mental state, but data regarding average
mental state scores are available. Risperidone depot is not signifi-
cantly different from oral risperidone, olanzapine or aripiprazole
in its effect on mental state, as measured through all domains of
PANSS, with the average scores for participants in all study arms
either improving or remaining largely the same (Analysis 7.2).
7.3 Leaving the study early for any reason
People randomised to risperidone depot were as likely to leave the
study early as those assigned to aripiprazole (n = 723, RR 0.83,
95% CI 0.53 to 1.30), oral risperidone (n = 690, RR 1.28, 95%
CI 0.92 to 1.79), or any oral antipsychotic (n = 382, RR 1.25,
95% CI 0.93 to 1.68). Compared to oral quetiapine and any
new-generation oral antipsychotic, participants in the risperidone
depot group were significantly less likely to leave the study early
(n = 666, RR 0.84, 95% CI 0.74 to 0.95 and n = 77, RR 0.72,
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95% CI 0.55 to 0.95, respectively), and significantly more likely
to drop out than participants randomised to olanzapine (n = 618,
RR 1.32, 95% CI 1.10 to 1.58).
7.4 Severe adverse effects
There is great inconsistency in the reporting of serious adverse ef-
fects amongst these studies, which makes any comparisons prob-
lematic. When severe effects were reported there were no differ-
ences in the rates at which they occurred when comparing de-
pot risperidone to quetiapine, aripiprazole or olanzapine. It is not
clear, though, whether the outcome of severe adverse effects if
comparable between these studies; of the three trials, none provide
a definition of what they consider to be a serious adverse event
and the reporting of the specific events is often very vague. Keks
2007 is the only study to explicitly list the severe adverse events
that were reported by more than 2% of either group; of the other
two studies, Gaebel 2010* only gives an overall rate and the rate
of the most common serious adverse events (psychiatric symp-
toms), while MacFadden 2010 states that psychotic disorder and
schizophrenia were the most common serious adverse events but
gives no details on their precise incidence.
With severe adverse events reported in such a scattergun manner
throughout these trials, it is impossible to perceive any trends or
patterns of severe adverse events emerging for any of the interven-
tions. A rare, but serious, side effect (or side effects) may occur
consistently at a rate below the reporting threshold yet remain un-
reported in the literature.
7.5 Economic costs of treatment
An analysis of Medical Resource Utilisation (MRU) using a small
subset of relapsed participants from Gaebel 2010* determined
that each individual cost their country’s health service an average
of EURO7592 in the three months following their relapse and
that this figure was EURO1525 higher in people who required
psychiatric hospitalisation during this time.
Drawing toomany conclusions from these data are dangerous; this
analysis is available only as a single abstract. As such, details on
the methods used to produce these figures are sparse; of particular
concern is that fact that Gaebel 2010* was spread out over 124
centres in 25 European countries. It is quite conceivable that there
is significant heterogeneity in the health services of these countries
that may affect how and where money is spent. The full version of
the paper may be able to address this, but until then it is unclear
exactly how applicable this evidence is.
Despite this, it is still clear that relapse, especially if it involves
hospitalisation, is expensive. Using administrative data from the
Veterans Administration (VA), the researchers in Rosenheck 2011
were able to determine the mean (SD) cost of in- and out-pa-
tient care, as well as medication costs, in each treatment group per
quarter (three months) of follow-up). They found that the overall
costs relating to service use for each group were similar, a result
that seems congruent with the finding that there was no difference
between groups in levels of post-randomisation hospitalisation or
out-patient care. Medication costs, however, were substantially
higher for depot risperidone. The study drug itself cost more than
the control group’s medication, but further to this, depot group
participants also received nearly $500 of extra oral antipsychotics.
They also required $357 more in concomitant medications, lead-
ing to approximately $1000 more per quarter being spent on each
patient with no quantifiable difference in outcomes.
Based solely on these data, it is not possible to claim that depot
risperidone is a cost-effective treatment option for schizophrenia.
Generalising these results specifically in terms of absolute amounts
spent may be an issue; the study they are based on was of a 90%
male population of military veterans with unstable schizophrenia,
whose needs could differ substantially from patients in other sit-
uations. There is also a reasonable risk that the unblinded nature
of follow-up could have lead to clinical decisions (e.g. whether to
hospitalise) being made differently depending on the intervention
a person was using, leading to performance bias. However, the
data regarding the price of depot risperidone compared to oral
treatment are important.
In the future, we plan to undertake full economic analysis to com-
plement the above findings.
8. Risperidone depot versus atypical depot
antipsychotics (paliperidone palmitate (PP))
8.1 Relapse
As with placebo, there is no direct evidence regarding relapse for
this comparison.
8.2 Clinically significant improvement in mental state
A clinically significant difference in mental state was considered
to be a 30% or greater reduction in total PANSS score by the
three studies. For Fleischhacker 2011, however, the high level of
overall study attrition (55% did not complete) combined with the
use of LOCF data means that more than half of the data used
to determine this outcome was based on assumptions. Synthesis
of the data from Li 2011 and Pandina 2011 shows there is no
difference between depot risperidone and paliperidone palmitate
for the number of PANSS responders, though Li 2011 did report
a greater improvement in total PANSS (RR 3.30 CI 0.24 to 6.36)
and positive symptom (P = 0.01, RR1.80CI 0.42 to 3.18, Analysis
8.4) scores for those receiving PP.
The PANSS responder rates reported by the two studies demon-
strate a significant level of heterogeneity, with around 50% of par-
ticipants in Pandina 2011 compared to 70% to 78% in Li 2011,
and it is not immediately apparent what has caused this difference.
Their respective designs are very similar, with common treatment
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period duration, the same range of doses used for each interven-
tion and the average final dose for each treatment was also similar
(the mean (SD) final PP dose was 104.5 (30.51) mg eq in Pandina
2011 and 115.8 (9.07) mg eq in Li 2011, but this difference can
probably be accounted for by the analysis set used to determine
these figures. Li 2011 gave the mean for the per protocol analysis
set, while Pandina 2011 gave it for the safety analysis set, which
includes participants who left the study after only one dose who
therefore would not have been titrated onto the higher doses yet).
The two important differences are probably blinding and sample
size; Li 2011 randomised 452 people and was open-label, whereas
Pandina 2011 had more than double the study population (n =
1220) and utilised a double-blind approach.
8.3 Leaving the study early for any reason
Participants assigned to depot risperidone were overall less likely
to leave the study early for any reason, but it is difficult to reason
exactly why that is. It could be related to efficacy; data frommental
and global state outcomes show that depot risperidone and PP are
essentially equivalent in their effects, yet there was a (not quite
statistically significant) trend towards PP group participants being
more likely to cite lack of efficacy when leaving the study. As PP is
a newer drug (albeit a derivative of risperidone), it is conceivable
that the dosing guidelines are less well supported, or that people
taking PP were less likely to be dosed appropriately than those
allocated to depot risperidone.
8.4 Severe adverse effects
Serious adverse events occurred at the same rate for depot risperi-
done and paliperidone palmitate, being reported by 10% to 13%
of participants in all three studies. If the two-year long trial
(Fleischhacker 2011) is excluded from this analysis to leave only
the shorter follow-up studies, the rate of serious adverse events goes
down to below 5%, which suggests that serious adverse events may
be more likely to occur after being on either of the study drugs for
a prolonged period. Fleischhacker 2011 also featured significantly
more severe adverse events in the paliperidone palmitate group.
Differences in study design other than the length of follow-up
are unlikely to account for the excess severe adverse events as all
three studies shall very similar methodology, with the exception
that Fleischhacker 2011 & Pandina 2011 are double-blind stud-
ies, while Li 2011 is open-label. This finding is important because
most people who are prescribed antipsychotics for schizophrenia
are presumably expecting to take them for more than 13 weeks,
so the short-term studies might not present an accurate represen-
tation of the risk.
Fleischhacker 2011 also raises the possibility that while the two
drugsmay be similar in the short term, over time, the risk of serious
adverse effects may be greater for PP; more long-term studies of
depot risperidone and paliperidone palmitate are needed to assess
this.
8.4.1 Adverse events related to movement disorder, weight
gain, prolactin levels and glucose metabolism
Keks 2007 has very strange analysis sets
8.5 Economic costs of treatment
Cost or cost-effectiveness outcomes are not included in any of
the three studies comparing depot risperidone versus paliperidone
palmitate.
9. Risperidone depot versus typical depot
antipsychotics
9.1 Relapse
Covell 2012 did not directly assess rates of relapse for this com-
parison, but if we use rates of hospitalisation as a proxy for this
outcome there was no difference between risperidone depot and
typical depots (n = 62, Covell 2012, Analysis 9.3).
9.2 Clinically significant improvement in mental state
The single study making this comparison (Covell 2012) did not
provide details of the number of participants making a clinically
significant improvement while on the study drugs, instead provid-
ing average PANNS total scores for each treatment arm at short-
, medium- and long-term (for this study) follow-up. These data
showed no difference between the two groups at any point, but
it is not possible to say anything about how many participants
experienced a significant change in their mental state. As the study
population were all initially being treated with typical depot an-
tipsychotics, it is unlikely that much by way of clinically signifi-
cant change took place.
9.3 Leaving the study early for any reason
Participants randomised to receive depot risperidone were more
likely to leave the study, both before commencement of their as-
signed treatment (RR7.50 95CI 1.00 to 56.44) and by sixmonths
(RR 3.05 95% CI 1.12 to 8.31, Analysis 9.2). As the researchers
themselves noted, this can probably be explained by the study
design; being randomised to risperidone depot came with a re-
quirement to switch their medication, whereas those in the typical
depot group were allowed to stay on the antipsychotics they had
already been taking. It is understandable that some people would
not feel comfortable switching andwould therefore leave the study
early, but it is not possible to differentiate these individuals from
those who left for other reasons.
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9.4 Serious adverse effects
Data relating to serious adverse effects are not available for Covell
2012. The adverse effects data that were collected are skewed, and
in accordance with our methodology, cannot be included in the
analysis.
9.5 Economic costs of treatment
There are no studies addressing the economic costs associated with
risperidone depot compared to typical depot antipsychotics.
Overall completeness and applicability of
evidence
Naturalistic protocols more closely resemble real-life clinical prac-
tice, but very high attrition in some of these makes the results less
useful.
The applicability of the evidence in this review to real-life practice
may be somewhat hindered by the nature of the participants re-
cruited to the included studies, more specifically the question of
whether or not they really reflect the types of patients in the real
world who would most benefit from taking depot antipsychotics
over oral preparations.
Depot antipsychotics are intended for people that do not want, or
are unable, to take daily oral drugs. If an individual has enough
stability and insight in their day to day life to adhere to an oral
regimen, then they probably would not gain any greater freedom
from their symptoms through a depot. In the real world, depots
are prescribed for patients for whom the severity of their illness
prevents this level of stability and control, and who may benefit
from having their medication delivered consistently in a manner
that is “out of their hands”, so to speak. The people recruited to
most, if not all, of these studies did not appear to be that ill, with
baseline PANSS total scores consistently in the 60 to 80 range
and recruitment criteria that excluded those with substance abuse
problems, a history of violent or suicidal behaviour or comorbid
psychiatric problems. The results can only really speak for the
effects of risperidone depot on patients for whom receiving their
medication as bi-weekly injections or daily oral preparations may
make very little difference to the amount of drug delivered to their
system.
Quality of the evidence
Kane 2002* features a very high level of attrition from the study,
almost 70% in the placebo group and just over 50% in the ac-
tive treatment group. The consequence of this is that the authors
conclusion, that depot risperidone is significantly more efficacious
than placebo for improving the symptoms of schizophrenia, is
based mainly on assumptions. Using the evidence from this study
alone, there is nothing to support the idea that depot risperidone
is any better than placebo. Yet despite the problems with this
study, which was included in the previously published version of
this review (Hosalli 2003), a decade later it is still the only ran-
domised controlled trial that compares depot risperidone versus
placebo. While the other results in this review demonstrate that
depot risperidone is very likely as effective as other antipsychotics,
it is worrying that these trials all took place in an environment
where the superiority of depot risperidone was taken as read.
Adverse event reporting was inconsistent amongst the included
studies; specifically there was no evidence that the criteria used to
define “serious adverse events/effects” were the same from study to
study. This makes it difficult to compare these outcomes between
studies to produce generalisable results.
Open-label study designs are associated with a high risk of perfor-
mance bias; whereby the participants’ knowledge of which inter-
vention they are receiving affects their response to it. Most of the
studies in this review utilised this design, resulting in widespread
risk of bias that may downgrade the quality of the evidence.
Potential biases in the review process
The review protocol and process of study selection were strictly
adhered to throughout the entire review process, and the process
for searching for studies was thorough and data were extracted
independently.We contacted authors of included studies to obtain
details of ongoing or unpublished studies, but there remains a
possibility that other unpublished trials of the intervention exist
for which the review authors do not currently have access.
Agreements and disagreements with other
studies or reviews
To the authors’ knowledge, this is the first systematic review to
comprehensively meta-analyse RCTs relating to risperidone depot
for schizophrenia.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Based on the evidence from the one study (Kane 2002*), depot
risperidonemay bemore acceptable than placebo injection but it is
hard to know if it is anymore effective in controlling the symptoms
of schizophrenia. The active drug, especially at higher doses, may
be associated with more movement disorders than placebo. People
already stabilised on oral risperidone may continue to maintain
benefit if treated with depot risperidone and avoid the need to
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take tablets, at least in the short term. In people who are happy to
take oral medication the depot, risperidone is approximately equal
to oral risperidone as seen within the considerable limitations of
the two relevant studies. It is possible that the depot formulation,
however, can bring a second-generation antipsychotic to people
who do not adhere to treatment. People with schizophrenia who
have difficulty adhering to treatment, however, are unlikely to
volunteer for a clinical trial. Such people may gain benefit from
the depot risperidone with no increased risk of extrapyramidal side
effects (EPS).
2. For clinicians
For reasonably well and stable people, it may mean they can avoid
taking regular oral doses but adverse affects are not well reported.
When given to more severely ill people, few benefits were demon-
strated in the short term, although it may increase compliance
with injections compared with placebo. Use of depot risperidone,
especially at the higher doses, is weakly associated with movement
disorders.
Review of the evidence on the efficacy of depot formulations of
first-generation antipsychotics in comparison with oral formula-
tions indicates that there is only a very modest advantage of depot.
There is very little difference between depot and oral formulations
in most studies. Patients who volunteer for research are often co-
operative patients who will take their medication, particularly if
they are seen every few weeks for ratings, reminding them of the
importance of adherence to the medication schedule. It is possible
that depot risperidone may have a unique benefit in non-compli-
ant patients, but the included studies do not address this issue.
3. For managers
Currently, no data are available on satisfaction with care or long-
term benefits and we know of no cost-benefit analysis of depot
risperidone. In view of this, it is unclear whether the increased
costs, which would be incurred purchasing the drug and the ad-
ditional arrangements needed to administer it, would be justified.
Implications for research
1. General
Researchers should provide more details when reporting trials so
that it is clear how many people really made significant progress.
There should be more effort to assess people at the end of desig-
nated study period even if they have failed to complete all follow-
up ratings. See Table 1 for a suggested design of future study.
2. Specific
2.1 Reviews
Excluded studieswith data relevant to other reviews are highlighted
in Table 2. Existing reviews are always in the process of update and
the older broad multi-comparison titles may be broken down into
smaller single comparison reviews. Several of the good studies we
had to exclude would find a home in these reviews.
2.2 Trials
This review highlights the need for good quality controlled clini-
cal trials to assess the effect and clinical outcomes of using depot
risperidone for people with schizophrenia. Such studies are diffi-
cult and need different designs if they are to be informative. De-
pots are used for people who do not want to take oral medication.
Such people are difficult to randomise. If they are avoided, in the
case of Chue 2002, the reasonably complete results are difficult to
apply. If this difficult group is not avoided, as in the case of Kane
2002*, the explanatory design results in such a degree of attrition
as to render results almost entirely without meaning. Pragmatic
design could help deal with these problems. People appropriate
for depot risperidone, if in agreement, could be randomised to an
oral antipsychotic or depot risperidone. Outcomes could then be
gathered for events that would be recorded in routine data (dis-
continuation of medication, specific adverse events, hospitalisa-
tion, global improvement whether or not the person stayed on the
allocated treatment).
According to themanufacturers of risperidone, Janssen-Cilag Lim-
ited, the reason why there are so few studies on depot risperidone is
that the compound is unmodified, and is merely delivered differ-
ently. More real world trials are required, to establish the efficacy
and safety of depot risperidone.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bai 2006
Methods Allocation: random.
Blinding: single blind, rater blind.
Duration: 12 weeks.
Design: parallel.
Setting: inpatient, large psychiatric teaching hospital, Taiwan
Participants Diagnosis: schizophrenia (DSM-IV).
Age: 18-65 years.
N = 50.
Sex: 25 M and 25 F.
History: symptomatically stable defined as PANSS total < 80, CGI-no change in score
between screening and baseline, previous treatment with oral risperidone for > 3 months
Included: ’good health’ based on physical examination, medical history and blood bio-
chemistry and haematology
Exclusion: History of NMS or organic CNS disorder; current seizure disorder; current
risk of violent behaviour against others; current suicidal ideas or suicidal ideas in the last
6 months
Consent and ethics: study performed in accordance with the Declaration of Helsinki
and approved by Ethics Review Committee. All participants provided written informed
consent before starting the study
Interventions 1. Risperidone depot: 25 mg, 37.5 mg or 50 mg once every 2 weeks, n = 25
2. Risperidone oral: mean 3.8 +/- 1.6 mg/day, n = 25.
Outcomes Quality of life (SF-36).
Adverse events (recorded spontaneously); AIMS; BARS; SAS; UKU;movement disorder
Mental state: PANSS.
Global state: CGI-S, GAF.
Leaving study early.
Unable to use -
Satisfaction with treatment - non-peer reviewed scale.
Pain at injection site (visual analogue scale) - no SD reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “this trial was a randomized, paral-
lel-group, rater-blind study of 52weeks du-
ration.” No information on how randomi-
sation was achieved
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Bai 2006 (Continued)
Allocation concealment (selection bias) Unclear risk No information.
Blinding (performance bias and detection
bias)
All outcomes
High risk Implied to be an open-label study. Not ex-
plicit, but implied open-label with regard
to participants and study drug administra-
tors. Detection: “rater blind”, but no in-
formation on how the blinding was main-
tained
Incomplete outcome data (attrition bias)
All outcomes
Low risk N = 49 participants completed the study
(98%).
Selective reporting (reporting bias) Low risk All outcomes listed in methods appear to
be reported.
Other bias High risk Funding: supported by Jassen-Cilag Tai-
wan, Johnson & Johnson co
Chue 2002
Methods Allocation: random.
Blinding: double.*
Duration: 12 weeks (preceded by 8-week open-label run-in).
Design: parallel, international multi-centre.
Setting: inpatient, 95 sites, UK, mainland Europe, North America, Africa
Participants Diagnosis: schizophrenia (DSM-IV).
Age: mean 40 ± 15 years, range 18-65.
N = 640.**
Sex: 415 M, 225 F.
History: inpatient or outpatient; PANSS score ≥ 50, but ~47% “not ill or only mildly
ill” on CGI, stabilised 8/52 on oral risperidone
Included: stable CGI scores for the previous 4weeks of the oral risperidone run-in period.
Excluded: moderate or severe symptoms of tardive dyskinesia at study entry; history
of neuroleptic malignant syndrome; known to be unresponsive to risperidone; required
mood stabilisers; treated with clozapine in past 2 months before screening; treated with
a depot antipsychotic within one treatment cycle of screening, or with antidepressants
within 30 days before run-in period
Consent and ethics: study performed in accordance with the Declaration of Helsinki;
consent obtained from participant, relative, guardian or legal representative at study
entry
Interventions 1. Risperidone depot: 25, 50 or 75 mg, every two weeks + daily placebo tablets, n = 319.
2. Risperidone oral: 2, 4 or 6 mg/day + placebo injections every two weeks, n = 321
Outcomes Global state: needing use of benzodiazepines or sedative drugs; CGI (dichotomised)
Mental state: PANSS.
Leaving the study early.
66Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chue 2002 (Continued)
Adverse events: others as reported by participants; death.
Unable to use -
Global state: CGI (data on subgroups only).
Adverse events: ESRS (no usable data).
Body weight: change (no usable data).
Pain at injection site (no usable data).
Physiological tests: including ECG (no usable data).
Notes * Blindness was maintained with different doses by using the same volume of diluent
** Numbers randomised not consistent in presentations (426 vs 640)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was stratified ac-
cording to site, PANSS score, ESRS total
score, use of depot antipsychotics in the
previous 6 months and daily dose of oral
risperidone at randomization” (p112)
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Placebo tablets and injections used to blind
participants. “Double blind” stated but it
is not clearly expressed who exactly was
blinded, cannot be sure if rater blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk N = 541 participants completed the study
(85%). Completer-only data for PANSS
Selective reporting (reporting bias) Unclear risk All outcomes reported, however not all pre-
sented as usable data, particularly continu-
ous data, with no means or SD
Other bias High risk Funding: supported by Janssen Research
Foundation, Beerse, Belgium
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Covell 2012
Methods Allocation: random.
Blinding: open-label, blinded clinical raters.
Duration: 6 months (+ 6 months naturalistic follow-up).
Design: parallel.
Setting: National Institute of Mental Health Schizophrenia Trials Network and five sites
in Conneticut’s public mental health system, USA
Participants Diagnosis: schizophrenia (DSM-IV).
Age: ≥18 years, mean age 48 yrs (risperidone depot: 48.5 ± 12.2; haloperidol/
fluphenazine depot: 47.3 ± 9.1)
N = 62.
Sex: 44 M (22 in each group), 18 F.
History: currently taking fluphenazine decanoate or haloperidol decanoate, “may benefit
from changing medication” and “willing to change”, able to afford own medication, at
least one 3-monthly clinic visit in past 6 months
Included: eligible patients were those who might benefit from switching to risperi-
done microspheres (with sub-optimal response to treatment because of persistent psy-
chopathology or significant side effects); people where change in medical opinion was a
reasonable clinical opinion, but not required; willingness to change antipsychotic med-
ication; access to medication without financial burden; at least 1 clinic visit every 3
months for past 6 months
Excluded: symptom severity indicating immediate change; exacerbation inprevious 3/12;
pregnancy; pending criminal charges; non-independent living; antipsychotic polyphar-
macy
Consent and ethics: written informed consent after thorough description of the study
to participants and assessment of understanding consent materials
Interventions 1. Risperidone depot: 25, 37.5 or 50 mg/ 2 weeks, n = 32.
2. Haloperidol decanoate OR fluphenazine*, n = 30.
*No data on dosages actually prescribed in this arm - “clinician’s judgement”
Outcomes Primary - time to all-cause treatment discontinuation.
Mental state: PANSS (completer-only).
Hospitalisation by 6 months.
Adverse events: Arizona Sexual Experiences Scale; weight; prolactin (completer-only,
skew data)
Unable to use -
AIMS (adapted scale used).
Subjective Side-effect Rating Scale (no data reported).
EPS (SAS); tardive dyskinesia (incomplete data for all participants - only 44% accounted
for)
Tardive dyskinesia (more than 50% participants did not complete assessment)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Covell 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised, quote, “stratified by gender
andbaseline decanoate.No exceptionswere
made to the predetermined randomisation
streams” (p670)
Allocation concealment (selection bias) Unclear risk No details given of how this was achieved.
Quote, “eligible patients were those who
might benefit from a switch to risperidone
microspheres” (p670)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study with assessment by
blinded clinical raters.
Incomplete outcome data (attrition bias)
All outcomes
High risk Data relating to loss to follow-up are given
and overall attrition is < 50%. Lost to fol-
low-up n = 8: reasons for discontinuation
included increase in psychiatric symptoms
(n = 4), EPS concerns (n = 1), participant
preference (n=2), hypertension andweight
gain (n = 1). However, not all participants
completed continuous outcome measures;
LOCF carried forward used in primary
study citation, completer-only data pro-
vided with means and SD for additional re-
quested information (unpublished)
Selective reporting (reporting bias) High risk Not all data reported, including means and
SDs for most continuous outcomes
Other bias Unclear risk Funding: quote, “research presented in this
article was funded by the National In-
stitute of Mental Health grant number
MH71663 and MH59312.” One author
(Schooler) “has previously received grant/
research support from... Janssen-Cilag, and
Johnson & Johnson.”
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Fleischhacker 2011
Methods Allocation: random.
Blinding: double.
Duration: 53 weeks.
Design: parallel.
Setting: international, multi-centre, 19 countries: North America, Australia, New
Zealand, Western and Eastern Europe
Participants Diagnosis: schizophrenia (DSM-IV).
Age: ≥ 18 years of age.
N = 749.
Sex: 444 M, 305 F.
History: DSM-IV diagnosis of schizophrenia for at least one year before screening
Included: PANSS score between 60-120; acutely symptomatic at screening and baseline;
BMI ≥ 15 kg
Excluded: DSM-IV Axis I diagnosis other than schizophrenia; decrease of ≥ 25% in the
PANSS total score between screening and baseline; substance dependence during the
three months preceding screening; history of treatment resistance; history of neuroleptic
malignant syndrome or any significant or unstable systematic disease; suicidal or violent
behaviour; pregnant or nursing or women planning pregnancy
Consent and ethics: Independent Ethics Committee or Institutional Review Board at
each study site approved the protocol. Study conducted in accordance with Declaration
of Helsinki and consistent with Good Clinical Practice (GCP) and applicable regulatory
requirements. All participants provided written informed consent before entry
Interventions 1. Risperidone depot*: IM, 25, 37.5 mg or 50 mg (placebo injections matched to risperi-
done depot on day 1, with first active injection delayed until day 8), n = 370
2. Paliperidone palmitate (PP): IM, 25, 50, 75 or 100 mg eq (placebo injections matched
to PP on day 22 then monthly thereafter), n = 379
*1-6 mg oral risperidone/ placebo supplementation was given for the first 4 weeks of
the double-blind treatment period. Oral risperidone (1-4 mg) supplementation was also
given at any dose increase from day 36 onwards, continuing up to week 3
Outcomes Adverse effects: various events, AIMS, BARS, SAS scores, laboratory results: various
mean change in serum levels, EKGs, evaluations of injection site (all adverse data relate
to participants who received at least one dose of the study drug)
Leaving the study early.
Death.
Unable to use -
Primary outcome: Non inferiority of PP with risperidone (high attrition and unable to
obtain data)
Secondary outcomes: average change in PANSS total score (high attrition and unable to
obtain data)
Global state: relapse, change in CGI-S (high attrition and unable to obtain data)
Social functioning: Change in PSP (high attrition and unable to obtain data)
Mental state: average change in PANSS (high attrition and unable to obtain data)
Notes Antiparkinson medication (at permitted maximum daily doses) as rescue treatment for
EPS; oral lorazepam (2-6 mg) or other short-acting benzodiazepines for agitation, anx-
iety or sleep difficulties; oral propranolol for akithisia were permitted. Antidepressents
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Fleischhacker 2011 (Continued)
permitted if used at a stable dose for at least 30 days before screening
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised: “computer generated ran-
domisation schedule (prepared by the
sponsor), balanced by using permuted
blocks of treatments, stratified by centre
and implemented using an interactive voice
response system (IVRS)”
Allocation concealment (selection bias) Low risk Use of interactive voice response system.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants were not allowed to view the
preparation or administration of the injec-
tion. Blinded raters used to measure out-
comes
Incomplete outcome data (attrition bias)
All outcomes
High risk High study attrition (55%): PP group
drop-out rate at n = 224 (n = 95 lack of
efficacy; n = 29 adverse events; n = 55 pa-
tient choice; n = 13 lost to follow-up; n =
1 pregnancy; n = 2 death; n = 29 other);
risperidone depot group drop-out rate at n
= 186 (n = 56 lack of efficacy; n = 25 ad-
verse events; n = 62 patient choice; n = 11
lost to follow-up; n = 1 pregnancy; n = 0
death; n-31 other)
Selective reporting (reporting bias) Unclear risk Missing outcomes in a supplementary table
(not obtainable - contact made with study
author, but no reply)
Other bias High risk Funding: sponsored by Johnson & John-
son Pharmaceutical Research andDevelop-
ment, L.L.C. The sponsor provided a for-
mal review of the manuscript. Two study
authors (Mr Remmerie and Dr Eerdekens)
were employees of Johnson & Johnson
Pharmaceutical Research and Develope-
ment, Division of Janssen Pharmaceutica
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Gaebel 2010*
Methods Allocation: random.
Blinding: open-label.
Duration: 2 year.
Design: parallel.
Setting: international, multi-centre, 25 countries (Europe).
Participants Diagnosis: schizophrenia or schizoaffective (DSM-IV).
N = 710.
Age:≥ 18 years, mean 40.6 +/- 12.5 in depot risperidone group; 42.6 +/- 13.1 quetiapine
group; 40.9 +/- 12.94 in aripiprazole group
Sex: 442 M, 270 F.
History: symptomatically stable.
Included: switching therapy because of insufficient symptom control with current treat-
ment, side effects or patient request; symptomatically stable- using stable dose of an-
tipsychotic for ≥ 4 weeks and living in same residence for ≥ 30 days
Excluded: previous non-response to risperidone, quetiapine or ≥ 2 antipsychotics de-
spite adequate drug plasma levels; DSM IV axis I diagnosis other than schizophrenia
or schizoaffective disorder; phenylketonuria or hypersensitivity to risperidone or queti-
apine; drug or alcohol dependence during preceding 1 month; acute risk of suicide or
history of suicide attempt
Consent and ethics: study conducted in accordance with guidelines of the International
Conference on Harmonisation for Good Clinical Practice. Study protocol and consent
were approved by ethics committees/ institutional review boards; informed consent ob-
tained from all participants before enrolment
Interventions 1. Risperidone depot: 25-50 mg IM every 2 weeks, n = 329.
2. Quetiapine oral: 25 mg twice a day: day 1, 300- 400 mg by day 4, max 750 mg a day,
n = 337
3. Aripiprazole oral: 10-30 mg per day, n = 46.
Outcomes Adverse events.
Leaving the study early.
Death.
Unable to use - (all due to high attrition)
Time to relapse.
Global state: CGI.
Mental state: PANSS.
Functioning assessment: SOFAS.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation according to pre-
vious treatment.
Allocation concealment (selection bias) Unclear risk No details given.
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Gaebel 2010* (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study.No evidence for any rater
blinding- follow-up methods differed be-
tween treatment groups (phone calls for
quetiapine group and in person with depot
risperidone)
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition: treatment completed by n
= 151/329 in risperidone depot; n = 120/
337 oral quetiapine; n = 9 oral aripiprazole.
Total follow-up of n = 280/710 (39%) -
only leaving study early and adverse event
data used
Selective reporting (reporting bias) Unclear risk Some outcomes comprising relapse are not
reported on their own
Other bias High risk Funding: study sponsored by Janssen-Cilag
Medical Affairs EMEA
Kane 2002*
Methods Allocation: random.
Blinding: double.
Duration: 12 weeks (preceded by up to 4 mg risperidone/day for 1 week).
Design: parallel.
Setting: inpatient and outpatient, multi-centre (41 centres in the USA)
Participants Diagnosis: schizophrenia (DSM-IV).
N = 400.
Age: 18 to 55 years of age; mean~37 ± 20 years.
Sex: 301 M, 99 F.
History: diagnosis of schizophrenia.
Included: baselines PANSS of 60 to 120; good general health; standard laboratory test
results ’within reference ranges or not clinically significant’.
Excluded: received depot in past 120 days before start of trial; substance dependant
diagnosis; tardive dyskinesia; history of neuroleptic malignant syndrome; clinically sig-
nificant ECG abnormality; pregnant (or likely to become pregnant) or lactating; at risk
of violent behaviour; current suicide ideation; history of severe drug sensitivity/ allergy
(sensitivity to risperidone); people who were unresponsive to risperidone
Consent: trial conducted in accordance with ’current ICH-Good Clinical Practice guide-
lines and the Declaration of Helsinki and its subsequent revisions’; written informed
consent obtained from each participant or guardian/ legal representative
Interventions 1. Risperidone depot: 25 mg 2 weekly + 2 mg/day oral risperidone for 3/52, n = 99.
2. Risperidone depot: 50 mg 2 weekly + 4 mg/day oral risperidone for 3/52, n = 100.
3. Risperidone depot: 75 mg 2 weekly + 6 mg/day oral risperidone for 3/52, n = 100.
4. Placebo injections: 2 weekly + placebo tablets for first 3/52, n = 100
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Kane 2002* (Continued)
Outcomes Adverse events: ESRS and others as reported by participants.
Leaving the study early.
Unable to use -
Global state: CGI.
Mental state: 20% reduction PANSS.
Body weight: change.
Pain at injection site.
Physiological tests: including ECG.
Mental state: change PANSS (no SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised: quote, “a dynamic method
(22) was used to randomly assign patients
to treatment groups. Stratification factors
included investigator, inpatient/outpatient
status, andPositive andNegative Syndrome
Scale (23) total score at randomization.”
Allocation concealment (selection bias) Unclear risk No details of allocation concealment.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double blind study” but not clear who ex-
actly was blinded, no indication given of
whether the raters were blinded. Study con-
trolled with “placebo injections that were
identical in appearance [to the study drug
injections]”
Incomplete outcome data (attrition bias)
All outcomes
High risk Greater than 50% attrition by study end.
Selective reporting (reporting bias) Unclear risk Unclear risk
Other bias High risk Funding: “supported by Johnson & John-
son Pharmaceutical Research and develop-
ment, Titusville, N.J.”
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Keks 2007
Methods Allocation: random.
Blinding: open-label.
Duration: 12 months.
Design: parallel.
Setting: international, multi-centre (48 centres in Australia, Belguim, France, Germany,
Greece, Luxumbourg, Poland, Russia, Spain, The Netherlands and UK)
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 629* (n = 11 not treated).
Age: mean~35 years, minimum 18 years.
Sex: 312 M, 235 F.
History: acute exacerbation of psychosis in previous 2 months and another episode
during previous 2 years
Excluded: prior treatment with clozapine or depot antipsychotic
Included: PANSS total score > 50; at least 18 years of age; BMI not exceeding 40 mg/
kg2.
resistance or sensitivity to risperidone or olanzapine
pregnant or breast feeding women, child bearing age women if not using contraception
Consent: study protocol and amendments reviewed by independent ethics committees/
institutional review boards; conducted in accordance with Declaration of Helsinki and
guidelines of International Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use. Written informed consent required
Interventions 1. Risperidone depot: 25, 50 or 75 mg*, n = 318.
2. Oral olanzapine: 5-20 mg/day, n = 300.
Outcomes Mental state: PANSS.
Specific adverse events; movement disorder; death and serious adverse events
Leaving the study early.
Notes *After study initiation protocol was amended to restrict the doses of depot risperidone
to 25 or 50 mg; 64 patients who had already received 75 mg of depot risperidone were
withdrawn from the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, “using a central dynamic ran-
domisation procedure. Randomisation was
based on a minimisation algorithm that
used a probability of assignment other
than 0.5 to maintain balance of treat-
ment groups within levels of each strati-
fication factor” (p132). stratification fac-
tors of PANSS total score, number of pre-
vious psychiatric hospitalisations, BMI, in-
patient or outpatient status, using a central
dynamic randomisation procedure
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Keks 2007 (Continued)
Allocation concealment (selection bias) Low risk Interactive voice response system (IVRS)
used to obtain randomisation number
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study. No evidence of rater
blinding.
Incomplete outcome data (attrition bias)
All outcomes
High risk N= 618 originally randomised and treated;
n = 264 (42%) completed at 12 months.
LOCF used for endpoint data including n
= 361 participants (58%)
Selective reporting (reporting bias) High risk Protocol amended to restrict risperidone
doses to 20 or 50 mg after investigators
found that, quote, “75 mg doses provide
no greater benefit than lower doses” (p132)
. The n = 64 participants receiving 75 mg
doses completed the study, their data were
withdrawn and they were invited to enrol
in an open-label extension study
Other bias High risk Funding: “M.I., A.K. andK.K. are employ-
ees of Johnson & Johnson... study was sup-
ported by Johnson & Johnson Pharmaceu-
tical Research and Development” (p138)
Li 2011
Methods Allocation: random.
Blinding: open-label.
Duration: 12 weeks (with 7 week washout pre-randomisation).
Design: parallel.
Setting: multi-centre, China.
Participants Diagnosis: schizophrenia (DSM-IV).
N = 452.
Age: ≥18 years of age.
Sex: 181 M, 271 F.
History: DSM-IV diagnosis of schizophrenia for at least one year before screening
Included: PANSS total score between 60 to 120; BMI of 17.0 kg/m2 or greater.
Excluded: DSM IV axis I diagnosis other than schizophrenia; 25% decrease in total
PANSS score between screening and baseline; active substance dependence within 3
months; significant risk of suicidal or violent behaviour; presence or history of any
significant or unstable systemic disease; history of treatment resistance towards two
different antipsychotic treatments; pregnancy or planning; clozapine within 3 months
before baseline; RIS-LAI within 6 weeks before screening; PP within 10 months before
baseline; ECT within 60 days before screening
Consent: Independent Ethics Committee or Institutional Review Board at each study
76Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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site approved the protocol; study conducted in accordance with ethical principles of
Declaration of Helsinki, consistent Good Clinical Practices and applicable regulatory
requirements. Written informed consent required
Interventions 1. Risperidone depot: once every two weeks, mean dose 29.8 ± 4.67 mg, n = 223
2. Paliperidone palmitate: once monthly injections, mean dose 115.8 ± 9.07 mg, n =
229
(Plus supplementary oral risperidone for risperidone depot participants: mean daily dose
2.5 ± 0.98 mg from days 1 to 28; 1.8 ± 0.52 mg from day 36 to 57; 1.7 ± 0.47 mg from
day 64 to 85).*
Outcomes Global state: CGI-S scale score change from baseline.
Mental state: change in PANSS total score; number of patients with a 30% or more
reduction in PANSS total score
Adverse events: treatment-emergent adverse events; EPSE; prolactin-related
General functioning; Personal and Social Performance (PSP).
Notes *Other medications permitted, including: antiparkinson medication; benzodiazepines;
beta-blockers; treatment for insomnia; topical anaesthetic cream; antidepressants; indi-
vidual psychotherapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised: (1:1) “based on a com-
puter-generated randomization schedule
balanced by usingpermuted blocks of treat-
ments.”
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label. Rater blinding: “all efficacy as-
sessments were administered and evaluated
by independent, blinded and trained raters
at each site.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk N=350 (77%) completed the study; n = 64
withdrawn from the PP groups for adverse
events (n = 4), pregnancy (n = 2), protocol
deviation (n = 3), lack of efficacy (n = 22)
, lost to follow-up (n = 9), withdrew con-
sent (n = 16), other reasons (n = 8). From
the risperidone depot group, n = 38 were
withdrawn for adverse events (n = 5), pro-
tocol deviation (n = 1), lack of efficacy (n
= 9), lost to follow-up (n = 14), withdrew
consent (n = 5), other reasons (n = 4). ITT
used
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Selective reporting (reporting bias) Unclear risk Not known.
Other bias High risk Funding: “funded by Xian-Janssen Phar-
maceutical Limited, Beijing, PR China.
The sponsor provided a formal review of
the manuscript.” A number of the authors
were employed by Xian-Janssen or Johnson
& Johnson at time of publication
MacFadden 2010
Methods Allocation: random.
Blinding: open-label, rater blind.
Duration: 2 years.
Design: parallel.
Setting: international, multi-centre (USA, South America, India)
Participants Diagnosis: schizophrenia (DSM-IV).
N = 355.
Age: ≥18 years of age.
Sex: 210 M, 139 F.
History: not described.
Included: DSM-IV schizophrenia not controlled by current medication (judged by clin-
ician); 2+ relapses (defined as “psychiatric hospitalisation caused by worsening of psy-
chiatric symptoms; a change in antipsychotic treatment or significant increase in an-
tipsychotic dose because of inadequate efficacy; a newly emergent, clinically important
symptom such as ’suicidality’; or a clinically notable increase in the frequency or intensity
of subject contact”) in the past 2 years. Stable for 2 months before randomisation
Excluded: PANSS≥100, current hospitalisation, major medication changes, or worsen-
ing of psychiatric symptoms within two months before study entry. Current treatment
with clozapine, carbamazepine or depot antipsychotics. Evidence of alcohol or drug de-
pendence (DSM-IV Axis I criteria) within six months before entry
Consent: study conducted in accordance withDeclaration ofHelsinki andGoodClinical
Practice; approved by Institutional Review Board or independent ethics committee at
each centre. Written informed consent required
Interventions 1. Risperidone depot: 25-50 mg/2 weeks, n = 177.
2. Oral aripiprazole: 5-30 mg/daily, n = 172.*
Outcomes Global state: mean time to relapse/time in remission.
Mental state: PANSS.
Specific adverse events; weight; movement disorders; death; serious adverse events
Laboratory tests.
Notes *Other medications permitted, including antidepressants, anxiolytics, mood stabilisers.
At clinician’s judgement, if psychotics symptoms worsened, another antipsychotic was
added (excluding clozapine) for up to seven days; this treatment continued if considered
appropriate by investigators. If this proved ineffective, the investigator had the option to
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use another different secondary antipsychotic
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised: “subjects were randomly as-
signed in a 1:1 ratio” but no details on how
this was achieved
Allocation concealment (selection bias) Unclear risk Concealment not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label, participants and study drug
administrators were not blinded, but with
blinded raters
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The proportions of injectable RLAT and
aripiprazole subjects who discontinued the
study before completing two years were 29.
6% and 28.4%, respectively” and reasons
for discontinuation are given. Of the orig-
inal n = 355 randomised, n = 346 were in-
cluded in ITT analysis
Selective reporting (reporting bias) Unclear risk None detected.
Other bias High risk Study authors employed by Janssen:
“Dr. Macfadden was with Ortho-McNeil
Janssen Scientific Affairs, LLC, Titusville,
New Jersey, at the time of this analysis; Drs.
Ma and Haskins are with Johnson & John-
son Pharmaceutical Research and Devel-
opment, LLC, Titusville, New Jersey; and
Drs. Bossie and Alphs are with Ortho-Mc-
Neil Janssen Scientific Affairs, LLC, Ti-
tusville, New Jersey.”
Pandina 2011
Methods Allocation: random.
Blinding: double.
Duration: 13 weeks.
Design: parallel, double dummy, non-inferiority comparative study
Setting: international multi-centre, 89 centres from 14 countries (Bulgaria; Czech Re-
public; Estonia; Hungary; Lithuania; Poland; Russia; Ukraine; USA; Austria; France;
Germany; Spain; India)
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Participants Diagnosis: schizophrenia (DSM-IV).
N = 1220.
Age: ≥18 years of age.
Sex: 701 M, 513 F.
History: 65% PP and 69% RIS-LAI participants were receiving atypical antipsychotics
prior to study, with oral risperidone used by similar percentage of participants in each
group;
Included: PANSS total score between 60 and 120, BMI ≥17 kg/m2 and <40 kg/m2;
schizophrenia DSM-IV criteria for >1 year.
Excluded: DSM-IV Axis I diagnoses other than schizophrenia; decrease in at least 25%
in PANSS total from screening to baseline; substance dependence within 3 months
before screening; history of treatment resistance; significant unstable systemic disease;
suicidal or violent behaviour; previously received injections of PP and treatment with any
other ’disallowed’ medications (including mood stabilisers, lithium and anticonvulsants)
; exposure to an experimental drug, biologic or medical device within past 6 months pre-
screening; pregnancy/ planning or currently nursing
Consent: Independent Ethics Committee or Institutional Review Board at each study
site approved protocol and amended protocol. Study conducted in accordance with
DeclarationofHelsinki andGoodClinical Practice guidelines.Written informed consent
required
Interventions 1. Risperidone depot: bi-weekly, oral supplementation (1 mg; mean final dose 3.3 ± 1.
59 mg) and placebo injections (matched to PP); 25, 37.5 and 50 mg; mean final dose
31.7 ± 9.28 mg, n = 613
2. Paliperidone palmitate (PP): initiation regimen*, monthly PP injections, placebo
injections (matched to RIS) and placebo oral supplementation; 50, 100 and 150 mg
equivalents; mean final dose 104.5 ±3 0.51 mg, n = 607
Outcomes Global state: CGI- S score change; Shedule for Deficit Syndrome
Mental state: PANSS total score change; responder rate with more than 30% reduction
in PANSS
Adverse events: treatment-emergent adverse events; EPS rating scales; Simpson and An-
gus Rating scale; BARS; AIMS
General functioning: Personal and Social Performance (PSP).
Notes *PP deltoid injections day 1, 150 mg eq, day 8, 100 mg eq and subsequent flexible dosing
(50, 100 or 150 mg eq) once a month
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised: 1:1, computer-
generated randomisation scheme, stratified
by centre, implemented by an interactive
voice response system
Allocation concealment (selection bias) Low risk Interactive voice response system used.
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Blinding (performance bias and detection
bias)
All outcomes
Low risk Study drug administrator was the only per-
son to contact IVRS to receive medication
number and was not allowed to commu-
nicate patient-related information to study
site personal or to perform any efficacy
and safety assessment. Patient and staff per-
forming study-related procedures were to
be precluded from seeing the contents of
syringe or observing the injection
Incomplete outcome data (attrition bias)
All outcomes
Low risk N = 927 (76%) completed the study (n =
456 in PP; n = 471 in RIS-LAI); n = 151
withdrawn from PP group (n = 55 with-
drawn consent, n = 40 lack of efficacy, n =
20 adverse events, n = 11 lost to follow-up,
n = 2 death, n = 1 pregnancy, n = 22 ’other’)
; n = 142 withdrawn from RIS-LAI group
(n = 52 withdrawn consent, n = 43 lack of
efficacy, n = 10 adverse event, n = 18, lost to
follow-up, n = 19 ’other’). ’Safety analysis’
conducted (n = 1214), which included all
participants that had received at least one
dose of the study drug
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias High risk Funding: “Johnson&JohnsonPharmaceu-
tical Research and Development, L.L.C.
funded this study and was responsible for
study design and data collection, analysis
and its interpretation...” (p225). Many of
the authors are employees of Johnson &
Johnson Pharmaceutical Research and De-
velopment, L.L.C
Quinn 2012*
Methods Allocation: random.
Blinding: open-label.
Duration: 24 months.
Design: parallel.
Setting: multi-centre, Canada.
Participants Diagnosis: schizophrenia, schizophreniform disorder or schizoaffective disorder (DSM-
IV)
N = 85.
Age: risperidone depot mean 22.5 +/- 3.12 years of age; oral SGA mean 23.0 +/- 2.93
years of age
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Sex: 65 M, 12 F.
History: early onset (within the past 3 years) of psychosis.
Included: no inclusion criteria stated.
Excluded: no exclusion criteria stated.
Consent: no details.
Interventions 1. Risperidone depot: every 2 weeks, median dose at 18 weeks 25 mg; at 9, 12 and final
visit 37.5 mg, n = 45
2. Oral second generation antipsychotics (risperidone, olanzapine or quetiapine) (dosage
not specified), n = 40
Outcomes Leaving the study early (discontinuation).
Global state (relapse).
Specific adverse events.
Unable to use -
Mental state: PANSS; Global state: CGI-S; Anxiety: Hamilton Anxiety scale; SAFS
(unclear as to participant numbers within groups)
Time to stabilisation (no SD).
Notes Note: extractable data limited due to only available results from this study derived from
conference poster
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote, “patients were randomized” - no
further details.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label described - no further details.
Incomplete outcome data (attrition bias)
All outcomes
High risk N = 46 (54%) discontinued the study;
Selective reporting (reporting bias) Unclear risk Conference poster, therefore results for all
outcomes were not provided
Other bias High risk Quinn AM and Mitchell D are both em-
ployees of Janssen Inc and Johnson and
Johnson Stockholders; Camacho F is con-
sultant to Janssen Inc; Chue P has received
research and travel grants from Janssen,
Pfizer, Eli Lilly, AstraZeneca, Sunovion,
Lundbeck, GlaxoSmithKline, Bristol May-
ers Squibb, Mylan, Novartis and Hoffman
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La Roche, Mella
Rosenheck 2011
Methods Allocation: random.
Blinding: single (rater).
Duration: 2 years.
Design: parallel.
Setting: multi-centre, 14 Veteran Affairs (VA) medical centres, inpatient, USA
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 382.
Age: ≥ 18 years of age.
Sex: not stated.
History: 64% participants reported problems with medication adherence in past (43%
patient-reported, and 60% physician-reported); 37% participants reported active prob-
lems with alcohol or drug use (25% patient-reported, and 36% physician-reported)
Included: at risk of hospitalisation as evidenced by current hospitalisation; hospitalisation
in the previous 2 years, or increased use of services to prevent relapse
Excluded: detoxification in the previous month; past intolerance to risperidone or IM
injections; current treatment with long-acting injectable antipsychotics; oral clozapine,
warfarin or a combination of those agents; serious medical conditions; unstable living
arrangements; and a history of assault or suicidal behavior requiring urgent intervention
Consent: guardian or participant consent permitted; participants’ decisional capacity
assessed with MacArthur Competence Assessment Tool
Interventions 1. Risperidone depot: 25 mg to 50 mg every 2 weeks; dosage increments of 12.5 mg
permitted every 4 weeks at discretion of treating physician, n = 190
2. Oral antipsychotics: as prescribed by treating physician, n = 192*
Outcomes Service utilisation: hospitalisation; outpatient care.
Global state: use of benzodiazepines or sedative drugs.
Adverse events: death; other specific events.
Not receiving allocation study medication.
Leaving the study early: any reason.
Unable to use -
Global state: CGI (follow-up rates less than 50%).
Metal State: Total PANSS score and Positive, negative and general subscale (follow-up
rates less than 50%)
Quality of life: Heinrichs-Carpenter Quality of Life Scale, Personal and Social Perfor-
mance scale (PSP), Quality of well being scale (follow-up rates less than 50%)
Adverse events: BARS; Abnormal involuntary movements rating scale; Simpson and
Angus rating scale for extrapyramidal side effects (follow-up rates less than 50%)
Notes *Concomitant psychotropic medication (anti-anxiety, anti-depressants, oral antipsy-
chotics and mood stabilisers, as well as anticholinergic medications were permitted
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly permuted blocks of various size,
centrally conducted and stratified accord-
ing to site
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Single blind (implied). Blinded video con-
ference assessment for some measures, but
others assessed in unblinded meetings
Incomplete outcome data (attrition bias)
All outcomes
High risk Of n = 382 randomised, n = 237 completed
the study; including n = 75 oral antipsy-
chotic treatment (n = 7 declined participa-
tion and did not receive intervention; n =
65 ’lost to follow-up or discontinued’; n = 3
excluded because participant did not have
a Social Security number or baseline data)
, and n = 74 in risperidone depot group (n
= 2 declined participation and did not re-
ceive intervention; n = 71 ’lost to follow-up
or discontinued’; n = 1 excluded because
participant did not have a Social Security
number or baseline data). ITTanalysis used
- follow-up rates in this analysis group in-
cluded n = 223 (60%) at year 1; n = 170
(46%) at 18 months; n = 107 (29%) at 24
months. Of the deaths, in the risperidone
group, n = 1 died in his sleep and n = 1
took his own life; in the oral antipsychotic
group, n = 1 died from chronic obstructive
pulmonary disease and n = 1 from acciden-
tal drowning
Selective reporting (reporting bias) Low risk Supplemental pages cover all outcomes.
Other bias Unclear risk Industry funded study but stated that
Janssen had no involvement beyond finan-
cial and intervention drug provision
AIMS: Abnormal Involuntary Movement Scale
BARS: Barnes Akathisia Rating Scale
BMI: body mass index
CGI: Clinical Global Impression
CNS: central nervous system
DSM-IV: Diagnostic and Statistical Mannual version 1V
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EPS: extrapyramidal symptoms
ESRS: Extrapyramidal Symptom Rating Scale
GAF: Global Assessment of Functioning
IM: intramuscular
ITT: intention to-treat
LOCF: last observation carried forward
N =: number of participants
NMS: neuroleptic malignant syndrome
PANSS: Positive And Negative Symptom Scale
PP: paliperidone palmitate
PSP: Personal and Social Performance Scale
RIS-LAI: risperidone long-acting injectable
SAFS: Social and Functioning Assessment Scale
SAS: Simpson and Angus Rating scale
SD: Standard Deviation
SF36: short form 36
SGA: Second-generation antipsychotic
SOFAS: Social and Occupational Functioning Assessment Scale
UKU:Udvalg for Kliniske Undersgelser side effects rating scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agid 2010 Allocation: not a randomised controlled trial.
Bouchard 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral risperidone versus conventional antipsychotic drugs (not depot risperidone)
Canas 2010 Allocation: not randomised; review article.
DeMartinis 2012a Allocation: randomised.
Participants: people with schizophrenia.
Intervention: not depot risperidone.
1. PF-02545920: 5 mg and 15 mg (titrated fixed doses. 3 mg (titrated).
2. Risperidone (oral) twice a day: 3 mg titrated.
3. Placebo.
Eerdekens 2002 a Allocation: not randomised; open-label.
Eerdekens 2002 b Allocation: not randomised; review.
Gallhofer 1995 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus haloperidol or fluphenazine, not depot risperidone
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Geffen 2012 Allocation: randomised.
Participants: people with chronic schizophrenia.
Intervention: BL-1020: 10 mg/day, BL-1020: 20 - 30 mg/day, risperidone (oral): 2 - 8 mg/day, placebo, not
depot risperidone
Gefvert 2001 Allocation: not a randomised controlled trial.
Kogeorgos 1995 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: sulpiride or risperidone versus chlorpromazine, trifluoperazine or haloperidol, not depot risperi-
done
Koola 2009 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: long-acting injectable risperidone or oral atypical antipsychotics
Outcomes: no useable data, only levels of insight and relapse at baseline
Lindenmayer 1995 Allocation: non-randomised comparison of two samples taken from randomised trials
Litman 2014 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: AZD8529 40 mg, risperidone (oral) 4 mg, or placebo, not depot risperidone
Littrell 1999 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus olanzapine, not depot risperidone
Liu 2014f Allocation: randomised.
Participants: people with early stage schizophrenia.
Intervention: minocycline or placebo, not depot risperidone.
Lloyd 2010 Allocation: not randomised.
Macfadden 2008 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: 25 mg or 50 mg of risperidone depot no other comparison group (post-hoc analysis from another
study)
McClure 2009a Allocation: randomised.
Participnats: females with schizotypal personality disorder, not schizophrenia
Pikalov 2012a Allocation: not randomised, a review of studies.
Procyshyn 2010 Allocation: non-random, pilot study.
Ritchie 1999 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus olanzapine, not depot risperidone
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Robinson 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus olanzapine, not depot risperidone
Schmechtig 2010 Allocation: randomised.
Participants: people with subclinical levels of schizophrenia-like symptoms
(high schizotypy).
Intervention: nicotine, risperidone, amisulpride or placebo, not depot risperidone
Simpson 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: two doses of depot risperidone, no control.
Vaughan 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: not a drug trial, study of effect of community treatment orders
Verma 2010 Interventions: participants switched to depot risperidone with no other comparison group
Weiden 2007 Allocation: randomised to recommendation of treatment.
Wiffen 2010 Allocation: non-randomised; depot risperidone was the only intervention
Characteristics of studies awaiting assessment [ordered by study ID]
Nasrallah 2002
Methods Randomised.
Participants People with schizophrenia.
Interventions Long-acting risperidone, placebo.
Outcomes Unsure
Notes Both conference abstracts, reports quality of life data with depot risperidone but it may be part of one of the included
studies (Kane 2002*). Authors have been contacted for more details
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Methods Allocation: randomised.
Blinding: unclear.
Setting: not stated.
Duration: not stated.
Participants Diagnosis: schizophrenia, first episode
N = 87
Age: not stated
Sex: not stated
History: not stated
Included: not stated
Excluded: not stated
Consent: not stated
Interventions 1. Risperidone depot, n = 18
2. Oral antipsychotic treatment, n = 21
Outcomes PAS Scale, neuropsychological battery, diagnostic assessment (SCID-I) and stability at one year follow-up, clinical
assessment (PANSS; CGI; SUMD; HDRS and YMRS), functional assessment (GAF), quality of life (WHO/DAS),
hospitalisations, urgency episodes and treatment compliance
Notes Unable to extract any usable data from the published conference poster and abstract. Number of total included
participants does not match numbers randomised
Turner 2000
Methods Allocation: unsure
Participants Diagnosis: schizophrenia
Interventions 1. Risperidone depot
2. Risperidone tablets
Outcomes Unsure.
Notes Unable to find any details: authors have been contacted for more details
CGI: Clinical Global Impression
GAF: Global Assessment of Functioning
HDRS: Hamilton Rating Scale for Depression
PANSS: Positive and Negative Syndrome Scale
PAS: Psychogeriatric Assessment Scale
SCID-1: Structured Clinical Interview for DSM-IV Axis I Disorders
SUMD: Scale to Assess Unawareness of Mental Disorder
YMRS: Young Mania Rating Scale
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D A T A A N D A N A L Y S E S
Comparison 1. RISPERIDONE DEPOT vs PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1. Change
(exacerbation) in specific
symptoms
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 anxiety - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.32, 1.05]
1.2 agitation - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.39, 0.92]
1.3 hallucinations - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.47, 3.22]
1.4 nervousness - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.12, 1.25]
1.5 psychosis - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.33, 0.83]
2 Leaving the study early: 1. Any
reason (by time period)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 very early on (<1 injection) 1 400 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.55, 3.08]
2.2 by 12 weeks 1 400 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.63, 0.88]
3 Leaving the study early: 2. Any
reason (by doses)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 all doses risperidone depot
- short term
1 400 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.63, 0.88]
3.2 25mg risperidone depot -
short term
1 197 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.59, 0.94]
3.3 50mg risperidone depot -
short term
1 201 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.59, 0.93]
3.4 75mg risperidone depot -
short term
1 198 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.60, 0.94]
4 Leaving the study early: 3.
Because of insufficient response
(by doses)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 all three doses - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.36, 0.79]
4.2 25mg depot risperidone
group - short term
1 197 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.45, 1.17]
4.3 50mg depot risperidone
group - short term
1 201 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.27, 0.83]
4.4 75mg depot risperidone
group - short term
1 198 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.21, 0.72]
5 Adverse events: 1. General: a.
Death
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.00, 2.65]
6 Adverse events: 1. General: b.
Severe adverse event (by doses)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 any dose risperidone depot
- short term
1 400 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.38, 0.93]
6.2 25mg risperidone depot -
short term
1 197 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.30, 1.04]
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6.3 50mg risperidone depot -
short term
1 201 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.32, 1.06]
6.4 75mg risperidone depot -
short term
1 198 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.36, 1.15]
7 Adverse events: 1. General: c.
Adverse event necessitating
withdrawal from study (by
doses)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 any dose risperidone depot
- short term
1 400 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.54, 1.84]
7.2 25mg risperidone depot -
short term
1 197 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.42, 1.96]
7.3 50mg risperidone depot -
short term
1 201 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.45, 2.02]
7.4 75mg risperidone depot -
short term
1 198 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.56, 2.35]
8 Adverse events: 2. Specific: a.
Cardiovascular
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 dizziness - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.62, 3.43]
8.2 tachycardia - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.11, 0.98]
9 Adverse events: 2. Specific: b.
Gastrointestinal
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 constipation - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 6.17 [0.84, 45.46]
9.2 diarrhoea - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.23, 3.20]
9.3 nausea - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.39, 2.76]
9.4 vomiting - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.23, 1.57]
10 Adverse events: 2. Specific:
c. Movement disorders: a.
Extrapyramidal disorder -
spontaneously reported (by
doses)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 all doses of depot
risperidone - short term
1 400 Risk Ratio (M-H, Random, 95% CI) 2.38 [0.73, 7.78]
10.2 25mg risperidone group
- short term
1 197 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.30, 5.74]
10.3 50mg risperidone group
- short term
1 201 Risk Ratio (M-H, Random, 95% CI) 2.54 [0.69, 9.29]
10.4 75mg risperidone group
- short term
1 198 Risk Ratio (M-H, Random, 95% CI) 3.27 [0.93, 11.51]
11 Adverse events: 2. Specific:
d. Movement disorders: b.
Hyperkinesia (by doses)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 all doses of risperidone -
short term
1 400 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.60, 4.84]
11.2 25mg risperidone group
- short term
1 197 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.09, 2.64]
11.3 50mg risperidone group
- short term
1 201 Risk Ratio (M-H, Random, 95% CI) 2.14 [0.68, 6.73]
11.4 75mg of risperidone
group - short term
1 198 Risk Ratio (M-H, Random, 95% CI) 2.45 [0.79, 7.55]
90Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
12 Adverse events: 2. Specific:
e. Movement disorders: c.
Hypertonia (by doses)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 all doses of depot
risperidone - short term
1 400 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.47, 3.22]
12.2 25mg risperidone - short
term
1 197 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.22, 2.86]
12.3 50mg risperidone - short
term
1 201 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.28, 3.19]
12.4 75mg risperidone - short
term
1 198 Risk Ratio (M-H, Random, 95% CI) 1.96 [0.70, 5.53]
13 Adverse events: 2. Specific: f.
Pain
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 headache - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.88, 2.80]
13.2 pain - unspecified - short
term
1 400 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.48, 4.00]
14 Adverse events: 2. Specific: g.
Salivation
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 decreased - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 2.92 [0.37, 22.76]
14.2 increased - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 2.92 [0.37, 22.76]
15 Adverse events: 2. Specific: h.
Sleep disturbances
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 insomnia - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.60, 1.82]
15.2 somnolence - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 2.27 [0.69, 7.45]
16 Adverse events: 2. Specific: i.
Weight gain
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 all doses of depot
risperidone - short term
1 400 Risk Ratio (M-H, Random, 95% CI) 2.11 [0.48, 9.18]
16.2 25mg risperidone - short
term
1 197 Risk Ratio (M-H, Random, 95% CI) 2.47 [0.49, 12.45]
16.3 50mg risperidone - short
term
1 201 Risk Ratio (M-H, Random, 95% CI) 1.90 [0.36, 10.16]
16.4 75mg risperidone - short
term
1 198 Risk Ratio (M-H, Random, 95% CI) 1.96 [0.37, 10.46]
17 Adverse events: 2. Specific: j.
Others
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 coughing - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.32, 2.95]
17.2 fatigue - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 8.82 [0.53, 147.05]
17.3 injury - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.13, 1.10]
17.4 rhinitis - short term 1 400 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.47, 2.17]
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Comparison 2. RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Relapse (any
reason)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 long term 1 63 Risk Ratio (M-H, Random, 95% CI) 2.13 [0.84, 5.43]
2 Global state: 2. Needing use
of benzodiazepine or sedative
drugs
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 long term 1 369 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.68, 1.47]
3 Service utilisation: 1.
Hospitalisation
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 long term 1 369 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.68, 1.10]
4 Service utilisation: 2. Outpatient
care - number of outpatient
visits (skewed data)
Other data No numeric data
4.1 long term Other data No numeric data
5 Not receiving allocated study
medication
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 long term 1 382 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.06, 1.37]
6 Leaving the study early: 1. Any
reason
2 467 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.98, 1.57]
6.1 long term 2 467 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.98, 1.57]
7 Leaving the study early: 2.
Specific
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 insufficient response -
long term
1 382 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.15, 2.50]
7.2 withdrawn consent - long
term
1 382 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.86, 2.31]
8 Adverse events: 1. General: a.
Death
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 long term 1 382 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.14, 7.10]
9 Adverse events: 2. Specific 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 anxiety - long term 1 85 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.42, 4.60]
9.2 diabetes mellitus - long
term
1 369 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.73, 3.96]
9.3 dizziness - long term 1 85 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.53, 4.19]
9.4 fatigue/somnolence - long
term
1 85 Risk Ratio (M-H, Random, 95% CI) 2.05 [0.78, 5.40]
9.5 gastrointestinal - long
term
1 369 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.95, 1.28]
9.6 general disorders and
administration site conditions -
long term
1 369 Risk Ratio (M-H, Random, 95% CI) 1.31 [1.02, 1.69]
9.7 headache - long term 1 85 Risk Ratio (M-H, Random, 95% CI) 2.80 [1.12, 7.00]
9.8 insomnia - long term 1 85 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.77, 3.91]
9.9 nausea/ vomiting - long
term
1 85 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.50, 6.97]
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9.10 prolactin related - long
term
1 85 Risk Ratio (M-H, Random, 95% CI) 10.27 [0.59, 180.05]
9.11 weight increase - long
term
1 85 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.56, 3.17]
10 Adverse events: Nervous system
disorders (inc. EPS)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 long term 1 369 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.13, 1.58]
Comparison 3. RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Moderate to
severely ill at end of study
period (CGI rating)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 short term 1 640 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.92, 1.22]
2 Global state: 2. Mean change
from baseline (CGI-S, high
score = worse)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 short term 1 50 Mean Difference (IV, Random, 95% CI) -0.04 [-0.25, 0.17]
3 Global state: 3. Mean (SD) GAF
score change to endpoint
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 short term 1 50 Mean Difference (IV, Random, 95% CI) -0.8 [-5.66, 4.06]
4 Global state: 4. Needing use
of benzodiazepine or sedative
drugs
2 690 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.74, 1.02]
4.1 short term 2 690 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.74, 1.02]
5 Mental state: 1. Average
change/endpoint scores
(PANSS, high score = worse)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 mean total (non ITT data) 1 541 Mean Difference (IV, Random, 95% CI) 0.0 [-2.91, 2.91]
5.2 average change: 1. total
(non ITT data)
2 591 Mean Difference (IV, Random, 95% CI) 1.05 [-0.77, 2.88]
5.3 average change: 2. positive
(non-ITT data)
2 591 Mean Difference (IV, Random, 95% CI) 0.83 [-0.69, 2.35]
5.4 average change: 3. negative
(non ITT data)
2 591 Mean Difference (IV, Random, 95% CI) 0.03 [-0.76, 0.82]
5.5 average change: 4.
disorganised thoughts
1 541 Mean Difference (IV, Random, 95% CI) 0.10 [-0.45, 0.65]
5.6 average change: 5.
hostility/excitement
1 541 Mean Difference (IV, Random, 95% CI) 0.10 [-0.18, 0.38]
5.7 average change: 6.
anxiety/depression
1 541 Mean Difference (IV, Random, 95% CI) 0.10 [-0.45, 0.65]
6 Leaving the study early: 1. Any
reason
2 690 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.92, 1.79]
6.1 short term 2 690 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.92, 1.79]
7 Leaving the study early: 2.
Specific
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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7.1 adverse events - short term 1 640 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.62, 2.35]
7.2 insufficient response -
short term
1 640 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.63, 3.64]
7.3 withdrawn consent - short
term
1 640 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.65, 2.66]
8 Quality of life: Mean (SD)
SF-36 score change/endpoint
(high score = better)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Physical component
summary
1 50 Mean Difference (IV, Random, 95% CI) 1.4 [-2.64, 5.44]
8.2 Mental component
summary
1 50 Mean Difference (IV, Random, 95% CI) -0.20 [-5.06, 4.66]
8.3 Role physical 1 50 Mean Difference (IV, Random, 95% CI) 1.0 [-20.71, 22.71]
8.4 Role emotional 1 50 Mean Difference (IV, Random, 95% CI) -10.60 [-34.13, 12.
93]
8.5 Vitality 1 50 Mean Difference (IV, Random, 95% CI) -1.6 [-10.24, 7.04]
8.6 General health 1 50 Mean Difference (IV, Random, 95% CI) -2.60 [-13.14, 7.94]
8.7 Mental health 1 50 Mean Difference (IV, Random, 95% CI) 5.8 [-5.20, 16.80]
8.8 Bodily pain 1 50 Mean Difference (IV, Random, 95% CI) 3.70 [-9.89, 17.29]
8.9 Physical function 1 50 Mean Difference (IV, Random, 95% CI) -4.6 [-14.25, 5.05]
8.10 Social function 1 50 Mean Difference (IV, Random, 95% CI) 18.5 [3.98, 33.02]
9 Adverse events: 1. General 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 any - short term 1 640 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.91, 1.18]
9.2 death - short term 1 640 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.20]
10 Adverse events: 1. General:
UKU average change score
(high = worse)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 short term 1 50 Mean Difference (IV, Random, 95% CI) -1.99 [-3.59, -0.39]
11 Adverse events: 2. Specific 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 anxiety 1 640 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.84, 2.34]
11.2 psychosis 1 640 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.58, 2.24]
11.3 prolactin related 1 640 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.15, 1.65]
11.4 impotence/ejaculation
failure
1 640 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.20]
11.5 dysmenorrhoea 1 640 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.06, 16.02]
11.6 hyperprolactinaemia 1 640 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.18]
11.7 galactorrhoea 1 640 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.14, 7.10]
11.8 headache 1 640 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.66, 1.95]
11.9 insomnia 1 640 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.66, 1.74]
11.10 sexual dysfunction 1 640 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.05, 5.52]
12 Adverse events: 2. Specific:
Mean (SD) weight increase in
kg
1 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 short term 1 640 Mean Difference (IV, Random, 95% CI) 0.2 [-0.35, 0.75]
13 Adverse events: 3. Movement
disorder
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 any extra pyramidal
symptoms - short term
1 640 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.59, 1.88]
13.2 participants requiring
anti-cholinergic drugs - short
term
2 690 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.66, 1.60]
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13.3 tardive dyskinesia - short
term
1 640 Risk Ratio (M-H, Random, 95% CI) 9.06 [0.49, 167.52]
14 Adverse events: Mean (SD)
change in movement disorder
rating scales
1 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 AIMS 1 50 Mean Difference (IV, Random, 95% CI) 1.16 [-1.23, 3.55]
14.2 BARS 1 50 Mean Difference (IV, Random, 95% CI) 0.16 [-0.65, 0.97]
14.3 SAS 1 50 Mean Difference (IV, Random, 95% CI) -0.55 [-3.71, 2.61]
Comparison 4. RISPERIDONE DEPOT vs ORAL QUETIAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Leaving the study early: 1. Any
reason
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 long term 1 666 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.74, 0.95]
2 Leaving the study early: 2.
Specific
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 due to relapse - long term 1 666 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.40, 0.73]
3 Adverse events: 1. General 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 any 1 666 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.09]
3.2 serious 1 666 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.62, 1.13]
3.3 death 1 666 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.26, 9.14]
4 Adverse events: 2. Specifc 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 psychiatric symptoms 1 666 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.84, 1.19]
4.2 prolactin related 1 666 Risk Ratio (M-H, Random, 95% CI) 3.07 [1.13, 8.36]
4.3 hyperprolactinaemia 1 666 Risk Ratio (M-H, Random, 95% CI) 8.81 [3.53, 21.96]
4.4 serious psychiatric
symptoms
1 666 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.58, 1.16]
4.5 weight increase 1 666 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.63, 1.99]
4.6 headache 1 666 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.64, 2.26]
4.7 fatigue/somnolence 1 666 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.07, 0.38]
5 Adverse events: 2. Specific: Mean
(SD) weight increase in kg
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 long term 1 666 Mean Difference (IV, Random, 95% CI) 1.25 [0.25, 2.25]
6 Adverse events: 3. Movement
disorder
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 any extra pyramidal
symptom
1 666 Risk Ratio (M-H, Random, 95% CI) 1.83 [1.07, 3.15]
6.2 tremor 1 666 Risk Ratio (M-H, Random, 95% CI) 5.12 [1.13, 23.20]
6.3 tardive dyskinesia 1 666 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.04, 3.27]
6.4 dystonia 1 666 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.05, 5.62]
6.5 parkinsonism 1 666 Risk Ratio (M-H, Random, 95% CI) 2.56 [1.01, 6.52]
6.6 hyperkinesia 1 666 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.70, 3.96]
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Comparison 5. RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Relapse (any
reason)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 long term 1 349 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.83, 1.33]
2 Global state: 3. Mean time in
remission (days)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 long term 1 348 Mean Difference (IV, Random, 95% CI) 16.80 [-43.59, 77.
19]
3 Mental state: 1. Average change
scores (PANSS, high score =
worse)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 long term 1 349 Mean Difference (IV, Random, 95% CI) -0.10 [-3.15, 2.95]
4 Leaving the study early: 1. Any
reason
2 723 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.53, 1.30]
4.1 long term 2 723 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.53, 1.30]
5 Leaving the study early: 2.
Specific
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 adverse events 2 723 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.05, 3.55]
5.2 insufficient response 1 349 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.29, 5.70]
5.3 withdrawn consent 2 723 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.67, 1.52]
5.4 due to relapse 1 374 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.36, 1.06]
5.5 loss to follow-up 1 349 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.83, 3.68]
6 Adverse events: 1. General 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 any 2 729 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.14]
6.2 serious 2 729 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.66, 1.39]
6.3 death 2 729 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.13, 7.36]
7 Adverse events: 2. Specific 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 anxiety 1 355 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.75, 1.94]
7.2 depression 1 355 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.85, 2.90]
7.3 psychosis 1 355 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.69, 1.56]
7.4 psychiatric symptoms 1 374 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.60, 1.09]
7.5 serious psychiatric
symptoms
1 374 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.27, 2.08]
7.6 schizophrenia 1 355 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.63, 1.64]
7.7 prolactin related 2 729 Risk Ratio (M-H, Random, 95% CI) 9.91 [2.78, 35.29]
7.8 hyperprolactinaemia 1 374 Risk Ratio (M-H, Random, 95% CI) 12.13 [0.76, 193.65]
7.9 weight increase 1 374 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.38, 6.45]
7.10 nausea/vomiting 1 349 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.64, 2.43]
7.11 gastrointestinal 1 374 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.14, 0.55]
7.12 decreased appetite 1 355 Risk Ratio (M-H, Random, 95% CI) 1.78 [1.00, 3.16]
7.13 diarrhoea 1 355 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.31, 1.24]
7.14 headache 2 729 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.46, 1.65]
7.15 insomnia 1 355 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.65, 1.27]
7.16 upper resp. tract
infection
1 355 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.16, 0.89]
7.17 pyrexia 1 355 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.69, 1.97]
7.18 nasopharyngitis 1 355 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.58, 2.10]
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7.19 dizziness 1 355 Risk Ratio (M-H, Random, 95% CI) 1.89 [1.00, 3.58]
7.20 glucose related 1 355 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.58, 2.10]
8 Adverse events: 2. Specific 12.
Mean (SD) weight increase in
kg
1 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 long term 1 355 Mean Difference (IV, Random, 95% CI) 1.0 [-0.42, 2.42]
9 Adverse events: 3. Movement
disorder
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 any extra pyramidal
symptoms
2 729 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.91, 1.55]
9.2 tremor 1 355 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.65, 1.41]
9.3 akathisia 1 355 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.55, 1.76]
Comparison 6. RISPERIDONE DEPOT vs ORAL OLANZAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1. Average change
scores (PANNS, high score =
worse)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 total - short term 1 377 Mean Difference (IV, Random, 95% CI) 0.90 [-2.25, 4.05]
1.2 total - long term 1 361 Mean Difference (IV, Random, 95% CI) 0.10 [-3.96, 4.16]
1.3 positive symptoms - long
term
1 361 Mean Difference (IV, Random, 95% CI) -0.30 [-1.61, 1.01]
1.4 negative symptoms - long
term
1 361 Mean Difference (IV, Random, 95% CI) 0.10 [-1.28, 1.48]
1.5 disorganised thoughts -
long term
1 361 Mean Difference (IV, Random, 95% CI) -0.30 [-1.34, 0.74]
1.6 hostility/excitement - long
term
1 361 Mean Difference (IV, Random, 95% CI) 0.20 [-0.60, 1.00]
1.7 anxiety/depression - long
term
1 361 Mean Difference (IV, Random, 95% CI) 0.30 [-0.46, 1.06]
2 Leaving the study early: 1. Any
reason
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 long term 1 618 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.10, 1.58]
3 Leaving the study early: 2.
Specific
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 adverse events 1 547 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.28, 1.77]
3.2 insufficient response 1 547 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.49, 1.35]
3.3 withdrawn consent 1 547 Risk Ratio (M-H, Random, 95% CI) 2.54 [1.56, 4.16]
3.4 due to weight gain 1 547 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.03, 2.07]
4 Adverse events: 1. General 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 serious 1 547 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.80, 1.51]
4.2 death 1 618 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.06, 1.55]
5 Adverse events: 2. Specific 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 agitation 1 532 Risk Ratio (M-H, Random, 95% CI) 1.98 [1.06, 3.68]
5.2 anxiety 1 532 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.58, 1.31]
5.3 depression 1 532 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.99, 2.12]
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5.4 psychosis 1 532 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.87, 1.52]
5.5 impotence/ejaculation
failure
1 547 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.17, 8.56]
5.6 galactorrhoea 1 547 Risk Ratio (M-H, Random, 95% CI) 3.04 [0.59, 15.52]
5.7 serious psychiatric
symptoms
1 547 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.64, 1.59]
5.8 serious anxiety 1 547 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.48, 4.16]
5.9 suicide attempt 1 547 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.56, 3.27]
5.10 serious injury 1 547 Risk Ratio (M-H, Random, 95% CI) 2.02 [0.49, 8.39]
5.11 weight increase 1 547 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.42, 0.75]
5.12 headache 1 532 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.81, 3.01]
5.13 insomnia 1 532 Risk Ratio (M-H, Random, 95% CI) 4.59 [2.61, 8.07]
5.14 fatigue/somnolence 1 532 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.35, 1.41]
5.15 nasopharyngitis 1 532 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.61, 2.21]
5.16 diabetes mellitus 1 547 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.08, 19.32]
5.17 hyperglycaemia 1 494 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.25, 3.95]
5.18 hypoglycaemia 1 547 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.02, 9.89]
6 Adverse events: 3. Movement
disorder
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 any extra pyramidal
symptoms
1 547 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.19, 2.36]
6.2 tremor 1 547 Risk Ratio (M-H, Random, 95% CI) 2.29 [1.04, 5.06]
6.3 tardive dyskinesia 1 547 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.17, 8.56]
6.4 hypertonia 1 547 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.56, 3.27]
6.5 dystonia 1 547 Risk Ratio (M-H, Random, 95% CI) 6.07 [0.29, 125.82]
6.6 hyperkinesia 1 547 Risk Ratio (M-H, Random, 95% CI) 2.02 [1.01, 4.06]
6.7 requiring antiparkinson
drugs
1 547 Risk Ratio (M-H, Random, 95% CI) 1.26 [1.02, 1.56]
Comparison 7. RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Relapse (any
reason)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 vs aripiprazole - long term 1 349 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.83, 1.33]
1.2 vs general oral
antipsychotics - long term
1 63 Risk Ratio (M-H, Random, 95% CI) 2.13 [0.84, 5.43]
2 Mental state: 1. Average change
scores (PANSS, high score =
worse) 1. total
4 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 vs oral risperidone (non
ITT data) - short term
2 591 Mean Difference (IV, Random, 95% CI) 1.05 [-0.77, 2.88]
2.2 vs olanzapine - short term 1 377 Mean Difference (IV, Random, 95% CI) 0.90 [-2.25, 4.05]
2.3 vs olanzapine - long term 1 361 Mean Difference (IV, Random, 95% CI) 0.10 [-3.96, 4.16]
2.4 vs aripiprazole - long term 1 349 Mean Difference (IV, Random, 95% CI) -0.10 [-3.15, 2.95]
3 Leaving the study early: 1. Any
reason
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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3.1 vs aripiprazole 2 723 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.53, 1.30]
3.2 vs quetiapine 1 666 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.74, 0.95]
3.3 vs oral risperidone 2 690 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.92, 1.79]
3.4 vs any new generation
antipsychotic
1 77 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.55, 0.95]
3.5 vs olanzapine 1 618 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.10, 1.58]
3.6 vs any oral antipsychotic 1 382 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.93, 1.68]
4 Adverse events: 1. Death 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 vs olanzapine 1 618 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.06, 1.55]
4.2 vs oral risperidone 1 640 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.20]
4.3 vs any oral antipsychotic 1 382 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.14, 7.10]
4.4 vs aripiprazole 2 729 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.13, 7.36]
4.5 vs quetiapine 1 666 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.26, 9.14]
5 Adverse events: 1. General: a.
any
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 vs aripiprazole 2 729 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.14]
5.2 vs oral risperidone 1 640 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.91, 1.18]
5.3 vs quetiapine 1 666 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.09]
6 Adverse events: 1. General: b.
serious
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 vs quetiapine 1 666 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.62, 1.13]
6.2 vs aripiprazole 2 729 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.66, 1.39]
6.3 vs olanzapine 1 547 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.80, 1.51]
7 Adverse events: 2. Movement
disorder: a. any extra pyramidal
symptoms
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 vs aripiprazole 2 729 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.91, 1.55]
7.2 vs quetiapine 1 666 Risk Ratio (M-H, Random, 95% CI) 1.83 [1.07, 3.15]
7.3 vs olanzapine 1 547 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.19, 2.36]
7.4 vs oral risperidone 1 640 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.59, 1.88]
Comparison 8. RISPERIDONEDEPOT vs ATYPICALDEPOTANTIPSYCHOTICS (PALIPERIDONE PALMI-
TATE)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global State: 1. CGI-S mean
change from baseline (high
score = worse)
2 1326 Mean Difference (IV, Random, 95% CI) -0.07 [-0.26, 0.11]
1.1 medium term 2 1326 Mean Difference (IV, Random, 95% CI) -0.07 [-0.26, 0.11]
2 Global state: 2. Schedule for
Deficit Syndrome (SDS) scale
(mean change from baseline,
high score = worse)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 medium term 1 913 Mean Difference (IV, Random, 95% CI) 0.10 [-0.29, 0.49]
3 Mental state: 1. PANSS scores
(high score = worse) - medium
term
2 Mean Difference (IV, Random, 95% CI) Subtotals only
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3.1 total mean change
to endpoint (ITT and per
protocol data)*
2 1326 Mean Difference (IV, Random, 95% CI) 1.12 [-2.79, 5.02]
3.2 positive symptoms score
change to endpoint
2 1326 Mean Difference (IV, Random, 95% CI) 0.66 [-1.39, 2.71]
3.3 negative symptoms score
change to endpoint (ITT data)
2 1326 Mean Difference (IV, Random, 95% CI) 0.06 [-0.47, 0.59]
3.4 disorganised thoughts
score change to endpoint (ITT
data)
2 1326 Mean Difference (IV, Random, 95% CI) 0.02 [-0.55, 0.59]
3.5 uncontrolled
hostility/excitement score
change to endpoint (ITT data)
2 1326 Mean Difference (IV, Random, 95% CI) -0.04 [-0.50, 0.41]
3.6 anxiety/depression score
change to endpoint (ITT data)
2 1326 Mean Difference (IV, Random, 95% CI) 0.01 [-0.67, 0.69]
4 Mental state: 2. Improved by
30% in total PANSS score
(ITT data)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 medium term 2 1326 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.83, 1.23]
5 General functioning: Personal
and Social Performance (PSP)
scale (high score = better)
2 1326 Mean Difference (IV, Random, 95% CI) 0.65 [-0.69, 1.98]
5.1 mean endpoint - medium
term
2 1326 Mean Difference (IV, Random, 95% CI) 0.65 [-0.69, 1.98]
6 Leaving the study early: 1. Any
reason
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Lack of efficacy - medium
term
2 1672 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.29, 1.75]
6.2 Lack of efficacy - long
term
1 749 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.45, 0.81]
6.3 Adverse events - medium
term
2 1672 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.28, 1.65]
6.4 Adverse events - long term 1 749 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.53, 1.48]
6.5 Patient choice/withdrawn
consent - medium term
2 1672 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.22, 1.71]
6.6 Patient choice/withdrawn
consent - long term
1 749 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.83, 1.61]
6.7 Lost to follow-up -
medium term
2 1672 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.93, 2.79]
6.8 Lost to follow-up - long
term
1 749 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.39, 1.91]
6.9 Pregnancy - medium term 2 1672 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.03, 2.32]
6.10 Pregnancy - long term 1 749 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.06, 16.32]
6.11 Death - long term 1 749 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.25]
6.12 Other - medium term 2 1672 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.45, 1.32]
6.13 Other - long term 1 749 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.67, 1.78]
6.14 Any reason - medium
term
2 1672 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.51, 1.17]
6.15 Any reason - long term 1 749 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.75, 0.97]
7 Adverse events: 1. General 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 overall rate - medium term 2 1666 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.33, 4.42]
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7.2 overall rate - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.58, 0.95]
7.3 worsening of
schizophrenia - medium term
2 1666 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.40, 1.69]
7.4 worsening of psychiatric
disorders - medium term
1 1214 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.22, 1.34]
7.5 death - medium term 2 1666 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.14, 6.54]
7.6 death - long term 1 749 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.25]
8 Adverse events: 2. Specific 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 overall rate - medium term 2 1666 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.86, 1.08]
8.2 overall rate - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.95, 1.11]
8.3 insomnia - medium term 1 1214 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.49, 1.05]
8.4 insomnia - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.71, 1.40]
8.5 psychotic disorder - long
term
1 747 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.59, 1.24]
8.6 worsening of
schizophrenia - long term
1 747 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.49, 1.16]
8.7 anxiety - medium term 1 1214 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.26, 0.96]
8.8 anxiety - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.01, 2.20]
8.9 headache - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.78, 1.87]
8.10 constipation - medium
term
1 1214 Risk Ratio (M-H, Random, 95% CI) 3.79 [1.42, 10.08]
8.11 injection site pain -
medium term
2 1666 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.07, 0.38]
8.12 somnolence - medium
term
1 452 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.21, 1.49]
8.13 weight gain (proportion
of participants with >7%
increase) - medium term
1 452 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.72, 1.75]
8.14 tachycardia - medium
term
1 452 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.26, 4.06]
8.15 tachycardia - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.11, 1.05]
9 Adverse events: 3. Prolactin
related
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 amenorrhoea - medium
term
2 784 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.24, 13.02]
9.2 galactorrhoea - medium
term
1 271 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.02, 8.92]
9.3 hyperprolactinaemia -
medium term
1 452 Risk Ratio (M-H, Random, 95% CI) 5.13 [0.60, 43.60]
9.4 erectile dysfunction -
medium term
1 701 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.18, 3.53]
9.5 increase in serum prolactin
- medium term
1 452 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.35, 1.48]
9.6
amenorrhoea-galactorrhoea
syndrome - medium term
1 271 Risk Ratio (M-H, Random, 95% CI) 3.3 [0.14, 80.29]
9.7 any prolactin related -
medium term
2 1666 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.71]
9.8 proportion of male
participants with abnormally
high prolactin - long term
1 424 Risk Ratio (M-H, Random, 95% CI) 1.68 [1.32, 2.14]
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9.9 proportion of female
participants with abnormally
high prolactin - long term
1 294 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.95, 1.55]
10 Adverse events: 4. Movement
disorder
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 akathisia - medium term 1 452 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.98, 2.31]
10.2 tremor - medium term 1 452 Risk Ratio (M-H, Random, 95% CI) 1.71 [1.07, 2.74]
10.3 tardive dyskinesia -
medium term
1 1214 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.06, 15.90]
10.4 requiring use of anti-EPS
medication - medium term
2 1666 Risk Ratio (M-H, Random, 95% CI) 1.46 [1.18, 1.80]
10.5 hyperkinesia - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 1.66 [1.00, 2.73]
10.6 neuroleptic malignant
syndrome - long term
1 747 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.40]
11 Adverse events: 5. Body weight
(mean increase)
3 2350 Mean Difference (IV, Random, 95% CI) 0.18 [-0.36, 0.72]
11.1 medium term 2 1666 Mean Difference (IV, Random, 95% CI) -0.07 [-0.38, 0.24]
11.2 long term 1 684 Mean Difference (IV, Random, 95% CI) 1.0 [0.13, 1.87]
12 Adverse events: 6. Mean
prolactin level increase (ng/mL)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 female participants 2 807 Mean Difference (IV, Random, 95% CI) -3.40 [-12.65, 5.85]
12.2 male participants 2 1125 Mean Difference (IV, Random, 95% CI) -0.43 [-5.88, 5.03]
13 Adverse events: 7. Glucose
related
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 increased blood glucose -
long term
1 747 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.44, 5.43]
13.2 hyperglycaemia - long
term
1 747 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.31, 6.09]
13.3 diabetes mellitus - long
term
1 747 Risk Ratio (M-H, Random, 95% CI) 4.12 [0.46, 36.68]
13.4 glycosuria - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.40]
13.5 ketonuria - long term 1 747 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.40]
13.6 urine ketone body
present - long term
1 747 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.40]
13.7 hypoglycaemia - long
term
1 747 Risk Ratio (M-H, Random, 95% CI) 3.09 [0.13, 75.59]
13.8 any glucose related -
medium term
2 1666 Risk Ratio (M-H, Random, 95% CI) 1.76 [0.52, 5.98]
13.9 any glucose related - long
term
1 747 Risk Ratio (M-H, Random, 95% CI) 1.80 [0.77, 4.25]
14 Adverse events: 8. Injection
site pain (mean (sd) Visual
Analogue Scale score
(0-100mm))
1 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 at baseline 1 747 Mean Difference (IV, Random, 95% CI) 1.80 [-0.24, 3.84]
14.2 at endpoint 1 747 Mean Difference (IV, Random, 95% CI) 0.0 [-1.07, 1.07]
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Comparison 9. RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1. Total endpoint
scores (PANNS, high score =
worse)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 short term 1 49 Mean Difference (IV, Random, 95% CI) 0.70 [-8.12, 9.52]
1.2 medium term 1 46 Mean Difference (IV, Random, 95% CI) -0.10 [-9.02, 8.82]
1.3 long term 1 43 Mean Difference (IV, Random, 95% CI) 1.80 [-10.04, 13.64]
2 Leaving the study early 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 before beginning assigned
treatment
1 62 Risk Ratio (M-H, Random, 95% CI) 7.50 [1.00, 56.44]
2.2 by 6 months 1 62 Risk Ratio (M-H, Random, 95% CI) 3.05 [1.12, 8.31]
2.3 due to increased
psychiatric symptoms
1 62 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.31, 25.58]
2.4 due to EPS effects 1 62 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.40]
2.5 due to weight gain and
hypertension
1 62 Risk Ratio (M-H, Random, 95% CI) 2.82 [0.12, 66.62]
2.6 due to participant
preference
1 62 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.06, 14.33]
3 Hospitalisation by 6 months 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 medium term 1 62 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.11, 3.48]
4 Adverse events: 1. Continuous
outcomes (skew)
Other data No numeric data
4.1 Change in BMI - short
term (skew)
Other data No numeric data
4.2 Change in BMI - medium
term (skew)
Other data No numeric data
4.3 Change in BMI - long
term (skew)
Other data No numeric data
4.4 Prolactin endpoint levels
(ng/mL) - short term (skew)
Other data No numeric data
4.5 Prolactin endpoint levels
(ng/mL) - medium term (skew)
Other data No numeric data
4.6 Prolactin endpoint levels
(ng/mL) - long term (skew)
Other data No numeric data
5 Adverse events: 2. Sexual
experiencesm, total endpoint
(ASEX, high score = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 short term 1 44 Mean Difference (IV, Fixed, 95% CI) 1.70 [-1.26, 4.66]
5.2 medium term 1 41 Mean Difference (IV, Fixed, 95% CI) 1.30 [-2.30, 4.90]
5.3 long term 1 40 Mean Difference (IV, Fixed, 95% CI) -0.10 [-4.08, 3.88]
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Analysis 1.1. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 1 Mental state: 1. Change
(exacerbation) in specific symptoms.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 1 Mental state: 1. Change (exacerbation) in specific symptoms
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anxiety - short term
Kane 2002* 27/302 15/98 100.0 % 0.58 [ 0.32, 1.05 ]
Subtotal (95% CI) 302 98 100.0 % 0.58 [ 0.32, 1.05 ]
Total events: 27 (Risperidone depot), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
2 agitation - short term
Kane 2002* 46/302 25/98 100.0 % 0.60 [ 0.39, 0.92 ]
Subtotal (95% CI) 302 98 100.0 % 0.60 [ 0.39, 0.92 ]
Total events: 46 (Risperidone depot), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
3 hallucinations - short term
Kane 2002* 19/302 5/98 100.0 % 1.23 [ 0.47, 3.22 ]
Subtotal (95% CI) 302 98 100.0 % 1.23 [ 0.47, 3.22 ]
Total events: 19 (Risperidone depot), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 nervousness - short term
Kane 2002* 6/302 5/98 100.0 % 0.39 [ 0.12, 1.25 ]
Subtotal (95% CI) 302 98 100.0 % 0.39 [ 0.12, 1.25 ]
Total events: 6 (Risperidone depot), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
5 psychosis - short term
Kane 2002* 37/302 23/98 100.0 % 0.52 [ 0.33, 0.83 ]
Subtotal (95% CI) 302 98 100.0 % 0.52 [ 0.33, 0.83 ]
Total events: 37 (Risperidone depot), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
0.1 0.2 0.5 1 2 5 10
Favours risperidone depot Favours placebo
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Analysis 1.2. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 2 Leaving the study early: 1.
Any reason (by time period).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 2 Leaving the study early: 1. Any reason (by time period)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 very early on (<1 injection)
Kane 2002* 24/302 6/98 100.0 % 1.30 [ 0.55, 3.08 ]
Subtotal (95% CI) 302 98 100.0 % 1.30 [ 0.55, 3.08 ]
Total events: 24 (Risperidone depot), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 by 12 weeks
Kane 2002* 156/302 68/98 100.0 % 0.74 [ 0.63, 0.88 ]
Subtotal (95% CI) 302 98 100.0 % 0.74 [ 0.63, 0.88 ]
Total events: 156 (Risperidone depot), 68 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.38 (P = 0.00071)
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Analysis 1.3. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 3 Leaving the study early: 2.
Any reason (by doses).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 3 Leaving the study early: 2. Any reason (by doses)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 all doses risperidone depot - short term
Kane 2002* 156/302 68/98 100.0 % 0.74 [ 0.63, 0.88 ]
Subtotal (95% CI) 302 98 100.0 % 0.74 [ 0.63, 0.88 ]
Total events: 156 (Risperidone depot), 68 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.38 (P = 0.00071)
2 25mg risperidone depot - short term
Kane 2002* 51/99 68/98 100.0 % 0.74 [ 0.59, 0.94 ]
Subtotal (95% CI) 99 98 100.0 % 0.74 [ 0.59, 0.94 ]
Total events: 51 (Risperidone depot), 68 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
3 50mg risperidone depot - short term
Kane 2002* 53/103 68/98 100.0 % 0.74 [ 0.59, 0.93 ]
Subtotal (95% CI) 103 98 100.0 % 0.74 [ 0.59, 0.93 ]
Total events: 53 (Risperidone depot), 68 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.011)
4 75mg risperidone depot - short term
Kane 2002* 52/100 68/98 100.0 % 0.75 [ 0.60, 0.94 ]
Subtotal (95% CI) 100 98 100.0 % 0.75 [ 0.60, 0.94 ]
Total events: 52 (Risperidone depot), 68 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
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Analysis 1.4. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 4 Leaving the study early: 3.
Because of insufficient response (by doses).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 4 Leaving the study early: 3. Because of insufficient response (by doses)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 all three doses - short term
Kane 2002* 49/302 30/98 100.0 % 0.53 [ 0.36, 0.79 ]
Subtotal (95% CI) 302 98 100.0 % 0.53 [ 0.36, 0.79 ]
Total events: 49 (Risperidone depot), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
2 25mg depot risperidone group - short term
Kane 2002* 22/99 30/98 100.0 % 0.73 [ 0.45, 1.17 ]
Subtotal (95% CI) 99 98 100.0 % 0.73 [ 0.45, 1.17 ]
Total events: 22 (Risperidone depot), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
3 50mg depot risperidone group - short term
Kane 2002* 15/103 30/98 100.0 % 0.48 [ 0.27, 0.83 ]
Subtotal (95% CI) 103 98 100.0 % 0.48 [ 0.27, 0.83 ]
Total events: 15 (Risperidone depot), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0087)
4 75mg depot risperidone group - short term
Kane 2002* 12/100 30/98 100.0 % 0.39 [ 0.21, 0.72 ]
Subtotal (95% CI) 100 98 100.0 % 0.39 [ 0.21, 0.72 ]
Total events: 12 (Risperidone depot), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0026)
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Analysis 1.5. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 5 Adverse events: 1. General:
a. Death.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 5 Adverse events: 1. General: a. Death
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term
Kane 2002* 0/302 1/98 100.0 % 0.11 [ 0.00, 2.65 ]
Subtotal (95% CI) 302 98 100.0 % 0.11 [ 0.00, 2.65 ]
Total events: 0 (Risperidone depot), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 6 Adverse events: 1. General:
b. Severe adverse event (by doses).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 6 Adverse events: 1. General: b. Severe adverse event (by doses)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any dose risperidone depot - short term
Kane 2002* 42/302 23/98 100.0 % 0.59 [ 0.38, 0.93 ]
Subtotal (95% CI) 302 98 100.0 % 0.59 [ 0.38, 0.93 ]
Total events: 42 (Risperidone depot), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
2 25mg risperidone depot - short term
Kane 2002* 13/99 23/98 100.0 % 0.56 [ 0.30, 1.04 ]
Subtotal (95% CI) 99 98 100.0 % 0.56 [ 0.30, 1.04 ]
Total events: 13 (Risperidone depot), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
3 50mg risperidone depot - short term
Kane 2002* 14/103 23/98 100.0 % 0.58 [ 0.32, 1.06 ]
Subtotal (95% CI) 103 98 100.0 % 0.58 [ 0.32, 1.06 ]
Total events: 14 (Risperidone depot), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
4 75mg risperidone depot - short term
Kane 2002* 15/100 23/98 100.0 % 0.64 [ 0.36, 1.15 ]
Subtotal (95% CI) 100 98 100.0 % 0.64 [ 0.36, 1.15 ]
Total events: 15 (Risperidone depot), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 0.10, df = 3 (P = 0.99), I2 =0.0%
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Analysis 1.7. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 7 Adverse events: 1. General:
c. Adverse event necessitating withdrawal from study (by doses).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 7 Adverse events: 1. General: c. Adverse event necessitating withdrawal from study (by doses)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any dose risperidone depot - short term
Kane 2002* 37/302 12/98 100.0 % 1.00 [ 0.54, 1.84 ]
Subtotal (95% CI) 302 98 100.0 % 1.00 [ 0.54, 1.84 ]
Total events: 37 (Risperidone depot), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
2 25mg risperidone depot - short term
Kane 2002* 11/99 12/98 100.0 % 0.91 [ 0.42, 1.96 ]
Subtotal (95% CI) 99 98 100.0 % 0.91 [ 0.42, 1.96 ]
Total events: 11 (Risperidone depot), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
3 50mg risperidone depot - short term
Kane 2002* 12/103 12/98 100.0 % 0.95 [ 0.45, 2.02 ]
Subtotal (95% CI) 103 98 100.0 % 0.95 [ 0.45, 2.02 ]
Total events: 12 (Risperidone depot), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
4 75mg risperidone depot - short term
Kane 2002* 14/100 12/98 100.0 % 1.14 [ 0.56, 2.35 ]
Subtotal (95% CI) 100 98 100.0 % 1.14 [ 0.56, 2.35 ]
Total events: 14 (Risperidone depot), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 1.8. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 8 Adverse events: 2. Specific: a.
Cardiovascular.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 8 Adverse events: 2. Specific: a. Cardiovascular
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 dizziness - short term
Kane 2002* 27/302 6/98 100.0 % 1.46 [ 0.62, 3.43 ]
Subtotal (95% CI) 302 98 100.0 % 1.46 [ 0.62, 3.43 ]
Total events: 27 (Risperidone depot), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
2 tachycardia - short term
Kane 2002* 6/302 6/98 100.0 % 0.32 [ 0.11, 0.98 ]
Subtotal (95% CI) 302 98 100.0 % 0.32 [ 0.11, 0.98 ]
Total events: 6 (Risperidone depot), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
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Analysis 1.9. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 9 Adverse events: 2. Specific:
b. Gastrointestinal.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 9 Adverse events: 2. Specific: b. Gastrointestinal
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 constipation - short term
Kane 2002* 19/302 1/98 100.0 % 6.17 [ 0.84, 45.46 ]
Subtotal (95% CI) 302 98 100.0 % 6.17 [ 0.84, 45.46 ]
Total events: 19 (Risperidone depot), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.074)
2 diarrhoea - short term
Kane 2002* 8/302 3/98 100.0 % 0.87 [ 0.23, 3.20 ]
Subtotal (95% CI) 302 98 100.0 % 0.87 [ 0.23, 3.20 ]
Total events: 8 (Risperidone depot), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
3 nausea - short term
Kane 2002* 16/302 5/98 100.0 % 1.04 [ 0.39, 2.76 ]
Subtotal (95% CI) 302 98 100.0 % 1.04 [ 0.39, 2.76 ]
Total events: 16 (Risperidone depot), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
4 vomiting - short term
Kane 2002* 11/302 6/98 100.0 % 0.59 [ 0.23, 1.57 ]
Subtotal (95% CI) 302 98 100.0 % 0.59 [ 0.23, 1.57 ]
Total events: 11 (Risperidone depot), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
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Analysis 1.10. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 10 Adverse events: 2.
Specific: c. Movement disorders: a. Extrapyramidal disorder - spontaneously reported (by doses).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 10 Adverse events: 2. Specific: c. Movement disorders: a. Extrapyramidal disorder - spontaneously reported (by doses)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 all doses of depot risperidone - short term
Kane 2002* 22/302 3/98 100.0 % 2.38 [ 0.73, 7.78 ]
Subtotal (95% CI) 302 98 100.0 % 2.38 [ 0.73, 7.78 ]
Total events: 22 (Risperidone depot), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
2 25mg risperidone group - short term
Kane 2002* 4/99 3/98 100.0 % 1.32 [ 0.30, 5.74 ]
Subtotal (95% CI) 99 98 100.0 % 1.32 [ 0.30, 5.74 ]
Total events: 4 (Risperidone depot), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
3 50mg risperidone group - short term
Kane 2002* 8/103 3/98 100.0 % 2.54 [ 0.69, 9.29 ]
Subtotal (95% CI) 103 98 100.0 % 2.54 [ 0.69, 9.29 ]
Total events: 8 (Risperidone depot), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
4 75mg risperidone group - short term
Kane 2002* 10/100 3/98 100.0 % 3.27 [ 0.93, 11.51 ]
Subtotal (95% CI) 100 98 100.0 % 3.27 [ 0.93, 11.51 ]
Total events: 10 (Risperidone depot), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
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Analysis 1.11. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 11 Adverse events: 2.
Specific: d. Movement disorders: b. Hyperkinesia (by doses).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 11 Adverse events: 2. Specific: d. Movement disorders: b. Hyperkinesia (by doses)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 all doses of risperidone - short term
Kane 2002* 21/302 4/98 100.0 % 1.70 [ 0.60, 4.84 ]
Subtotal (95% CI) 302 98 100.0 % 1.70 [ 0.60, 4.84 ]
Total events: 21 (Risperidone depot), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
2 25mg risperidone group - short term
Kane 2002* 2/99 4/98 100.0 % 0.49 [ 0.09, 2.64 ]
Subtotal (95% CI) 99 98 100.0 % 0.49 [ 0.09, 2.64 ]
Total events: 2 (Risperidone depot), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
3 50mg risperidone group - short term
Kane 2002* 9/103 4/98 100.0 % 2.14 [ 0.68, 6.73 ]
Subtotal (95% CI) 103 98 100.0 % 2.14 [ 0.68, 6.73 ]
Total events: 9 (Risperidone depot), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
4 75mg of risperidone group - short term
Kane 2002* 10/100 4/98 100.0 % 2.45 [ 0.79, 7.55 ]
Subtotal (95% CI) 100 98 100.0 % 2.45 [ 0.79, 7.55 ]
Total events: 10 (Risperidone depot), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
0.02 0.1 1 10 50
Favours risperidone depot Favours placebo
114Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.12. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 12 Adverse events: 2.
Specific: e. Movement disorders: c. Hypertonia (by doses).
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 12 Adverse events: 2. Specific: e. Movement disorders: c. Hypertonia (by doses)
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 all doses of depot risperidone - short term
Kane 2002* 19/302 5/98 100.0 % 1.23 [ 0.47, 3.22 ]
Subtotal (95% CI) 302 98 100.0 % 1.23 [ 0.47, 3.22 ]
Total events: 19 (Risperidone depot), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 25mg risperidone - short term
Kane 2002* 4/99 5/98 100.0 % 0.79 [ 0.22, 2.86 ]
Subtotal (95% CI) 99 98 100.0 % 0.79 [ 0.22, 2.86 ]
Total events: 4 (Risperidone depot), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
3 50mg risperidone - short term
Kane 2002* 5/103 5/98 100.0 % 0.95 [ 0.28, 3.19 ]
Subtotal (95% CI) 103 98 100.0 % 0.95 [ 0.28, 3.19 ]
Total events: 5 (Risperidone depot), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
4 75mg risperidone - short term
Kane 2002* 10/100 5/98 100.0 % 1.96 [ 0.70, 5.53 ]
Subtotal (95% CI) 100 98 100.0 % 1.96 [ 0.70, 5.53 ]
Total events: 10 (Risperidone depot), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
0.1 0.2 0.5 1 2 5 10
Favours risperidone depot Favours placebo
115Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.13. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 13 Adverse events: 2.
Specific: f. Pain.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 13 Adverse events: 2. Specific: f. Pain
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 headache - short term
Kane 2002* 58/302 12/98 100.0 % 1.57 [ 0.88, 2.80 ]
Subtotal (95% CI) 302 98 100.0 % 1.57 [ 0.88, 2.80 ]
Total events: 58 (Risperidone depot), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
2 pain - unspecified - short term
Kane 2002* 17/302 4/98 100.0 % 1.38 [ 0.48, 4.00 ]
Subtotal (95% CI) 302 98 100.0 % 1.38 [ 0.48, 4.00 ]
Total events: 17 (Risperidone depot), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
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Analysis 1.14. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 14 Adverse events: 2.
Specific: g. Salivation.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 14 Adverse events: 2. Specific: g. Salivation
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 decreased - short term
Kane 2002* 9/302 1/98 100.0 % 2.92 [ 0.37, 22.76 ]
Subtotal (95% CI) 302 98 100.0 % 2.92 [ 0.37, 22.76 ]
Total events: 9 (Risperidone depot), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 increased - short term
Kane 2002* 9/302 1/98 100.0 % 2.92 [ 0.37, 22.76 ]
Subtotal (95% CI) 302 98 100.0 % 2.92 [ 0.37, 22.76 ]
Total events: 9 (Risperidone depot), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
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Analysis 1.15. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 15 Adverse events: 2.
Specific: h. Sleep disturbances.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 15 Adverse events: 2. Specific: h. Sleep disturbances
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 insomnia - short term
Kane 2002* 45/302 14/98 100.0 % 1.04 [ 0.60, 1.82 ]
Subtotal (95% CI) 302 98 100.0 % 1.04 [ 0.60, 1.82 ]
Total events: 45 (Risperidone depot), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 somnolence - short term
Kane 2002* 21/302 3/98 100.0 % 2.27 [ 0.69, 7.45 ]
Subtotal (95% CI) 302 98 100.0 % 2.27 [ 0.69, 7.45 ]
Total events: 21 (Risperidone depot), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 1.16. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 16 Adverse events: 2.
Specific: i. Weight gain.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 16 Adverse events: 2. Specific: i. Weight gain
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 all doses of depot risperidone - short term
Kane 2002* 13/302 2/98 100.0 % 2.11 [ 0.48, 9.18 ]
Subtotal (95% CI) 302 98 100.0 % 2.11 [ 0.48, 9.18 ]
Total events: 13 (Risperidone depot), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
2 25mg risperidone - short term
Kane 2002* 5/99 2/98 100.0 % 2.47 [ 0.49, 12.45 ]
Subtotal (95% CI) 99 98 100.0 % 2.47 [ 0.49, 12.45 ]
Total events: 5 (Risperidone depot), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
3 50mg risperidone - short term
Kane 2002* 4/103 2/98 100.0 % 1.90 [ 0.36, 10.16 ]
Subtotal (95% CI) 103 98 100.0 % 1.90 [ 0.36, 10.16 ]
Total events: 4 (Risperidone depot), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
4 75mg risperidone - short term
Kane 2002* 4/100 2/98 100.0 % 1.96 [ 0.37, 10.46 ]
Subtotal (95% CI) 100 98 100.0 % 1.96 [ 0.37, 10.46 ]
Total events: 4 (Risperidone depot), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
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Analysis 1.17. Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 17 Adverse events: 2.
Specific: j. Others.
Review: Risperidone (depot) for schizophrenia
Comparison: 1 RISPERIDONE DEPOT vs PLACEBO
Outcome: 17 Adverse events: 2. Specific: j. Others
Study or subgroup Risperidone depot Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 coughing - short term
Kane 2002* 12/302 4/98 100.0 % 0.97 [ 0.32, 2.95 ]
Subtotal (95% CI) 302 98 100.0 % 0.97 [ 0.32, 2.95 ]
Total events: 12 (Risperidone depot), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 fatigue - short term
Kane 2002* 13/302 0/98 100.0 % 8.82 [ 0.53, 147.05 ]
Subtotal (95% CI) 302 98 100.0 % 8.82 [ 0.53, 147.05 ]
Total events: 13 (Risperidone depot), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
3 injury - short term
Kane 2002* 7/302 6/98 100.0 % 0.38 [ 0.13, 1.10 ]
Subtotal (95% CI) 302 98 100.0 % 0.38 [ 0.13, 1.10 ]
Total events: 7 (Risperidone depot), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
4 rhinitis - short term
Kane 2002* 25/302 8/98 100.0 % 1.01 [ 0.47, 2.17 ]
Subtotal (95% CI) 302 98 100.0 % 1.01 [ 0.47, 2.17 ]
Total events: 25 (Risperidone depot), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 2.1. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 1
Global state: 1. Relapse (any reason).
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 1 Global state: 1. Relapse (any reason)
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Quinn 2012* 11/32 5/31 100.0 % 2.13 [ 0.84, 5.43 ]
Subtotal (95% CI) 32 31 100.0 % 2.13 [ 0.84, 5.43 ]
Total events: 11 (Risperidone depot), 5 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 2
Global state: 2. Needing use of benzodiazepine or sedative drugs.
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 2 Global state: 2. Needing use of benzodiazepine or sedative drugs
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Rosenheck 2011 41/187 40/182 100.0 % 1.00 [ 0.68, 1.47 ]
Subtotal (95% CI) 187 182 100.0 % 1.00 [ 0.68, 1.47 ]
Total events: 41 (Risperidone depot), 40 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 3
Service utilisation: 1. Hospitalisation.
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 3 Service utilisation: 1. Hospitalisation
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Rosenheck 2011 72/187 81/182 100.0 % 0.87 [ 0.68, 1.10 ]
Subtotal (95% CI) 187 182 100.0 % 0.87 [ 0.68, 1.10 ]
Total events: 72 (Risperidone depot), 81 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 4
Service utilisation: 2. Outpatient care - number of outpatient visits (skewed data).
Service utilisation: 2. Outpatient care - number of outpatient visits (skewed data)
Study Intervention Mean SD N
long term
Rosenheck 2011 Risperidone depot 122.4 130.9 187
Rosenheck 2011 Oral control 136.5 137 182
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Analysis 2.5. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 5
Not receiving allocated study medication.
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 5 Not receiving allocated study medication
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Rosenheck 2011 2/190 7/192 100.0 % 0.29 [ 0.06, 1.37 ]
Subtotal (95% CI) 190 192 100.0 % 0.29 [ 0.06, 1.37 ]
Total events: 2 (Risperidone depot), 7 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 6
Leaving the study early: 1. Any reason.
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 6 Leaving the study early: 1. Any reason
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Quinn 2012* 26/44 20/41 35.2 % 1.21 [ 0.81, 1.80 ]
Rosenheck 2011 68/190 55/192 64.8 % 1.25 [ 0.93, 1.68 ]
Total (95% CI) 234 233 100.0 % 1.24 [ 0.98, 1.57 ]
Total events: 94 (Risperidone depot), 75 (Oral control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours risperidone depot Favours oral control
124Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.7. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 7
Leaving the study early: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 7 Leaving the study early: 2. Specific
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 insufficient response - long term
Rosenheck 2011 3/190 5/192 100.0 % 0.61 [ 0.15, 2.50 ]
Subtotal (95% CI) 190 192 100.0 % 0.61 [ 0.15, 2.50 ]
Total events: 3 (Risperidone depot), 5 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 withdrawn consent - long term
Rosenheck 2011 32/190 23/192 100.0 % 1.41 [ 0.86, 2.31 ]
Subtotal (95% CI) 190 192 100.0 % 1.41 [ 0.86, 2.31 ]
Total events: 32 (Risperidone depot), 23 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi2 = 1.20, df = 1 (P = 0.27), I2 =17%
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Analysis 2.8. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 8
Adverse events: 1. General: a. Death.
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 8 Adverse events: 1. General: a. Death
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Rosenheck 2011 2/190 2/192 100.0 % 1.01 [ 0.14, 7.10 ]
Subtotal (95% CI) 190 192 100.0 % 1.01 [ 0.14, 7.10 ]
Total events: 2 (Risperidone depot), 2 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 9
Adverse events: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 9 Adverse events: 2. Specific
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anxiety - long term
Quinn 2012* 6/44 4/41 100.0 % 1.40 [ 0.42, 4.60 ]
Subtotal (95% CI) 44 41 100.0 % 1.40 [ 0.42, 4.60 ]
Total events: 6 (Risperidone depot), 4 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 diabetes mellitus - long term
Rosenheck 2011 14/187 8/182 100.0 % 1.70 [ 0.73, 3.96 ]
Subtotal (95% CI) 187 182 100.0 % 1.70 [ 0.73, 3.96 ]
Total events: 14 (Risperidone depot), 8 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
3 dizziness - long term
Quinn 2012* 8/44 5/41 100.0 % 1.49 [ 0.53, 4.19 ]
Subtotal (95% CI) 44 41 100.0 % 1.49 [ 0.53, 4.19 ]
Total events: 8 (Risperidone depot), 5 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
4 fatigue/somnolence - long term
Quinn 2012* 11/44 5/41 100.0 % 2.05 [ 0.78, 5.40 ]
Subtotal (95% CI) 44 41 100.0 % 2.05 [ 0.78, 5.40 ]
Total events: 11 (Risperidone depot), 5 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
5 gastrointestinal - long term
Rosenheck 2011 129/187 114/182 100.0 % 1.10 [ 0.95, 1.28 ]
Subtotal (95% CI) 187 182 100.0 % 1.10 [ 0.95, 1.28 ]
Total events: 129 (Risperidone depot), 114 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
6 general disorders and administration site conditions - long term
Rosenheck 2011 85/187 63/182 100.0 % 1.31 [ 1.02, 1.69 ]
Subtotal (95% CI) 187 182 100.0 % 1.31 [ 1.02, 1.69 ]
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(. . . Continued)
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 85 (Risperidone depot), 63 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
7 headache - long term
Quinn 2012* 15/44 5/41 100.0 % 2.80 [ 1.12, 7.00 ]
Subtotal (95% CI) 44 41 100.0 % 2.80 [ 1.12, 7.00 ]
Total events: 15 (Risperidone depot), 5 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
8 insomnia - long term
Quinn 2012* 13/44 7/41 100.0 % 1.73 [ 0.77, 3.91 ]
Subtotal (95% CI) 44 41 100.0 % 1.73 [ 0.77, 3.91 ]
Total events: 13 (Risperidone depot), 7 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
9 nausea/ vomiting - long term
Quinn 2012* 6/44 3/41 100.0 % 1.86 [ 0.50, 6.97 ]
Subtotal (95% CI) 44 41 100.0 % 1.86 [ 0.50, 6.97 ]
Total events: 6 (Risperidone depot), 3 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
10 prolactin related - long term
Quinn 2012* 5/44 0/41 100.0 % 10.27 [ 0.59, 180.05 ]
Subtotal (95% CI) 44 41 100.0 % 10.27 [ 0.59, 180.05 ]
Total events: 5 (Risperidone depot), 0 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
11 weight increase - long term
Quinn 2012* 10/44 7/41 100.0 % 1.33 [ 0.56, 3.17 ]
Subtotal (95% CI) 44 41 100.0 % 1.33 [ 0.56, 3.17 ]
Total events: 10 (Risperidone depot), 7 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi2 = 10.46, df = 10 (P = 0.40), I2 =4%
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Analysis 2.10. Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome
10 Adverse events: Nervous system disorders (inc. EPS).
Review: Risperidone (depot) for schizophrenia
Comparison: 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Outcome: 10 Adverse events: Nervous system disorders (inc. EPS)
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Rosenheck 2011 129/187 94/182 100.0 % 1.34 [ 1.13, 1.58 ]
Subtotal (95% CI) 187 182 100.0 % 1.34 [ 1.13, 1.58 ]
Total events: 129 (Risperidone depot), 94 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.33 (P = 0.00086)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 1 Global state: 1.
Moderate to severely ill at end of study period (CGI rating).
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 1 Global state: 1. Moderate to severely ill at end of study period (CGI rating)
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term
Chue 2002 177/319 168/321 100.0 % 1.06 [ 0.92, 1.22 ]
Subtotal (95% CI) 319 321 100.0 % 1.06 [ 0.92, 1.22 ]
Total events: 177 (Risperidone depot), 168 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 2 Global state: 2.
Mean change from baseline (CGI-S, high score = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 2 Global state: 2. Mean change from baseline (CGI-S, high score = worse)
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Bai 2006 25 -0.08 (0.28) 25 -0.04 (0.45) 100.0 % -0.04 [ -0.25, 0.17 ]
Subtotal (95% CI) 25 25 100.0 % -0.04 [ -0.25, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 3 Global state: 3.
Mean (SD) GAF score change to endpoint.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 3 Global state: 3. Mean (SD) GAF score change to endpoint
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Bai 2006 25 0.8 (8.1) 25 1.6 (9.4) 100.0 % -0.80 [ -5.66, 4.06 ]
Subtotal (95% CI) 25 25 100.0 % -0.80 [ -5.66, 4.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 4 Global state: 4.
Needing use of benzodiazepine or sedative drugs.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 4 Global state: 4. Needing use of benzodiazepine or sedative drugs
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term
Bai 2006 18/25 19/25 24.8 % 0.95 [ 0.68, 1.32 ]
Chue 2002 118/319 141/321 75.2 % 0.84 [ 0.70, 1.02 ]
Total (95% CI) 344 346 100.0 % 0.87 [ 0.74, 1.02 ]
Total events: 136 (Risperidone depot), 160 (Risperidone oral)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.088)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 5 Mental state: 1.
Average change/endpoint scores (PANSS, high score = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 5 Mental state: 1. Average change/endpoint scores (PANSS, high score = worse)
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 mean total (non ITT data)
Chue 2002 266 63.3 (17.94) 275 63.3 (16.58) 100.0 % 0.0 [ -2.91, 2.91 ]
Subtotal (95% CI) 266 275 100.0 % 0.0 [ -2.91, 2.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 average change: 1. total (non ITT data)
Bai 2006 25 -0.16 (9.04) 25 -2.4 (10.4) 11.4 % 2.24 [ -3.16, 7.64 ]
Chue 2002 266 -5.4 (11.41) 275 -6.3 (11.6) 88.6 % 0.90 [ -1.04, 2.84 ]
Subtotal (95% CI) 291 300 100.0 % 1.05 [ -0.77, 2.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 average change: 2. positive (non-ITT data)
Bai 2006 25 0.72 (3.52) 25 -1.24 (3.81) 32.0 % 1.96 [ -0.07, 3.99 ]
Chue 2002 266 -1.7 (3.33) 275 -2 (3.31) 68.0 % 0.30 [ -0.26, 0.86 ]
Subtotal (95% CI) 291 300 100.0 % 0.83 [ -0.69, 2.35 ]
Heterogeneity: Tau2 = 0.80; Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.07 (P = 0.28)
4 average change: 3. negative (non ITT data)
Bai 2006 25 -0.64 (3.83) 25 0.08 (5.66) 8.7 % -0.72 [ -3.40, 1.96 ]
Chue 2002 266 -1.5 (4.89) 275 -1.6 (4.95) 91.3 % 0.10 [ -0.73, 0.93 ]
Subtotal (95% CI) 291 300 100.0 % 0.03 [ -0.76, 0.82 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
5 average change: 4. disorganised thoughts
Chue 2002 266 -1.1 (3.2619) 275 -1.2 (3.3166) 100.0 % 0.10 [ -0.45, 0.65 ]
Subtotal (95% CI) 266 275 100.0 % 0.10 [ -0.45, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
6 average change: 5. hostility/excitement
Chue 2002 266 -0.3 (1.631) 275 -0.4 (1.6583) 100.0 % 0.10 [ -0.18, 0.38 ]
Subtotal (95% CI) 266 275 100.0 % 0.10 [ -0.18, 0.38 ]
-10 -5 0 5 10
Favours risperidone depot Favours risperidone oral
(Continued . . . )
132Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
7 average change: 6. anxiety/depression
Chue 2002 266 -0.9 (3.2619) 275 -1 (3.3166) 100.0 % 0.10 [ -0.45, 0.65 ]
Subtotal (95% CI) 266 275 100.0 % 0.10 [ -0.45, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 1.93, df = 6 (P = 0.93), I2 =0.0%
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Analysis 3.6. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 6 Leaving the study
early: 1. Any reason.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 6 Leaving the study early: 1. Any reason
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term
Bai 2006 1/25 0/25 1.1 % 3.00 [ 0.13, 70.30 ]
Chue 2002 63/319 50/321 98.9 % 1.27 [ 0.90, 1.78 ]
Total (95% CI) 344 346 100.0 % 1.28 [ 0.92, 1.79 ]
Total events: 64 (Risperidone depot), 50 (Risperidone oral)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 7 Leaving the study
early: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 7 Leaving the study early: 2. Specific
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 adverse events - short term
Chue 2002 18/319 15/321 100.0 % 1.21 [ 0.62, 2.35 ]
Subtotal (95% CI) 319 321 100.0 % 1.21 [ 0.62, 2.35 ]
Total events: 18 (Risperidone depot), 15 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 insufficient response - short term
Chue 2002 12/319 8/321 100.0 % 1.51 [ 0.63, 3.64 ]
Subtotal (95% CI) 319 321 100.0 % 1.51 [ 0.63, 3.64 ]
Total events: 12 (Risperidone depot), 8 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 withdrawn consent - short term
Chue 2002 17/319 13/321 100.0 % 1.32 [ 0.65, 2.66 ]
Subtotal (95% CI) 319 321 100.0 % 1.32 [ 0.65, 2.66 ]
Total events: 17 (Risperidone depot), 13 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.16, df = 2 (P = 0.92), I2 =0.0%
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Analysis 3.8. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 8 Quality of life:
Mean (SD) SF-36 score change/endpoint (high score = better).
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 8 Quality of life: Mean (SD) SF-36 score change/endpoint (high score = better)
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Physical component summary
Bai 2006 25 -0.9 (6.1) 25 -2.3 (8.3) 100.0 % 1.40 [ -2.64, 5.44 ]
Subtotal (95% CI) 25 25 100.0 % 1.40 [ -2.64, 5.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Mental component summary
Bai 2006 25 0.4 (8.1) 25 0.6 (9.4) 100.0 % -0.20 [ -5.06, 4.66 ]
Subtotal (95% CI) 25 25 100.0 % -0.20 [ -5.06, 4.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
3 Role physical
Bai 2006 25 -9 (41.4) 25 -10 (36.8) 100.0 % 1.00 [ -20.71, 22.71 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ -20.71, 22.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
4 Role emotional
Bai 2006 25 -13.3 (45.1) 25 -2.7 (39.6) 100.0 % -10.60 [ -34.13, 12.93 ]
Subtotal (95% CI) 25 25 100.0 % -10.60 [ -34.13, 12.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
5 Vitality
Bai 2006 25 3.6 (13.9) 25 5.2 (17.1) 100.0 % -1.60 [ -10.24, 7.04 ]
Subtotal (95% CI) 25 25 100.0 % -1.60 [ -10.24, 7.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
6 General health
Bai 2006 25 -1.2 (18.1) 25 1.4 (19.9) 100.0 % -2.60 [ -13.14, 7.94 ]
Subtotal (95% CI) 25 25 100.0 % -2.60 [ -13.14, 7.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
7 Mental health
Bai 2006 25 2.4 (18.4) 25 -3.4 (21.2) 100.0 % 5.80 [ -5.20, 16.80 ]
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Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 25 25 100.0 % 5.80 [ -5.20, 16.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
8 Bodily pain
Bai 2006 25 -0.7 (12.6) 25 -4.4 (32.3) 100.0 % 3.70 [ -9.89, 17.29 ]
Subtotal (95% CI) 25 25 100.0 % 3.70 [ -9.89, 17.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
9 Physical function
Bai 2006 25 -2.8 (17.7) 25 1.8 (17.1) 100.0 % -4.60 [ -14.25, 5.05 ]
Subtotal (95% CI) 25 25 100.0 % -4.60 [ -14.25, 5.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
10 Social function
Bai 2006 25 7.5 (20.1) 25 -11 (31.1) 100.0 % 18.50 [ 3.98, 33.02 ]
Subtotal (95% CI) 25 25 100.0 % 18.50 [ 3.98, 33.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Chi2 = 9.73, df = 9 (P = 0.37), I2 =7%
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Analysis 3.9. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 9 Adverse events:
1. General.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 9 Adverse events: 1. General
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any - short term
Chue 2002 195/319 189/321 100.0 % 1.04 [ 0.91, 1.18 ]
Subtotal (95% CI) 319 321 100.0 % 1.04 [ 0.91, 1.18 ]
Total events: 195 (Risperidone depot), 189 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 death - short term
Chue 2002 0/319 1/321 100.0 % 0.34 [ 0.01, 8.20 ]
Subtotal (95% CI) 319 321 100.0 % 0.34 [ 0.01, 8.20 ]
Total events: 0 (Risperidone depot), 1 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 3.10. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 10 Adverse
events: 1. General: UKU average change score (high = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 10 Adverse events: 1. General: UKU average change score (high = worse)
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Bai 2006 25 -2.12 (3.46) 25 -0.13 (2.17) 100.0 % -1.99 [ -3.59, -0.39 ]
Subtotal (95% CI) 25 25 100.0 % -1.99 [ -3.59, -0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 11 Adverse
events: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 11 Adverse events: 2. Specific
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anxiety
Chue 2002 32/319 23/321 100.0 % 1.40 [ 0.84, 2.34 ]
Subtotal (95% CI) 319 321 100.0 % 1.40 [ 0.84, 2.34 ]
Total events: 32 (Risperidone depot), 23 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
2 psychosis
Chue 2002 17/319 15/321 100.0 % 1.14 [ 0.58, 2.24 ]
Subtotal (95% CI) 319 321 100.0 % 1.14 [ 0.58, 2.24 ]
Total events: 17 (Risperidone depot), 15 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
3 prolactin related
Chue 2002 4/319 8/321 100.0 % 0.50 [ 0.15, 1.65 ]
Subtotal (95% CI) 319 321 100.0 % 0.50 [ 0.15, 1.65 ]
Total events: 4 (Risperidone depot), 8 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
4 impotence/ejaculation failure
Chue 2002 0/319 1/321 100.0 % 0.34 [ 0.01, 8.20 ]
Subtotal (95% CI) 319 321 100.0 % 0.34 [ 0.01, 8.20 ]
Total events: 0 (Risperidone depot), 1 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
5 dysmenorrhoea
Chue 2002 1/319 1/321 100.0 % 1.01 [ 0.06, 16.02 ]
Subtotal (95% CI) 319 321 100.0 % 1.01 [ 0.06, 16.02 ]
Total events: 1 (Risperidone depot), 1 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
6 hyperprolactinaemia
Chue 2002 0/319 2/321 100.0 % 0.20 [ 0.01, 4.18 ]
Subtotal (95% CI) 319 321 100.0 % 0.20 [ 0.01, 4.18 ]
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(. . . Continued)
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Risperidone depot), 2 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
7 galactorrhoea
Chue 2002 2/319 2/321 100.0 % 1.01 [ 0.14, 7.10 ]
Subtotal (95% CI) 319 321 100.0 % 1.01 [ 0.14, 7.10 ]
Total events: 2 (Risperidone depot), 2 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
8 headache
Chue 2002 26/319 23/321 100.0 % 1.14 [ 0.66, 1.95 ]
Subtotal (95% CI) 319 321 100.0 % 1.14 [ 0.66, 1.95 ]
Total events: 26 (Risperidone depot), 23 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
9 insomnia
Chue 2002 31/319 29/321 100.0 % 1.08 [ 0.66, 1.74 ]
Subtotal (95% CI) 319 321 100.0 % 1.08 [ 0.66, 1.74 ]
Total events: 31 (Risperidone depot), 29 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
10 sexual dysfunction
Chue 2002 1/319 2/321 100.0 % 0.50 [ 0.05, 5.52 ]
Subtotal (95% CI) 319 321 100.0 % 0.50 [ 0.05, 5.52 ]
Total events: 1 (Risperidone depot), 2 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Chi2 = 4.70, df = 9 (P = 0.86), I2 =0.0%
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Analysis 3.12. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 12 Adverse
events: 2. Specific: Mean (SD) weight increase in kg.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 12 Adverse events: 2. Specific: Mean (SD) weight increase in kg
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Chue 2002 319 0.5 (3.5721) 321 0.3 (3.5833) 100.0 % 0.20 [ -0.35, 0.75 ]
Subtotal (95% CI) 319 321 100.0 % 0.20 [ -0.35, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 13 Adverse
events: 3. Movement disorder.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 13 Adverse events: 3. Movement disorder
Study or subgroup Risperidone depot Risperidone oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any extra pyramidal symptoms - short term
Chue 2002 22/319 21/321 100.0 % 1.05 [ 0.59, 1.88 ]
Subtotal (95% CI) 319 321 100.0 % 1.05 [ 0.59, 1.88 ]
Total events: 22 (Risperidone depot), 21 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
2 participants requiring anti-cholinergic drugs - short term
Bai 2006 15/25 18/25 49.4 % 0.83 [ 0.56, 1.25 ]
Chue 2002 49/319 39/321 50.6 % 1.26 [ 0.86, 1.87 ]
Subtotal (95% CI) 344 346 100.0 % 1.03 [ 0.66, 1.60 ]
Total events: 64 (Risperidone depot), 57 (Risperidone oral)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.50, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.13 (P = 0.90)
3 tardive dyskinesia - short term
Chue 2002 4/319 0/321 100.0 % 9.06 [ 0.49, 167.52 ]
Subtotal (95% CI) 319 321 100.0 % 9.06 [ 0.49, 167.52 ]
Total events: 4 (Risperidone depot), 0 (Risperidone oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Chi2 = 2.09, df = 2 (P = 0.35), I2 =4%
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Analysis 3.14. Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 14 Adverse
events: Mean (SD) change in movement disorder rating scales.
Review: Risperidone (depot) for schizophrenia
Comparison: 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE
Outcome: 14 Adverse events: Mean (SD) change in movement disorder rating scales
Study or subgroup Risperidone depot Risperidone oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 AIMS
Bai 2006 25 -3.2 (4.7) 25 -4.36 (3.9) 100.0 % 1.16 [ -1.23, 3.55 ]
Subtotal (95% CI) 25 25 100.0 % 1.16 [ -1.23, 3.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
2 BARS
Bai 2006 25 -0.04 (1.74) 25 -0.2 (1.11) 100.0 % 0.16 [ -0.65, 0.97 ]
Subtotal (95% CI) 25 25 100.0 % 0.16 [ -0.65, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
3 SAS
Bai 2006 25 -3.5 (5.57) 25 -2.95 (5.82) 100.0 % -0.55 [ -3.71, 2.61 ]
Subtotal (95% CI) 25 25 100.0 % -0.55 [ -3.71, 2.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Chi2 = 0.84, df = 2 (P = 0.66), I2 =0.0%
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Analysis 4.1. Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 1 Leaving the study
early: 1. Any reason.
Review: Risperidone (depot) for schizophrenia
Comparison: 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE
Outcome: 1 Leaving the study early: 1. Any reason
Study or subgroup Risperidone depot Quetiapine oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Gaebel 2010* 178/329 217/337 100.0 % 0.84 [ 0.74, 0.95 ]
Subtotal (95% CI) 329 337 100.0 % 0.84 [ 0.74, 0.95 ]
Total events: 178 (Risperidone depot), 217 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 2 Leaving the study
early: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE
Outcome: 2 Leaving the study early: 2. Specific
Study or subgroup Risperidone depot Quetiapine oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 due to relapse - long term
Gaebel 2010* 54/329 102/337 100.0 % 0.54 [ 0.40, 0.73 ]
Subtotal (95% CI) 329 337 100.0 % 0.54 [ 0.40, 0.73 ]
Total events: 54 (Risperidone depot), 102 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 4.10 (P = 0.000042)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 3 Adverse events: 1.
General.
Review: Risperidone (depot) for schizophrenia
Comparison: 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE
Outcome: 3 Adverse events: 1. General
Study or subgroup Risperidone depot Quetiapine oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any
Gaebel 2010* 225/329 235/337 100.0 % 0.98 [ 0.89, 1.09 ]
Subtotal (95% CI) 329 337 100.0 % 0.98 [ 0.89, 1.09 ]
Total events: 225 (Risperidone depot), 235 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
2 serious
Gaebel 2010* 63/329 77/337 100.0 % 0.84 [ 0.62, 1.13 ]
Subtotal (95% CI) 329 337 100.0 % 0.84 [ 0.62, 1.13 ]
Total events: 63 (Risperidone depot), 77 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
3 death
Gaebel 2010* 3/329 2/337 100.0 % 1.54 [ 0.26, 9.14 ]
Subtotal (95% CI) 329 337 100.0 % 1.54 [ 0.26, 9.14 ]
Total events: 3 (Risperidone depot), 2 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 1.23, df = 2 (P = 0.54), I2 =0.0%
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Analysis 4.4. Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 4 Adverse events: 2.
Specifc.
Review: Risperidone (depot) for schizophrenia
Comparison: 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE
Outcome: 4 Adverse events: 2. Specifc
Study or subgroup Risperidone depot Quetiapine oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 psychiatric symptoms
Gaebel 2010* 142/329 145/337 100.0 % 1.00 [ 0.84, 1.19 ]
Subtotal (95% CI) 329 337 100.0 % 1.00 [ 0.84, 1.19 ]
Total events: 142 (Risperidone depot), 145 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 prolactin related
Gaebel 2010* 15/329 5/337 100.0 % 3.07 [ 1.13, 8.36 ]
Subtotal (95% CI) 329 337 100.0 % 3.07 [ 1.13, 8.36 ]
Total events: 15 (Risperidone depot), 5 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
3 hyperprolactinaemia
Gaebel 2010* 43/329 5/337 100.0 % 8.81 [ 3.53, 21.96 ]
Subtotal (95% CI) 329 337 100.0 % 8.81 [ 3.53, 21.96 ]
Total events: 43 (Risperidone depot), 5 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 4.67 (P < 0.00001)
4 serious psychiatric symptoms
Gaebel 2010* 49/329 61/337 100.0 % 0.82 [ 0.58, 1.16 ]
Subtotal (95% CI) 329 337 100.0 % 0.82 [ 0.58, 1.16 ]
Total events: 49 (Risperidone depot), 61 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
5 weight increase
Gaebel 2010* 23/329 21/337 100.0 % 1.12 [ 0.63, 1.99 ]
Subtotal (95% CI) 329 337 100.0 % 1.12 [ 0.63, 1.99 ]
Total events: 23 (Risperidone depot), 21 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
6 headache
Gaebel 2010* 20/329 17/337 100.0 % 1.21 [ 0.64, 2.26 ]
Subtotal (95% CI) 329 337 100.0 % 1.21 [ 0.64, 2.26 ]
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(. . . Continued)
Study or subgroup Risperidone depot Quetiapine oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 20 (Risperidone depot), 17 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
7 fatigue/somnolence
Gaebel 2010* 6/329 38/337 100.0 % 0.16 [ 0.07, 0.38 ]
Subtotal (95% CI) 329 337 100.0 % 0.16 [ 0.07, 0.38 ]
Total events: 6 (Risperidone depot), 38 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 4.21 (P = 0.000025)
Test for subgroup differences: Chi2 = 46.09, df = 6 (P = 0.00), I2 =87%
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Analysis 4.5. Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 5 Adverse events: 2.
Specific: Mean (SD) weight increase in kg.
Review: Risperidone (depot) for schizophrenia
Comparison: 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE
Outcome: 5 Adverse events: 2. Specific: Mean (SD) weight increase in kg
Study or subgroup Risperidone depot Quetiapine oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 long term
Gaebel 2010* 329 1.25 (6.61) 337 0 (6.55) 100.0 % 1.25 [ 0.25, 2.25 ]
Subtotal (95% CI) 329 337 100.0 % 1.25 [ 0.25, 2.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 6 Adverse events: 3.
Movement disorder.
Review: Risperidone (depot) for schizophrenia
Comparison: 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE
Outcome: 6 Adverse events: 3. Movement disorder
Study or subgroup Risperidone depot Quetiapine oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any extra pyramidal symptom
Gaebel 2010* 34/329 19/337 100.0 % 1.83 [ 1.07, 3.15 ]
Subtotal (95% CI) 329 337 100.0 % 1.83 [ 1.07, 3.15 ]
Total events: 34 (Risperidone depot), 19 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
2 tremor
Gaebel 2010* 10/329 2/337 100.0 % 5.12 [ 1.13, 23.20 ]
Subtotal (95% CI) 329 337 100.0 % 5.12 [ 1.13, 23.20 ]
Total events: 10 (Risperidone depot), 2 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
3 tardive dyskinesia
Gaebel 2010* 1/329 3/337 100.0 % 0.34 [ 0.04, 3.27 ]
Subtotal (95% CI) 329 337 100.0 % 0.34 [ 0.04, 3.27 ]
Total events: 1 (Risperidone depot), 3 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
4 dystonia
Gaebel 2010* 1/329 2/337 100.0 % 0.51 [ 0.05, 5.62 ]
Subtotal (95% CI) 329 337 100.0 % 0.51 [ 0.05, 5.62 ]
Total events: 1 (Risperidone depot), 2 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
5 parkinsonism
Gaebel 2010* 15/329 6/337 100.0 % 2.56 [ 1.01, 6.52 ]
Subtotal (95% CI) 329 337 100.0 % 2.56 [ 1.01, 6.52 ]
Total events: 15 (Risperidone depot), 6 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
6 hyperkinesia
Gaebel 2010* 13/329 8/337 100.0 % 1.66 [ 0.70, 3.96 ]
Subtotal (95% CI) 329 337 100.0 % 1.66 [ 0.70, 3.96 ]
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(. . . Continued)
Study or subgroup Risperidone depot Quetiapine oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 13 (Risperidone depot), 8 (Quetiapine oral)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 5.52, df = 5 (P = 0.36), I2 =9%
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Analysis 5.1. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 1 Global state: 1.
Relapse (any reason).
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 1 Global state: 1. Relapse (any reason)
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
MacFadden 2010 81/177 75/172 100.0 % 1.05 [ 0.83, 1.33 ]
Subtotal (95% CI) 177 172 100.0 % 1.05 [ 0.83, 1.33 ]
Total events: 81 (Risperidone depot), 75 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 2 Global state: 3.
Mean time in remission (days).
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 2 Global state: 3. Mean time in remission (days)
Study or subgroup Risperidone depot Oral aripiprazole
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 long term
MacFadden 2010 176 373.5 (282.6) 172 356.7 (292) 100.0 % 16.80 [ -43.59, 77.19 ]
Subtotal (95% CI) 176 172 100.0 % 16.80 [ -43.59, 77.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 3 Mental state: 1.
Average change scores (PANSS, high score = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 3 Mental state: 1. Average change scores (PANSS, high score = worse)
Study or subgroup Risperidone depot Oral aripiprazole
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 long term
MacFadden 2010 177 -11 (14.6345) 172 -10.9 (14.4264) 100.0 % -0.10 [ -3.15, 2.95 ]
Subtotal (95% CI) 177 172 100.0 % -0.10 [ -3.15, 2.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 4 Leaving the
study early: 1. Any reason.
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 4 Leaving the study early: 1. Any reason
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Gaebel 2010* 178/329 35/45 54.6 % 0.70 [ 0.58, 0.84 ]
MacFadden 2010 52/177 49/172 45.4 % 1.03 [ 0.74, 1.43 ]
Total (95% CI) 506 217 100.0 % 0.83 [ 0.53, 1.30 ]
Total events: 230 (Risperidone depot), 84 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.09; Chi2 = 5.67, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 5 Leaving the
study early: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 5 Leaving the study early: 2. Specific
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 adverse events
Gaebel 2010* 7/329 1/45 60.6 % 0.96 [ 0.12, 7.60 ]
MacFadden 2010 0/177 4/172 39.4 % 0.11 [ 0.01, 1.99 ]
Subtotal (95% CI) 506 217 100.0 % 0.41 [ 0.05, 3.55 ]
Total events: 7 (Risperidone depot), 5 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.91; Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.81 (P = 0.42)
2 insufficient response
MacFadden 2010 4/177 3/172 100.0 % 1.30 [ 0.29, 5.70 ]
Subtotal (95% CI) 177 172 100.0 % 1.30 [ 0.29, 5.70 ]
Total events: 4 (Risperidone depot), 3 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
3 withdrawn consent
Gaebel 2010* 59/329 9/45 41.9 % 0.90 [ 0.48, 1.68 ]
MacFadden 2010 25/177 22/172 58.1 % 1.10 [ 0.65, 1.88 ]
Subtotal (95% CI) 506 217 100.0 % 1.01 [ 0.67, 1.52 ]
Total events: 84 (Risperidone depot), 31 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
4 due to relapse
Gaebel 2010* 54/329 12/45 100.0 % 0.62 [ 0.36, 1.06 ]
Subtotal (95% CI) 329 45 100.0 % 0.62 [ 0.36, 1.06 ]
Total events: 54 (Risperidone depot), 12 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.079)
5 loss to follow-up
MacFadden 2010 18/177 10/172 100.0 % 1.75 [ 0.83, 3.68 ]
Subtotal (95% CI) 177 172 100.0 % 1.75 [ 0.83, 3.68 ]
Total events: 18 (Risperidone depot), 10 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 5.90, df = 4 (P = 0.21), I2 =32%
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Analysis 5.6. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 6 Adverse events:
1. General.
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 6 Adverse events: 1. General
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any
Gaebel 2010* 225/329 34/45 33.8 % 0.91 [ 0.75, 1.09 ]
MacFadden 2010 161/179 152/176 66.2 % 1.04 [ 0.96, 1.12 ]
Subtotal (95% CI) 508 221 100.0 % 0.99 [ 0.87, 1.14 ]
Total events: 386 (Risperidone depot), 186 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.10 (P = 0.92)
2 serious
Gaebel 2010* 63/329 7/45 27.1 % 1.23 [ 0.60, 2.52 ]
MacFadden 2010 31/179 35/176 72.9 % 0.87 [ 0.56, 1.35 ]
Subtotal (95% CI) 508 221 100.0 % 0.96 [ 0.66, 1.39 ]
Total events: 94 (Risperidone depot), 42 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
3 death
Gaebel 2010* 3/329 0/45 46.8 % 0.98 [ 0.05, 18.59 ]
MacFadden 2010 1/179 1/176 53.2 % 0.98 [ 0.06, 15.60 ]
Subtotal (95% CI) 508 221 100.0 % 0.98 [ 0.13, 7.36 ]
Total events: 4 (Risperidone depot), 1 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 0.03, df = 2 (P = 0.98), I2 =0.0%
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Analysis 5.7. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 7 Adverse events:
2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 7 Adverse events: 2. Specific
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anxiety
MacFadden 2010 32/179 26/176 100.0 % 1.21 [ 0.75, 1.94 ]
Subtotal (95% CI) 179 176 100.0 % 1.21 [ 0.75, 1.94 ]
Total events: 32 (Risperidone depot), 26 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 depression
MacFadden 2010 24/179 15/176 100.0 % 1.57 [ 0.85, 2.90 ]
Subtotal (95% CI) 179 176 100.0 % 1.57 [ 0.85, 2.90 ]
Total events: 24 (Risperidone depot), 15 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
3 psychosis
MacFadden 2010 38/179 36/176 100.0 % 1.04 [ 0.69, 1.56 ]
Subtotal (95% CI) 179 176 100.0 % 1.04 [ 0.69, 1.56 ]
Total events: 38 (Risperidone depot), 36 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
4 psychiatric symptoms
Gaebel 2010* 142/329 24/45 100.0 % 0.81 [ 0.60, 1.09 ]
Subtotal (95% CI) 329 45 100.0 % 0.81 [ 0.60, 1.09 ]
Total events: 142 (Risperidone depot), 24 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
5 serious psychiatric symptoms
Gaebel 2010* 22/329 4/45 100.0 % 0.75 [ 0.27, 2.08 ]
Subtotal (95% CI) 329 45 100.0 % 0.75 [ 0.27, 2.08 ]
Total events: 22 (Risperidone depot), 4 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
6 schizophrenia
MacFadden 2010 29/179 28/176 100.0 % 1.02 [ 0.63, 1.64 ]
Subtotal (95% CI) 179 176 100.0 % 1.02 [ 0.63, 1.64 ]
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(. . . Continued)
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 29 (Risperidone depot), 28 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
7 prolactin related
Gaebel 2010* 15/329 0/45 20.6 % 4.32 [ 0.26, 71.01 ]
MacFadden 2010 25/179 2/176 79.4 % 12.29 [ 2.96, 51.11 ]
Subtotal (95% CI) 508 221 100.0 % 9.91 [ 2.78, 35.29 ]
Total events: 40 (Risperidone depot), 2 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.54 (P = 0.00040)
8 hyperprolactinaemia
Gaebel 2010* 43/329 0/45 100.0 % 12.13 [ 0.76, 193.65 ]
Subtotal (95% CI) 329 45 100.0 % 12.13 [ 0.76, 193.65 ]
Total events: 43 (Risperidone depot), 0 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.078)
9 weight increase
Gaebel 2010* 23/329 2/45 100.0 % 1.57 [ 0.38, 6.45 ]
Subtotal (95% CI) 329 45 100.0 % 1.57 [ 0.38, 6.45 ]
Total events: 23 (Risperidone depot), 2 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
10 nausea/vomiting
MacFadden 2010 18/177 14/172 100.0 % 1.25 [ 0.64, 2.43 ]
Subtotal (95% CI) 177 172 100.0 % 1.25 [ 0.64, 2.43 ]
Total events: 18 (Risperidone depot), 14 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
11 gastrointestinal
Gaebel 2010* 20/329 10/45 100.0 % 0.27 [ 0.14, 0.55 ]
Subtotal (95% CI) 329 45 100.0 % 0.27 [ 0.14, 0.55 ]
Total events: 20 (Risperidone depot), 10 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 3.67 (P = 0.00024)
12 decreased appetite
MacFadden 2010 29/179 16/176 100.0 % 1.78 [ 1.00, 3.16 ]
Subtotal (95% CI) 179 176 100.0 % 1.78 [ 1.00, 3.16 ]
Total events: 29 (Risperidone depot), 16 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.048)
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(. . . Continued)
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
13 diarrhoea
MacFadden 2010 12/179 19/176 100.0 % 0.62 [ 0.31, 1.24 ]
Subtotal (95% CI) 179 176 100.0 % 0.62 [ 0.31, 1.24 ]
Total events: 12 (Risperidone depot), 19 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
14 headache
Gaebel 2010* 20/329 5/45 32.7 % 0.55 [ 0.22, 1.39 ]
MacFadden 2010 30/179 27/176 67.3 % 1.09 [ 0.68, 1.76 ]
Subtotal (95% CI) 508 221 100.0 % 0.87 [ 0.46, 1.65 ]
Total events: 50 (Risperidone depot), 32 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.42 (P = 0.67)
15 insomnia
MacFadden 2010 47/179 51/176 100.0 % 0.91 [ 0.65, 1.27 ]
Subtotal (95% CI) 179 176 100.0 % 0.91 [ 0.65, 1.27 ]
Total events: 47 (Risperidone depot), 51 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
16 upper resp. tract infection
MacFadden 2010 7/179 18/176 100.0 % 0.38 [ 0.16, 0.89 ]
Subtotal (95% CI) 179 176 100.0 % 0.38 [ 0.16, 0.89 ]
Total events: 7 (Risperidone depot), 18 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
17 pyrexia
MacFadden 2010 26/179 22/176 100.0 % 1.16 [ 0.69, 1.97 ]
Subtotal (95% CI) 179 176 100.0 % 1.16 [ 0.69, 1.97 ]
Total events: 26 (Risperidone depot), 22 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
18 nasopharyngitis
MacFadden 2010 18/179 16/176 100.0 % 1.11 [ 0.58, 2.10 ]
Subtotal (95% CI) 179 176 100.0 % 1.11 [ 0.58, 2.10 ]
Total events: 18 (Risperidone depot), 16 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
19 dizziness
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(. . . Continued)
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MacFadden 2010 25/179 13/176 100.0 % 1.89 [ 1.00, 3.58 ]
Subtotal (95% CI) 179 176 100.0 % 1.89 [ 1.00, 3.58 ]
Total events: 25 (Risperidone depot), 13 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
20 glucose related
MacFadden 2010 18/179 16/176 100.0 % 1.11 [ 0.58, 2.10 ]
Subtotal (95% CI) 179 176 100.0 % 1.11 [ 0.58, 2.10 ]
Total events: 18 (Risperidone depot), 16 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 50.42, df = 19 (P = 0.00), I2 =62%
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Analysis 5.8. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 8 Adverse events:
2. Specific 12. Mean (SD) weight increase in kg.
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 8 Adverse events: 2. Specific 12. Mean (SD) weight increase in kg
Study or subgroup Risperidone depot Oral aripiprazole
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 long term
MacFadden 2010 179 2.6 (5.8) 176 1.6 (7.7) 100.0 % 1.00 [ -0.42, 2.42 ]
Subtotal (95% CI) 179 176 100.0 % 1.00 [ -0.42, 2.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 5.9. Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 9 Adverse events:
3. Movement disorder.
Review: Risperidone (depot) for schizophrenia
Comparison: 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Outcome: 9 Adverse events: 3. Movement disorder
Study or subgroup Risperidone depot Oral aripiprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any extra pyramidal symptoms
Gaebel 2010* 34/329 2/45 3.6 % 2.33 [ 0.58, 9.35 ]
MacFadden 2010 72/179 61/176 96.4 % 1.16 [ 0.89, 1.52 ]
Subtotal (95% CI) 508 221 100.0 % 1.19 [ 0.91, 1.55 ]
Total events: 106 (Risperidone depot), 63 (Oral aripiprazole)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
2 tremor
MacFadden 2010 39/179 40/176 100.0 % 0.96 [ 0.65, 1.41 ]
Subtotal (95% CI) 179 176 100.0 % 0.96 [ 0.65, 1.41 ]
Total events: 39 (Risperidone depot), 40 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
3 akathisia
MacFadden 2010 20/179 20/176 100.0 % 0.98 [ 0.55, 1.76 ]
Subtotal (95% CI) 179 176 100.0 % 0.98 [ 0.55, 1.76 ]
Total events: 20 (Risperidone depot), 20 (Oral aripiprazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.96, df = 2 (P = 0.62), I2 =0.0%
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Analysis 6.1. Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 1 Mental state: 1.
Average change scores (PANNS, high score = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE
Outcome: 1 Mental state: 1. Average change scores (PANNS, high score = worse)
Study or subgroup Risperidone depot Oral olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total - short term
Keks 2007 164 -16.9 (15.5) 213 -17.8 (15.4) 100.0 % 0.90 [ -2.25, 4.05 ]
Subtotal (95% CI) 164 213 100.0 % 0.90 [ -2.25, 4.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 total - long term
Keks 2007 155 -20.4 (18.8) 206 -20.5 (20.3) 100.0 % 0.10 [ -3.96, 4.16 ]
Subtotal (95% CI) 155 206 100.0 % 0.10 [ -3.96, 4.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 positive symptoms - long term
Keks 2007 155 -6.8 (5.8) 206 -6.5 (6.9) 100.0 % -0.30 [ -1.61, 1.01 ]
Subtotal (95% CI) 155 206 100.0 % -0.30 [ -1.61, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
4 negative symptoms - long term
Keks 2007 155 -4.7 (6.6) 206 -4.8 (6.6) 100.0 % 0.10 [ -1.28, 1.48 ]
Subtotal (95% CI) 155 206 100.0 % 0.10 [ -1.28, 1.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
5 disorganised thoughts - long term
Keks 2007 155 -4.3 (4.8) 206 -4 (5.2) 100.0 % -0.30 [ -1.34, 0.74 ]
Subtotal (95% CI) 155 206 100.0 % -0.30 [ -1.34, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
6 hostility/excitement - long term
Keks 2007 155 -1.6 (3.7) 206 -1.8 (4) 100.0 % 0.20 [ -0.60, 1.00 ]
Subtotal (95% CI) 155 206 100.0 % 0.20 [ -0.60, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
7 anxiety/depression - long term
Keks 2007 155 -3.1 (3.6) 206 -3.4 (3.7) 100.0 % 0.30 [ -0.46, 1.06 ]
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(. . . Continued)
Study or subgroup Risperidone depot Oral olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 155 206 100.0 % 0.30 [ -0.46, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 1.50, df = 6 (P = 0.96), I2 =0.0%
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Analysis 6.2. Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 2 Leaving the study
early: 1. Any reason.
Review: Risperidone (depot) for schizophrenia
Comparison: 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE
Outcome: 2 Leaving the study early: 1. Any reason
Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term
Keks 2007 158/318 113/300 100.0 % 1.32 [ 1.10, 1.58 ]
Subtotal (95% CI) 318 300 100.0 % 1.32 [ 1.10, 1.58 ]
Total events: 158 (Risperidone depot), 113 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
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Analysis 6.3. Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 3 Leaving the study
early: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE
Outcome: 3 Leaving the study early: 2. Specific
Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 adverse events
Keks 2007 7/247 12/300 100.0 % 0.71 [ 0.28, 1.77 ]
Subtotal (95% CI) 247 300 100.0 % 0.71 [ 0.28, 1.77 ]
Total events: 7 (Risperidone depot), 12 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
2 insufficient response
Keks 2007 22/247 33/300 100.0 % 0.81 [ 0.49, 1.35 ]
Subtotal (95% CI) 247 300 100.0 % 0.81 [ 0.49, 1.35 ]
Total events: 22 (Risperidone depot), 33 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
3 withdrawn consent
Keks 2007 44/247 21/300 100.0 % 2.54 [ 1.56, 4.16 ]
Subtotal (95% CI) 247 300 100.0 % 2.54 [ 1.56, 4.16 ]
Total events: 44 (Risperidone depot), 21 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.72 (P = 0.00020)
4 due to weight gain
Keks 2007 1/247 5/300 100.0 % 0.24 [ 0.03, 2.07 ]
Subtotal (95% CI) 247 300 100.0 % 0.24 [ 0.03, 2.07 ]
Total events: 1 (Risperidone depot), 5 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
Test for subgroup differences: Chi2 = 14.48, df = 3 (P = 0.00), I2 =79%
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Analysis 6.4. Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 4 Adverse events:
1. General.
Review: Risperidone (depot) for schizophrenia
Comparison: 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE
Outcome: 4 Adverse events: 1. General
Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 serious
Keks 2007 57/247 63/300 100.0 % 1.10 [ 0.80, 1.51 ]
Subtotal (95% CI) 247 300 100.0 % 1.10 [ 0.80, 1.51 ]
Total events: 57 (Risperidone depot), 63 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 death
Keks 2007 2/318 6/300 100.0 % 0.31 [ 0.06, 1.55 ]
Subtotal (95% CI) 318 300 100.0 % 0.31 [ 0.06, 1.55 ]
Total events: 2 (Risperidone depot), 6 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Chi2 = 2.28, df = 1 (P = 0.13), I2 =56%
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Analysis 6.5. Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 5 Adverse events:
2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE
Outcome: 5 Adverse events: 2. Specific
Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 agitation
Keks 2007 24/238 15/294 100.0 % 1.98 [ 1.06, 3.68 ]
Subtotal (95% CI) 238 294 100.0 % 1.98 [ 1.06, 3.68 ]
Total events: 24 (Risperidone depot), 15 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
2 anxiety
Keks 2007 33/238 47/294 100.0 % 0.87 [ 0.58, 1.31 ]
Subtotal (95% CI) 238 294 100.0 % 0.87 [ 0.58, 1.31 ]
Total events: 33 (Risperidone depot), 47 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 depression
Keks 2007 48/238 41/294 100.0 % 1.45 [ 0.99, 2.12 ]
Subtotal (95% CI) 238 294 100.0 % 1.45 [ 0.99, 2.12 ]
Total events: 48 (Risperidone depot), 41 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
4 psychosis
Keks 2007 69/238 74/294 100.0 % 1.15 [ 0.87, 1.52 ]
Subtotal (95% CI) 238 294 100.0 % 1.15 [ 0.87, 1.52 ]
Total events: 69 (Risperidone depot), 74 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
5 impotence/ejaculation failure
Keks 2007 2/247 2/300 100.0 % 1.21 [ 0.17, 8.56 ]
Subtotal (95% CI) 247 300 100.0 % 1.21 [ 0.17, 8.56 ]
Total events: 2 (Risperidone depot), 2 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.85)
6 galactorrhoea
Keks 2007 5/247 2/300 100.0 % 3.04 [ 0.59, 15.52 ]
Subtotal (95% CI) 247 300 100.0 % 3.04 [ 0.59, 15.52 ]
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Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 5 (Risperidone depot), 2 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
7 serious psychiatric symptoms
Keks 2007 30/247 36/300 100.0 % 1.01 [ 0.64, 1.59 ]
Subtotal (95% CI) 247 300 100.0 % 1.01 [ 0.64, 1.59 ]
Total events: 30 (Risperidone depot), 36 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
8 serious anxiety
Keks 2007 7/247 6/300 100.0 % 1.42 [ 0.48, 4.16 ]
Subtotal (95% CI) 247 300 100.0 % 1.42 [ 0.48, 4.16 ]
Total events: 7 (Risperidone depot), 6 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
9 suicide attempt
Keks 2007 10/247 9/300 100.0 % 1.35 [ 0.56, 3.27 ]
Subtotal (95% CI) 247 300 100.0 % 1.35 [ 0.56, 3.27 ]
Total events: 10 (Risperidone depot), 9 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
10 serious injury
Keks 2007 5/247 3/300 100.0 % 2.02 [ 0.49, 8.39 ]
Subtotal (95% CI) 247 300 100.0 % 2.02 [ 0.49, 8.39 ]
Total events: 5 (Risperidone depot), 3 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
11 weight increase
Keks 2007 50/247 108/300 100.0 % 0.56 [ 0.42, 0.75 ]
Subtotal (95% CI) 247 300 100.0 % 0.56 [ 0.42, 0.75 ]
Total events: 50 (Risperidone depot), 108 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.89 (P = 0.000099)
12 headache
Keks 2007 19/238 15/294 100.0 % 1.56 [ 0.81, 3.01 ]
Subtotal (95% CI) 238 294 100.0 % 1.56 [ 0.81, 3.01 ]
Total events: 19 (Risperidone depot), 15 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
13 insomnia
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Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keks 2007 52/238 14/294 100.0 % 4.59 [ 2.61, 8.07 ]
Subtotal (95% CI) 238 294 100.0 % 4.59 [ 2.61, 8.07 ]
Total events: 52 (Risperidone depot), 14 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 5.29 (P < 0.00001)
14 fatigue/somnolence
Keks 2007 12/238 21/294 100.0 % 0.71 [ 0.35, 1.41 ]
Subtotal (95% CI) 238 294 100.0 % 0.71 [ 0.35, 1.41 ]
Total events: 12 (Risperidone depot), 21 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
15 nasopharyngitis
Keks 2007 17/238 18/294 100.0 % 1.17 [ 0.61, 2.21 ]
Subtotal (95% CI) 238 294 100.0 % 1.17 [ 0.61, 2.21 ]
Total events: 17 (Risperidone depot), 18 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
16 diabetes mellitus
Keks 2007 1/247 1/300 100.0 % 1.21 [ 0.08, 19.32 ]
Subtotal (95% CI) 247 300 100.0 % 1.21 [ 0.08, 19.32 ]
Total events: 1 (Risperidone depot), 1 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
17 hyperglycaemia
Keks 2007 4/247 4/247 100.0 % 1.00 [ 0.25, 3.95 ]
Subtotal (95% CI) 247 247 100.0 % 1.00 [ 0.25, 3.95 ]
Total events: 4 (Risperidone depot), 4 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
18 hypoglycaemia
Keks 2007 0/247 1/300 100.0 % 0.40 [ 0.02, 9.89 ]
Subtotal (95% CI) 247 300 100.0 % 0.40 [ 0.02, 9.89 ]
Total events: 0 (Risperidone depot), 1 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 57.81, df = 17 (P = 0.00), I2 =71%
0.01 0.1 1 10 100
Favours risperidone depot Favours oral olanzapine
165Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.6. Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 6 Adverse events:
3. Movement disorder.
Review: Risperidone (depot) for schizophrenia
Comparison: 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE
Outcome: 6 Adverse events: 3. Movement disorder
Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any extra pyramidal symptoms
Keks 2007 62/247 45/300 100.0 % 1.67 [ 1.19, 2.36 ]
Subtotal (95% CI) 247 300 100.0 % 1.67 [ 1.19, 2.36 ]
Total events: 62 (Risperidone depot), 45 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
2 tremor
Keks 2007 17/247 9/300 100.0 % 2.29 [ 1.04, 5.06 ]
Subtotal (95% CI) 247 300 100.0 % 2.29 [ 1.04, 5.06 ]
Total events: 17 (Risperidone depot), 9 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
3 tardive dyskinesia
Keks 2007 2/247 2/300 100.0 % 1.21 [ 0.17, 8.56 ]
Subtotal (95% CI) 247 300 100.0 % 1.21 [ 0.17, 8.56 ]
Total events: 2 (Risperidone depot), 2 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.85)
4 hypertonia
Keks 2007 10/247 9/300 100.0 % 1.35 [ 0.56, 3.27 ]
Subtotal (95% CI) 247 300 100.0 % 1.35 [ 0.56, 3.27 ]
Total events: 10 (Risperidone depot), 9 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
5 dystonia
Keks 2007 2/247 0/300 100.0 % 6.07 [ 0.29, 125.82 ]
Subtotal (95% CI) 247 300 100.0 % 6.07 [ 0.29, 125.82 ]
Total events: 2 (Risperidone depot), 0 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
6 hyperkinesia
Keks 2007 20/247 12/300 100.0 % 2.02 [ 1.01, 4.06 ]
Subtotal (95% CI) 247 300 100.0 % 2.02 [ 1.01, 4.06 ]
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Study or subgroup Risperidone depot Oral olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 20 (Risperidone depot), 12 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
7 requiring antiparkinson drugs
Keks 2007 106/247 102/300 100.0 % 1.26 [ 1.02, 1.56 ]
Subtotal (95% CI) 247 300 100.0 % 1.26 [ 1.02, 1.56 ]
Total events: 106 (Risperidone depot), 102 (Oral olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Chi2 = 5.36, df = 6 (P = 0.50), I2 =0.0%
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OUTCOMES), Outcome 1 Global state: 1. Relapse (any reason).
Review: Risperidone (depot) for schizophrenia
Comparison: 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome: 1 Global state: 1. Relapse (any reason)
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs aripiprazole - long term
MacFadden 2010 81/177 75/172 100.0 % 1.05 [ 0.83, 1.33 ]
Subtotal (95% CI) 177 172 100.0 % 1.05 [ 0.83, 1.33 ]
Total events: 81 (Risperidone depot), 75 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.69)
2 vs general oral antipsychotics - long term
Quinn 2012* 11/32 5/31 100.0 % 2.13 [ 0.84, 5.43 ]
Subtotal (95% CI) 32 31 100.0 % 2.13 [ 0.84, 5.43 ]
Total events: 11 (Risperidone depot), 5 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 2.08, df = 1 (P = 0.15), I2 =52%
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Analysis 7.2. Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY
OUTCOMES), Outcome 2 Mental state: 1. Average change scores (PANSS, high score = worse) 1. total.
Review: Risperidone (depot) for schizophrenia
Comparison: 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome: 2 Mental state: 1. Average change scores (PANSS, high score = worse) 1. total
Study or subgroup Risperidone depot Oral control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs oral risperidone (non ITT data) - short term
Bai 2006 25 -0.16 (9.04) 25 -2.4 (10.4) 11.4 % 2.24 [ -3.16, 7.64 ]
Chue 2002 266 -5.4 (11.41) 275 -6.3 (11.6) 88.6 % 0.90 [ -1.04, 2.84 ]
Subtotal (95% CI) 291 300 100.0 % 1.05 [ -0.77, 2.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
2 vs olanzapine - short term
Keks 2007 164 -16.9 (15.5) 213 -17.8 (15.4) 100.0 % 0.90 [ -2.25, 4.05 ]
Subtotal (95% CI) 164 213 100.0 % 0.90 [ -2.25, 4.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
3 vs olanzapine - long term
Keks 2007 155 -20.4 (18.8) 206 -20.5 (20.3) 100.0 % 0.10 [ -3.96, 4.16 ]
Subtotal (95% CI) 155 206 100.0 % 0.10 [ -3.96, 4.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
4 vs aripiprazole - long term
MacFadden 2010 177 -11 (14.6345) 172 -10.9 (14.4264) 100.0 % -0.10 [ -3.15, 2.95 ]
Subtotal (95% CI) 177 172 100.0 % -0.10 [ -3.15, 2.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.51, df = 3 (P = 0.92), I2 =0.0%
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Analysis 7.3. Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY
OUTCOMES), Outcome 3 Leaving the study early: 1. Any reason.
Review: Risperidone (depot) for schizophrenia
Comparison: 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome: 3 Leaving the study early: 1. Any reason
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs aripiprazole
Gaebel 2010* 178/329 35/45 54.6 % 0.70 [ 0.58, 0.84 ]
MacFadden 2010 52/177 49/172 45.4 % 1.03 [ 0.74, 1.43 ]
Subtotal (95% CI) 506 217 100.0 % 0.83 [ 0.53, 1.30 ]
Total events: 230 (Risperidone depot), 84 (Oral control)
Heterogeneity: Tau2 = 0.09; Chi2 = 5.67, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.81 (P = 0.42)
2 vs quetiapine
Gaebel 2010* 178/329 217/337 100.0 % 0.84 [ 0.74, 0.95 ]
Subtotal (95% CI) 329 337 100.0 % 0.84 [ 0.74, 0.95 ]
Total events: 178 (Risperidone depot), 217 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0074)
3 vs oral risperidone
Bai 2006 1/25 0/25 1.1 % 3.00 [ 0.13, 70.30 ]
Chue 2002 63/319 50/321 98.9 % 1.27 [ 0.90, 1.78 ]
Subtotal (95% CI) 344 346 100.0 % 1.28 [ 0.92, 1.79 ]
Total events: 64 (Risperidone depot), 50 (Oral control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
4 vs any new generation antipsychotic
Quinn 2012* 26/42 30/35 100.0 % 0.72 [ 0.55, 0.95 ]
Subtotal (95% CI) 42 35 100.0 % 0.72 [ 0.55, 0.95 ]
Total events: 26 (Risperidone depot), 30 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.020)
5 vs olanzapine
Keks 2007 158/318 113/300 100.0 % 1.32 [ 1.10, 1.58 ]
Subtotal (95% CI) 318 300 100.0 % 1.32 [ 1.10, 1.58 ]
Total events: 158 (Risperidone depot), 113 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
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Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 vs any oral antipsychotic
Rosenheck 2011 68/190 55/192 100.0 % 1.25 [ 0.93, 1.68 ]
Subtotal (95% CI) 190 192 100.0 % 1.25 [ 0.93, 1.68 ]
Total events: 68 (Risperidone depot), 55 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 26.14, df = 5 (P = 0.00), I2 =81%
0.02 0.1 1 10 50
Favours risperidone depot Favours oral control
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OUTCOMES), Outcome 4 Adverse events: 1. Death.
Review: Risperidone (depot) for schizophrenia
Comparison: 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome: 4 Adverse events: 1. Death
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs olanzapine
Keks 2007 2/318 6/300 100.0 % 0.31 [ 0.06, 1.55 ]
Subtotal (95% CI) 318 300 100.0 % 0.31 [ 0.06, 1.55 ]
Total events: 2 (Risperidone depot), 6 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
2 vs oral risperidone
Chue 2002 0/319 1/321 100.0 % 0.34 [ 0.01, 8.20 ]
Subtotal (95% CI) 319 321 100.0 % 0.34 [ 0.01, 8.20 ]
Total events: 0 (Risperidone depot), 1 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 vs any oral antipsychotic
Rosenheck 2011 2/190 2/192 100.0 % 1.01 [ 0.14, 7.10 ]
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Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 190 192 100.0 % 1.01 [ 0.14, 7.10 ]
Total events: 2 (Risperidone depot), 2 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4 vs aripiprazole
Gaebel 2010* 3/329 0/45 46.8 % 0.98 [ 0.05, 18.59 ]
MacFadden 2010 1/179 1/176 53.2 % 0.98 [ 0.06, 15.60 ]
Subtotal (95% CI) 508 221 100.0 % 0.98 [ 0.13, 7.36 ]
Total events: 4 (Risperidone depot), 1 (Oral control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
5 vs quetiapine
Gaebel 2010* 3/329 2/337 100.0 % 1.54 [ 0.26, 9.14 ]
Subtotal (95% CI) 329 337 100.0 % 1.54 [ 0.26, 9.14 ]
Total events: 3 (Risperidone depot), 2 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 2.16, df = 4 (P = 0.71), I2 =0.0%
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Analysis 7.5. Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY
OUTCOMES), Outcome 5 Adverse events: 1. General: a. any.
Review: Risperidone (depot) for schizophrenia
Comparison: 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome: 5 Adverse events: 1. General: a. any
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs aripiprazole
Gaebel 2010* 225/329 34/45 33.8 % 0.91 [ 0.75, 1.09 ]
MacFadden 2010 161/179 152/176 66.2 % 1.04 [ 0.96, 1.12 ]
Subtotal (95% CI) 508 221 100.0 % 0.99 [ 0.87, 1.14 ]
Total events: 386 (Risperidone depot), 186 (Oral control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.10 (P = 0.92)
2 vs oral risperidone
Chue 2002 195/319 189/321 100.0 % 1.04 [ 0.91, 1.18 ]
Subtotal (95% CI) 319 321 100.0 % 1.04 [ 0.91, 1.18 ]
Total events: 195 (Risperidone depot), 189 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
3 vs quetiapine
Gaebel 2010* 225/329 235/337 100.0 % 0.98 [ 0.89, 1.09 ]
Subtotal (95% CI) 329 337 100.0 % 0.98 [ 0.89, 1.09 ]
Total events: 225 (Risperidone depot), 235 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Chi2 = 0.49, df = 2 (P = 0.78), I2 =0.0%
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Analysis 7.6. Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY
OUTCOMES), Outcome 6 Adverse events: 1. General: b. serious.
Review: Risperidone (depot) for schizophrenia
Comparison: 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome: 6 Adverse events: 1. General: b. serious
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs quetiapine
Gaebel 2010* 63/329 77/337 100.0 % 0.84 [ 0.62, 1.13 ]
Subtotal (95% CI) 329 337 100.0 % 0.84 [ 0.62, 1.13 ]
Total events: 63 (Risperidone depot), 77 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 vs aripiprazole
Gaebel 2010* 63/329 7/45 27.1 % 1.23 [ 0.60, 2.52 ]
MacFadden 2010 31/179 35/176 72.9 % 0.87 [ 0.56, 1.35 ]
Subtotal (95% CI) 508 221 100.0 % 0.96 [ 0.66, 1.39 ]
Total events: 94 (Risperidone depot), 42 (Oral control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
3 vs olanzapine
Keks 2007 57/247 63/300 100.0 % 1.10 [ 0.80, 1.51 ]
Subtotal (95% CI) 247 300 100.0 % 1.10 [ 0.80, 1.51 ]
Total events: 57 (Risperidone depot), 63 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 1.50, df = 2 (P = 0.47), I2 =0.0%
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Analysis 7.7. Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY
OUTCOMES), Outcome 7 Adverse events: 2. Movement disorder: a. any extra pyramidal symptoms.
Review: Risperidone (depot) for schizophrenia
Comparison: 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)
Outcome: 7 Adverse events: 2. Movement disorder: a. any extra pyramidal symptoms
Study or subgroup Risperidone depot Oral control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs aripiprazole
Gaebel 2010* 34/329 2/45 3.6 % 2.33 [ 0.58, 9.35 ]
MacFadden 2010 72/179 61/176 96.4 % 1.16 [ 0.89, 1.52 ]
Subtotal (95% CI) 508 221 100.0 % 1.19 [ 0.91, 1.55 ]
Total events: 106 (Risperidone depot), 63 (Oral control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
2 vs quetiapine
Gaebel 2010* 34/329 19/337 100.0 % 1.83 [ 1.07, 3.15 ]
Subtotal (95% CI) 329 337 100.0 % 1.83 [ 1.07, 3.15 ]
Total events: 34 (Risperidone depot), 19 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
3 vs olanzapine
Keks 2007 62/247 45/300 100.0 % 1.67 [ 1.19, 2.36 ]
Subtotal (95% CI) 247 300 100.0 % 1.67 [ 1.19, 2.36 ]
Total events: 62 (Risperidone depot), 45 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
4 vs oral risperidone
Chue 2002 22/319 21/321 100.0 % 1.05 [ 0.59, 1.88 ]
Subtotal (95% CI) 319 321 100.0 % 1.05 [ 0.59, 1.88 ]
Total events: 22 (Risperidone depot), 21 (Oral control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 4.28, df = 3 (P = 0.23), I2 =30%
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Analysis 8.1. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 1 Global State: 1. CGI-S mean change from baseline (high score =
worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 1 Global State: 1. CGI-S mean change from baseline (high score = worse)
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 medium term
Li 2011 208 -1.7 (1.16) 205 -1.5 (1.24) 37.5 % -0.20 [ -0.43, 0.03 ]
Pandina 2011 460 -0.9 (0.93) 453 -0.9 (0.97) 62.5 % 0.0 [ -0.12, 0.12 ]
Total (95% CI) 668 658 100.0 % -0.07 [ -0.26, 0.11 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.23, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 2 Global state: 2. Schedule for Deficit Syndrome (SDS) scale (mean
change from baseline, high score = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 2 Global state: 2. Schedule for Deficit Syndrome (SDS) scale (mean change from baseline, high score = worse)
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 medium term
Pandina 2011 460 -1.8 (2.91) 453 -1.9 (3.03) 100.0 % 0.10 [ -0.29, 0.49 ]
Subtotal (95% CI) 460 453 100.0 % 0.10 [ -0.29, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 3 Mental state: 1. PANSS scores (high score = worse) - medium
term.
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 3 Mental state: 1. PANSS scores (high score = worse) - medium term
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total mean change to endpoint (ITT and per protocol data)*
Li 2011 208 26.9 (15.43) 205 23.6 (16.28) 45.4 % 3.30 [ 0.24, 6.36 ]
Pandina 2011 460 17.9 (14.24) 453 18.6 (15.45) 54.6 % -0.70 [ -2.63, 1.23 ]
Subtotal (95% CI) 668 658 100.0 % 1.12 [ -2.79, 5.02 ]
Heterogeneity: Tau2 = 6.30; Chi2 = 4.70, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.56 (P = 0.58)
2 positive symptoms score change to endpoint
Li 2011 208 10.9 (7.07) 205 9.1 (7.28) 45.7 % 1.80 [ 0.42, 3.18 ]
Pandina 2011 460 5.3 (5.04) 453 5.6 (5.53) 54.3 % -0.30 [ -0.99, 0.39 ]
Subtotal (95% CI) 668 658 100.0 % 0.66 [ -1.39, 2.71 ]
Heterogeneity: Tau2 = 1.89; Chi2 = 7.09, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.63 (P = 0.53)
3 negative symptoms score change to endpoint (ITT data)
Li 2011 208 5.6 (5.96) 205 5.3 (6.39) 20.1 % 0.30 [ -0.89, 1.49 ]
Pandina 2011 460 3.8 (4.61) 453 3.8 (4.61) 79.9 % 0.0 [ -0.60, 0.60 ]
Subtotal (95% CI) 668 658 100.0 % 0.06 [ -0.47, 0.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
4 disorganised thoughts score change to endpoint (ITT data)
Li 2011 208 4.6 (4.26) 205 4.2 (4) 36.9 % 0.40 [ -0.40, 1.20 ]
Pandina 2011 460 3.2 (3.92) 453 3.4 (4.14) 63.1 % -0.20 [ -0.72, 0.32 ]
Subtotal (95% CI) 668 658 100.0 % 0.02 [ -0.55, 0.59 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.07 (P = 0.94)
5 uncontrolled hostility/excitement score change to endpoint (ITT data)
Li 2011 208 3.4 (3.67) 205 3.1 (3.71) 31.5 % 0.30 [ -0.41, 1.01 ]
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(. . . Continued)
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pandina 2011 460 1.5 (2.97) 453 1.7 (3.01) 68.5 % -0.20 [ -0.59, 0.19 ]
Subtotal (95% CI) 668 658 100.0 % -0.04 [ -0.50, 0.41 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 1.46, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.18 (P = 0.85)
6 anxiety/depression score change to endpoint (ITT data)
Li 2011 208 2.3 (3.16) 205 1.9 (3.02) 44.6 % 0.40 [ -0.20, 1.00 ]
Pandina 2011 460 2.4 (2.88) 453 2.7 (3.15) 55.4 % -0.30 [ -0.69, 0.09 ]
Subtotal (95% CI) 668 658 100.0 % 0.01 [ -0.67, 0.69 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 3.70, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.77, df = 5 (P = 0.98), I2 =0.0%
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Analysis 8.4. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 4 Mental state: 2. Improved by 30% in total PANSS score (ITT data).
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 4 Mental state: 2. Improved by 30% in total PANSS score (ITT data)
Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 medium term
Li 2011 163/208 145/205 51.1 % 1.11 [ 0.99, 1.24 ]
Pandina 2011 223/460 240/453 48.9 % 0.92 [ 0.81, 1.04 ]
Subtotal (95% CI) 668 658 100.0 % 1.01 [ 0.83, 1.23 ]
Total events: 386 (Risperidone depot), 385 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.31, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 5 General functioning: Personal and Social Performance (PSP) scale
(high score = better).
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 5 General functioning: Personal and Social Performance (PSP) scale (high score = better)
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 mean endpoint - medium term
Li 2011 208 18.6 (13.92) 205 16.8 (14.76) 23.2 % 1.80 [ -0.97, 4.57 ]
Pandina 2011 460 8.8 (11.65) 453 8.5 (11.82) 76.8 % 0.30 [ -1.22, 1.82 ]
Total (95% CI) 668 658 100.0 % 0.65 [ -0.69, 1.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 6 Leaving the study early: 1. Any reason.
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 6 Leaving the study early: 1. Any reason
Study or subgroup
Favours
risperidone
depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Lack of efficacy - medium term
Li 2011 9/223 22/229 44.1 % 0.42 [ 0.20, 0.89 ]
Pandina 2011 43/613 40/607 55.9 % 1.06 [ 0.70, 1.61 ]
Subtotal (95% CI) 836 836 100.0 % 0.71 [ 0.29, 1.75 ]
Total events: 52 (Favours risperidone depot), 62 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.34; Chi2 = 4.50, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Lack of efficacy - long term
Fleischhacker 2011 56/370 95/379 100.0 % 0.60 [ 0.45, 0.81 ]
Subtotal (95% CI) 370 379 100.0 % 0.60 [ 0.45, 0.81 ]
Total events: 56 (Favours risperidone depot), 95 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 3.32 (P = 0.00089)
3 Adverse events - medium term
Li 2011 5/223 4/229 33.8 % 1.28 [ 0.35, 4.72 ]
Pandina 2011 10/613 20/607 66.2 % 0.50 [ 0.23, 1.05 ]
Subtotal (95% CI) 836 836 100.0 % 0.68 [ 0.28, 1.65 ]
Total events: 15 (Favours risperidone depot), 24 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.16; Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.85 (P = 0.40)
4 Adverse events - long term
Fleischhacker 2011 25/370 29/379 100.0 % 0.88 [ 0.53, 1.48 ]
Subtotal (95% CI) 370 379 100.0 % 0.88 [ 0.53, 1.48 ]
Total events: 25 (Favours risperidone depot), 29 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
5 Patient choice/withdrawn consent - medium term
Li 2011 5/223 16/229 40.5 % 0.32 [ 0.12, 0.86 ]
Pandina 2011 52/613 55/607 59.5 % 0.94 [ 0.65, 1.34 ]
Subtotal (95% CI) 836 836 100.0 % 0.61 [ 0.22, 1.71 ]
Total events: 57 (Favours risperidone depot), 71 (Paliperidone palmitate)
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(. . . Continued)
Study or subgroup
Favours
risperidone
depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.43; Chi2 = 4.02, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.95 (P = 0.34)
6 Patient choice/withdrawn consent - long term
Fleischhacker 2011 62/370 55/379 100.0 % 1.15 [ 0.83, 1.61 ]
Subtotal (95% CI) 370 379 100.0 % 1.15 [ 0.83, 1.61 ]
Total events: 62 (Favours risperidone depot), 55 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
7 Lost to follow-up - medium term
Li 2011 14/223 9/229 45.2 % 1.60 [ 0.71, 3.62 ]
Pandina 2011 18/613 11/607 54.8 % 1.62 [ 0.77, 3.40 ]
Subtotal (95% CI) 836 836 100.0 % 1.61 [ 0.93, 2.79 ]
Total events: 32 (Favours risperidone depot), 20 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
8 Lost to follow-up - long term
Fleischhacker 2011 11/370 13/379 100.0 % 0.87 [ 0.39, 1.91 ]
Subtotal (95% CI) 370 379 100.0 % 0.87 [ 0.39, 1.91 ]
Total events: 11 (Favours risperidone depot), 13 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
9 Pregnancy - medium term
Li 2011 0/223 2/229 52.7 % 0.21 [ 0.01, 4.25 ]
Pandina 2011 0/613 1/607 47.3 % 0.33 [ 0.01, 8.09 ]
Subtotal (95% CI) 836 836 100.0 % 0.26 [ 0.03, 2.32 ]
Total events: 0 (Favours risperidone depot), 3 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
10 Pregnancy - long term
Fleischhacker 2011 1/370 1/379 100.0 % 1.02 [ 0.06, 16.32 ]
Subtotal (95% CI) 370 379 100.0 % 1.02 [ 0.06, 16.32 ]
Total events: 1 (Favours risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
11 Death - long term
Fleischhacker 2011 0/370 2/379 100.0 % 0.20 [ 0.01, 4.25 ]
Subtotal (95% CI) 370 379 100.0 % 0.20 [ 0.01, 4.25 ]
Total events: 0 (Favours risperidone depot), 2 (Paliperidone palmitate)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup
Favours
risperidone
depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.02 (P = 0.31)
12 Other - medium term
Li 2011 4/223 8/229 20.6 % 0.51 [ 0.16, 1.68 ]
Pandina 2011 19/613 22/607 79.4 % 0.86 [ 0.47, 1.56 ]
Subtotal (95% CI) 836 836 100.0 % 0.77 [ 0.45, 1.32 ]
Total events: 23 (Favours risperidone depot), 30 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
13 Other - long term
Fleischhacker 2011 31/370 29/379 100.0 % 1.09 [ 0.67, 1.78 ]
Subtotal (95% CI) 370 379 100.0 % 1.09 [ 0.67, 1.78 ]
Total events: 31 (Favours risperidone depot), 29 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
14 Any reason - medium term
Li 2011 38/223 64/229 43.7 % 0.61 [ 0.43, 0.87 ]
Pandina 2011 142/613 151/607 56.3 % 0.93 [ 0.76, 1.14 ]
Subtotal (95% CI) 836 836 100.0 % 0.77 [ 0.51, 1.17 ]
Total events: 180 (Favours risperidone depot), 215 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.13, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.22 (P = 0.22)
15 Any reason - long term
Fleischhacker 2011 186/370 224/379 100.0 % 0.85 [ 0.75, 0.97 ]
Subtotal (95% CI) 370 379 100.0 % 0.85 [ 0.75, 0.97 ]
Total events: 186 (Favours risperidone depot), 224 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
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Analysis 8.7. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 7 Adverse events: 1. General.
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 7 Adverse events: 1. General
Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 overall rate - medium term
Li 2011 8/223 3/229 39.3 % 2.74 [ 0.74, 10.19 ]
Pandina 2011 29/608 41/606 60.7 % 0.70 [ 0.44, 1.12 ]
Subtotal (95% CI) 831 835 100.0 % 1.20 [ 0.33, 4.42 ]
Total events: 37 (Risperidone depot), 44 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.67; Chi2 = 3.66, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.28 (P = 0.78)
2 overall rate - long term
Fleischhacker 2011 80/368 111/379 100.0 % 0.74 [ 0.58, 0.95 ]
Subtotal (95% CI) 368 379 100.0 % 0.74 [ 0.58, 0.95 ]
Total events: 80 (Risperidone depot), 111 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
3 worsening of schizophrenia - medium term
Li 2011 0/223 1/229 5.0 % 0.34 [ 0.01, 8.36 ]
Pandina 2011 13/608 15/606 95.0 % 0.86 [ 0.41, 1.80 ]
Subtotal (95% CI) 831 835 100.0 % 0.82 [ 0.40, 1.69 ]
Total events: 13 (Risperidone depot), 16 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
4 worsening of psychiatric disorders - medium term
Pandina 2011 7/608 13/606 100.0 % 0.54 [ 0.22, 1.34 ]
Subtotal (95% CI) 608 606 100.0 % 0.54 [ 0.22, 1.34 ]
Total events: 7 (Risperidone depot), 13 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
5 death - medium term
Li 2011 1/223 0/229 36.0 % 3.08 [ 0.13, 75.22 ]
Pandina 2011 1/608 2/606 64.0 % 0.50 [ 0.05, 5.48 ]
Subtotal (95% CI) 831 835 100.0 % 0.96 [ 0.14, 6.54 ]
Total events: 2 (Risperidone depot), 2 (Paliperidone palmitate)
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Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
6 death - long term
Fleischhacker 2011 0/370 2/379 100.0 % 0.20 [ 0.01, 4.25 ]
Subtotal (95% CI) 370 379 100.0 % 0.20 [ 0.01, 4.25 ]
Total events: 0 (Risperidone depot), 2 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Chi2 = 1.86, df = 5 (P = 0.87), I2 =0.0%
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Analysis 8.8. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 8 Adverse events: 2. Specific.
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 8 Adverse events: 2. Specific
Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 overall rate - medium term
Li 2011 167/223 168/229 48.5 % 1.02 [ 0.92, 1.14 ]
Pandina 2011 321/608 351/606 51.5 % 0.91 [ 0.82, 1.01 ]
Subtotal (95% CI) 831 835 100.0 % 0.96 [ 0.86, 1.08 ]
Total events: 488 (Risperidone depot), 519 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.65 (P = 0.52)
2 overall rate - long term
Fleischhacker 2011 289/368 289/379 100.0 % 1.03 [ 0.95, 1.11 ]
Subtotal (95% CI) 368 379 100.0 % 1.03 [ 0.95, 1.11 ]
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Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 289 (Risperidone depot), 289 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
3 insomnia - medium term
Pandina 2011 41/608 57/606 100.0 % 0.72 [ 0.49, 1.05 ]
Subtotal (95% CI) 608 606 100.0 % 0.72 [ 0.49, 1.05 ]
Total events: 41 (Risperidone depot), 57 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
4 insomnia - long term
Fleischhacker 2011 55/368 57/379 100.0 % 0.99 [ 0.71, 1.40 ]
Subtotal (95% CI) 368 379 100.0 % 0.99 [ 0.71, 1.40 ]
Total events: 55 (Risperidone depot), 57 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
5 psychotic disorder - long term
Fleischhacker 2011 44/368 53/379 100.0 % 0.86 [ 0.59, 1.24 ]
Subtotal (95% CI) 368 379 100.0 % 0.86 [ 0.59, 1.24 ]
Total events: 44 (Risperidone depot), 53 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
6 worsening of schizophrenia - long term
Fleischhacker 2011 33/368 45/379 100.0 % 0.76 [ 0.49, 1.16 ]
Subtotal (95% CI) 368 379 100.0 % 0.76 [ 0.49, 1.16 ]
Total events: 33 (Risperidone depot), 45 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
7 anxiety - medium term
Pandina 2011 13/608 26/606 100.0 % 0.50 [ 0.26, 0.96 ]
Subtotal (95% CI) 608 606 100.0 % 0.50 [ 0.26, 0.96 ]
Total events: 13 (Risperidone depot), 26 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
8 anxiety - long term
Fleischhacker 2011 55/368 38/379 100.0 % 1.49 [ 1.01, 2.20 ]
Subtotal (95% CI) 368 379 100.0 % 1.49 [ 1.01, 2.20 ]
Total events: 55 (Risperidone depot), 38 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.044)
9 headache - long term
Fleischhacker 2011 40/368 34/379 100.0 % 1.21 [ 0.78, 1.87 ]
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Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 368 379 100.0 % 1.21 [ 0.78, 1.87 ]
Total events: 40 (Risperidone depot), 34 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
10 constipation - medium term
Pandina 2011 19/608 5/606 100.0 % 3.79 [ 1.42, 10.08 ]
Subtotal (95% CI) 608 606 100.0 % 3.79 [ 1.42, 10.08 ]
Total events: 19 (Risperidone depot), 5 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0077)
11 injection site pain - medium term
Li 2011 1/223 6/229 16.5 % 0.17 [ 0.02, 1.41 ]
Pandina 2011 5/608 31/606 83.5 % 0.16 [ 0.06, 0.41 ]
Subtotal (95% CI) 831 835 100.0 % 0.16 [ 0.07, 0.38 ]
Total events: 6 (Risperidone depot), 37 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.16 (P = 0.000032)
12 somnolence - medium term
Li 2011 6/223 11/229 100.0 % 0.56 [ 0.21, 1.49 ]
Subtotal (95% CI) 223 229 100.0 % 0.56 [ 0.21, 1.49 ]
Total events: 6 (Risperidone depot), 11 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
13 weight gain (proportion of participants with >7% increase) - medium term
Li 2011 35/223 32/229 100.0 % 1.12 [ 0.72, 1.75 ]
Subtotal (95% CI) 223 229 100.0 % 1.12 [ 0.72, 1.75 ]
Total events: 35 (Risperidone depot), 32 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
14 tachycardia - medium term
Li 2011 4/223 4/229 100.0 % 1.03 [ 0.26, 4.06 ]
Subtotal (95% CI) 223 229 100.0 % 1.03 [ 0.26, 4.06 ]
Total events: 4 (Risperidone depot), 4 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
15 tachycardia - long term
Fleischhacker 2011 4/368 12/379 100.0 % 0.34 [ 0.11, 1.05 ]
Subtotal (95% CI) 368 379 100.0 % 0.34 [ 0.11, 1.05 ]
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Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 4 (Risperidone depot), 12 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Chi2 = 44.73, df = 14 (P = 0.00), I2 =69%
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Analysis 8.9. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 9 Adverse events: 3. Prolactin related.
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 9 Adverse events: 3. Prolactin related
Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 amenorrhoea - medium term
Li 2011 3/129 0/142 31.4 % 7.70 [ 0.40, 147.65 ]
Pandina 2011 4/268 4/245 68.6 % 0.91 [ 0.23, 3.62 ]
Subtotal (95% CI) 397 387 100.0 % 1.78 [ 0.24, 13.02 ]
Total events: 7 (Risperidone depot), 4 (Paliperidone palmitate)
Heterogeneity: Tau2 = 1.01; Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.57 (P = 0.57)
2 galactorrhoea - medium term
Li 2011 0/129 1/142 100.0 % 0.37 [ 0.02, 8.92 ]
Subtotal (95% CI) 129 142 100.0 % 0.37 [ 0.02, 8.92 ]
Total events: 0 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
3 hyperprolactinaemia - medium term
Li 2011 5/223 1/229 100.0 % 5.13 [ 0.60, 43.60 ]
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Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 223 229 100.0 % 5.13 [ 0.60, 43.60 ]
Total events: 5 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
4 erectile dysfunction - medium term
Pandina 2011 3/340 4/361 100.0 % 0.80 [ 0.18, 3.53 ]
Subtotal (95% CI) 340 361 100.0 % 0.80 [ 0.18, 3.53 ]
Total events: 3 (Risperidone depot), 4 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
5 increase in serum prolactin - medium term
Li 2011 12/223 17/229 100.0 % 0.72 [ 0.35, 1.48 ]
Subtotal (95% CI) 223 229 100.0 % 0.72 [ 0.35, 1.48 ]
Total events: 12 (Risperidone depot), 17 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
6 amenorrhoea-galactorrhoea syndrome - medium term
Li 2011 1/129 0/142 100.0 % 3.30 [ 0.14, 80.29 ]
Subtotal (95% CI) 129 142 100.0 % 3.30 [ 0.14, 80.29 ]
Total events: 1 (Risperidone depot), 0 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
7 any prolactin related - medium term
Li 2011 20/223 19/229 73.8 % 1.08 [ 0.59, 1.97 ]
Pandina 2011 7/608 8/606 26.2 % 0.87 [ 0.32, 2.39 ]
Subtotal (95% CI) 831 835 100.0 % 1.02 [ 0.61, 1.71 ]
Total events: 27 (Risperidone depot), 27 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
8 proportion of male participants with abnormally high prolactin - long term
Fleischhacker 2011 115/219 64/205 100.0 % 1.68 [ 1.32, 2.14 ]
Subtotal (95% CI) 219 205 100.0 % 1.68 [ 1.32, 2.14 ]
Total events: 115 (Risperidone depot), 64 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 4.26 (P = 0.000020)
9 proportion of female participants with abnormally high prolactin - long term
Fleischhacker 2011 68/133 68/161 100.0 % 1.21 [ 0.95, 1.55 ]
Subtotal (95% CI) 133 161 100.0 % 1.21 [ 0.95, 1.55 ]
Total events: 68 (Risperidone depot), 68 (Paliperidone palmitate)
Heterogeneity: not applicable
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Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Chi2 = 11.03, df = 8 (P = 0.20), I2 =27%
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Analysis 8.10. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 10 Adverse events: 4. Movement disorder.
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 10 Adverse events: 4. Movement disorder
Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 akathisia - medium term
Li 2011 44/223 30/229 100.0 % 1.51 [ 0.98, 2.31 ]
Subtotal (95% CI) 223 229 100.0 % 1.51 [ 0.98, 2.31 ]
Total events: 44 (Risperidone depot), 30 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.059)
2 tremor - medium term
Li 2011 40/223 24/229 100.0 % 1.71 [ 1.07, 2.74 ]
Subtotal (95% CI) 223 229 100.0 % 1.71 [ 1.07, 2.74 ]
Total events: 40 (Risperidone depot), 24 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.025)
3 tardive dyskinesia - medium term
Pandina 2011 1/608 1/606 100.0 % 1.00 [ 0.06, 15.90 ]
Subtotal (95% CI) 608 606 100.0 % 1.00 [ 0.06, 15.90 ]
Total events: 1 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
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Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.00 (P = 1.0)
4 requiring use of anti-EPS medication - medium term
Li 2011 103/223 72/229 78.3 % 1.47 [ 1.16, 1.86 ]
Pandina 2011 43/608 30/606 21.7 % 1.43 [ 0.91, 2.25 ]
Subtotal (95% CI) 831 835 100.0 % 1.46 [ 1.18, 1.80 ]
Total events: 146 (Risperidone depot), 102 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.52 (P = 0.00043)
5 hyperkinesia - long term
Fleischhacker 2011 37/368 23/379 100.0 % 1.66 [ 1.00, 2.73 ]
Subtotal (95% CI) 368 379 100.0 % 1.66 [ 1.00, 2.73 ]
Total events: 37 (Risperidone depot), 23 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
6 neuroleptic malignant syndrome - long term
Fleischhacker 2011 0/368 1/379 100.0 % 0.34 [ 0.01, 8.40 ]
Subtotal (95% CI) 368 379 100.0 % 0.34 [ 0.01, 8.40 ]
Total events: 0 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 1.41, df = 5 (P = 0.92), I2 =0.0%
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Analysis 8.11. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 11 Adverse events: 5. Body weight (mean increase).
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 11 Adverse events: 5. Body weight (mean increase)
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 medium term
Li 2011 223 1.5 (3.24) 229 1.5 (3.1) 33.5 % 0.0 [ -0.58, 0.58 ]
Pandina 2011 608 1 (3.14) 606 1.1 (3.36) 44.0 % -0.10 [ -0.47, 0.27 ]
Subtotal (95% CI) 831 835 77.4 % -0.07 [ -0.38, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
2 long term
Fleischhacker 2011 338 0.8 (5.65) 346 -0.2 (6.01) 22.6 % 1.00 [ 0.13, 1.87 ]
Subtotal (95% CI) 338 346 22.6 % 1.00 [ 0.13, 1.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Total (95% CI) 1169 1181 100.0 % 0.18 [ -0.36, 0.72 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 5.21, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 5.13, df = 1 (P = 0.02), I2 =81%
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Analysis 8.12. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 12 Adverse events: 6. Mean prolactin level increase (ng/mL).
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 12 Adverse events: 6. Mean prolactin level increase (ng/mL)
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 female participants
Fleischhacker 2011 133 22.4 (68.65) 161 22.5 (45.89) 45.9 % -0.10 [ -13.75, 13.55 ]
Pandina 2011 268 15.6 (63.12) 245 21.8 (80.34) 54.1 % -6.20 [ -18.78, 6.38 ]
Subtotal (95% CI) 401 406 100.0 % -3.40 [ -12.65, 5.85 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 male participants
Fleischhacker 2011 219 9.1 (14.46) 205 6.9 (16.73) 52.9 % 2.20 [ -0.79, 5.19 ]
Pandina 2011 340 6 (26.18) 361 9.38 (27.8) 47.1 % -3.38 [ -7.38, 0.62 ]
Subtotal (95% CI) 559 566 100.0 % -0.43 [ -5.88, 5.03 ]
Heterogeneity: Tau2 = 12.33; Chi2 = 4.81, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 8.13. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 13 Adverse events: 7. Glucose related.
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 13 Adverse events: 7. Glucose related
Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 increased blood glucose - long term
Fleischhacker 2011 6/368 4/379 100.0 % 1.54 [ 0.44, 5.43 ]
Subtotal (95% CI) 368 379 100.0 % 1.54 [ 0.44, 5.43 ]
Total events: 6 (Risperidone depot), 4 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 hyperglycaemia - long term
Fleischhacker 2011 4/368 3/379 100.0 % 1.37 [ 0.31, 6.09 ]
Subtotal (95% CI) 368 379 100.0 % 1.37 [ 0.31, 6.09 ]
Total events: 4 (Risperidone depot), 3 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
3 diabetes mellitus - long term
Fleischhacker 2011 4/368 1/379 100.0 % 4.12 [ 0.46, 36.68 ]
Subtotal (95% CI) 368 379 100.0 % 4.12 [ 0.46, 36.68 ]
Total events: 4 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
4 glycosuria - long term
Fleischhacker 2011 0/368 1/379 100.0 % 0.34 [ 0.01, 8.40 ]
Subtotal (95% CI) 368 379 100.0 % 0.34 [ 0.01, 8.40 ]
Total events: 0 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
5 ketonuria - long term
Fleischhacker 2011 0/368 1/379 100.0 % 0.34 [ 0.01, 8.40 ]
Subtotal (95% CI) 368 379 100.0 % 0.34 [ 0.01, 8.40 ]
Total events: 0 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
6 urine ketone body present - long term
Fleischhacker 2011 0/368 1/379 100.0 % 0.34 [ 0.01, 8.40 ]
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(. . . Continued)
Study or subgroup Risperidone depot
Paliperidone
palmitate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 368 379 100.0 % 0.34 [ 0.01, 8.40 ]
Total events: 0 (Risperidone depot), 1 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
7 hypoglycaemia - long term
Fleischhacker 2011 1/368 0/379 100.0 % 3.09 [ 0.13, 75.59 ]
Subtotal (95% CI) 368 379 100.0 % 3.09 [ 0.13, 75.59 ]
Total events: 1 (Risperidone depot), 0 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
8 any glucose related - medium term
Li 2011 2/223 1/229 26.2 % 2.05 [ 0.19, 22.49 ]
Pandina 2011 5/608 3/606 73.8 % 1.66 [ 0.40, 6.92 ]
Subtotal (95% CI) 831 835 100.0 % 1.76 [ 0.52, 5.98 ]
Total events: 7 (Risperidone depot), 4 (Paliperidone palmitate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
9 any glucose related - long term
Fleischhacker 2011 14/368 8/379 100.0 % 1.80 [ 0.77, 4.25 ]
Subtotal (95% CI) 368 379 100.0 % 1.80 [ 0.77, 4.25 ]
Total events: 14 (Risperidone depot), 8 (Paliperidone palmitate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 3.69, df = 8 (P = 0.88), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 8.14. Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS
(PALIPERIDONE PALMITATE), Outcome 14 Adverse events: 8. Injection site pain (mean (sd) Visual Analogue
Scale score (0-100mm)).
Review: Risperidone (depot) for schizophrenia
Comparison: 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Outcome: 14 Adverse events: 8. Injection site pain (mean (sd) Visual Analogue Scale score (0-100mm))
Study or subgroup Risperidone depot
Paliperidone
palmitate
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 at baseline
Fleischhacker 2011 368 9.6 (14.3) 379 7.8 (14.12) 100.0 % 1.80 [ -0.24, 3.84 ]
Subtotal (95% CI) 368 379 100.0 % 1.80 [ -0.24, 3.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
2 at endpoint
Fleischhacker 2011 368 3.4 (7.64) 379 3.4 (7.22) 100.0 % 0.0 [ -1.07, 1.07 ]
Subtotal (95% CI) 368 379 100.0 % 0.0 [ -1.07, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 2.35, df = 1 (P = 0.13), I2 =57%
-4 -2 0 2 4
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Analysis 9.1. Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 1
Mental state: 1. Total endpoint scores (PANNS, high score = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Outcome: 1 Mental state: 1. Total endpoint scores (PANNS, high score = worse)
Study or subgroup Risperidone depot Typical depot
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term
Covell 2012 23 63.1 (13.6) 26 62.4 (17.8) 100.0 % 0.70 [ -8.12, 9.52 ]
Subtotal (95% CI) 23 26 100.0 % 0.70 [ -8.12, 9.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
2 medium term
Covell 2012 22 60.9 (10.7) 24 61 (19.3) 100.0 % -0.10 [ -9.02, 8.82 ]
Subtotal (95% CI) 22 24 100.0 % -0.10 [ -9.02, 8.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
3 long term
Covell 2012 18 64 (19.2) 25 62.2 (20) 100.0 % 1.80 [ -10.04, 13.64 ]
Subtotal (95% CI) 18 25 100.0 % 1.80 [ -10.04, 13.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 0.06, df = 2 (P = 0.97), I2 =0.0%
-20 -10 0 10 20
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Analysis 9.2. Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 2
Leaving the study early.
Review: Risperidone (depot) for schizophrenia
Comparison: 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Outcome: 2 Leaving the study early
Study or subgroup Risperidone depot Typical depot Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 before beginning assigned treatment
Covell 2012 8/32 1/30 100.0 % 7.50 [ 1.00, 56.44 ]
Subtotal (95% CI) 32 30 100.0 % 7.50 [ 1.00, 56.44 ]
Total events: 8 (Risperidone depot), 1 (Typical depot)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 by 6 months
Covell 2012 13/32 4/30 100.0 % 3.05 [ 1.12, 8.31 ]
Subtotal (95% CI) 32 30 100.0 % 3.05 [ 1.12, 8.31 ]
Total events: 13 (Risperidone depot), 4 (Typical depot)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
3 due to increased psychiatric symptoms
Covell 2012 3/32 1/30 100.0 % 2.81 [ 0.31, 25.58 ]
Subtotal (95% CI) 32 30 100.0 % 2.81 [ 0.31, 25.58 ]
Total events: 3 (Risperidone depot), 1 (Typical depot)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 due to EPS effects
Covell 2012 0/32 1/30 100.0 % 0.31 [ 0.01, 7.40 ]
Subtotal (95% CI) 32 30 100.0 % 0.31 [ 0.01, 7.40 ]
Total events: 0 (Risperidone depot), 1 (Typical depot)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
5 due to weight gain and hypertension
Covell 2012 1/32 0/30 100.0 % 2.82 [ 0.12, 66.62 ]
Subtotal (95% CI) 32 30 100.0 % 2.82 [ 0.12, 66.62 ]
Total events: 1 (Risperidone depot), 0 (Typical depot)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
6 due to participant preference
Covell 2012 1/32 1/30 100.0 % 0.94 [ 0.06, 14.33 ]
Subtotal (95% CI) 32 30 100.0 % 0.94 [ 0.06, 14.33 ]
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(. . . Continued)
Study or subgroup Risperidone depot Typical depot Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 1 (Risperidone depot), 1 (Typical depot)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 3.40, df = 5 (P = 0.64), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 9.3. Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 3
Hospitalisation by 6 months.
Review: Risperidone (depot) for schizophrenia
Comparison: 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Outcome: 3 Hospitalisation by 6 months
Study or subgroup Risperidone depot Typical depot Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 medium term
Covell 2012 2/32 3/30 100.0 % 0.63 [ 0.11, 3.48 ]
Subtotal (95% CI) 32 30 100.0 % 0.63 [ 0.11, 3.48 ]
Total events: 2 (Risperidone depot), 3 (Typical depot)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 9.4. Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 4
Adverse events: 1. Continuous outcomes (skew).
Adverse events: 1. Continuous outcomes (skew)
Study Intervention Mean SD N
Change in BMI - short term (skew)
Covell 2012 Risperidone depot 1.29 1.9 23
Covell 2012 Typical depot
antipsychotics
0.48 1.4 26
Change in BMI - medium term (skew)
Covell 2012 Risperidone depot 1.53 2.2 22
Covell 2012 Typical depot
antipsychotics
0.53 1.3 24
Change in BMI - long term (skew)
Covell 2012 Risperidone depot 1.04 2.0 17
Covell 2012 Typical depot
antipsychotics
-0.28 1.7 24
Prolactin endpoint levels (ng/mL) - short term (skew)
Covell 2012 Risperidone depot 22.5 19.1 19
Covell 2012 Typical depot
antipsychotics
15.1 7.6 22
Prolactin endpoint levels (ng/mL) - medium term (skew)
Covell 2012 Risperidone depot 23.4 13.8 18
Covell 2012 Typical depot
antipsychotics
16 7.5 21
Prolactin endpoint levels (ng/mL) - long term (skew)
Covell 2012 Risperidone depot 19 10.6 14
Covell 2012 Typical depot
antipsychotics
15.2 5.1 18
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Analysis 9.5. Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 5
Adverse events: 2. Sexual experiencesm, total endpoint (ASEX, high score = worse).
Review: Risperidone (depot) for schizophrenia
Comparison: 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Outcome: 5 Adverse events: 2. Sexual experiencesm, total endpoint (ASEX, high score = worse)
Study or subgroup Risperidone depot Typical depot
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term
Covell 2012 20 16.6 (4.9) 24 14.9 (5.1) 100.0 % 1.70 [ -1.26, 4.66 ]
Subtotal (95% CI) 20 24 100.0 % 1.70 [ -1.26, 4.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 medium term
Covell 2012 18 16.7 (6.3) 23 15.4 (5.2) 100.0 % 1.30 [ -2.30, 4.90 ]
Subtotal (95% CI) 18 23 100.0 % 1.30 [ -2.30, 4.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 long term
Covell 2012 16 16.9 (5.7) 24 17 (7.1) 100.0 % -0.10 [ -4.08, 3.88 ]
Subtotal (95% CI) 16 24 100.0 % -0.10 [ -4.08, 3.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.52, df = 2 (P = 0.77), I2 =0.0%
-10 -5 0 5 10
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A D D I T I O N A L T A B L E S
Table 1. Suggested design of study
Methods Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment.
Blinding: single, tested.
Setting: community rather than hospital.
Duration: 12 weeks treatment, and then follow-up to at least 52 weeks
Participants Diagnosis: schizophrenia (ICD/DSM/CCMD).
N = 300.*
Age: adults.
Sex: both.
199Risperidone (depot) for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Suggested design of study (Continued)
Interventions 1. Depot risperidone. N = 150.
2. Standard care. N = 150.
Outcomes General: time to all-cause treatment failure marked by its discontinuation, relapse, general impression of clinician
(CGI), career/other, compliance with treatment., healthy days,
Mental state: BPRS and PANSS.
Global state: CGI (Clinical Global Impression).
Quality of life. QOL (Quality of Life Questionnaire).
Family burden: FBQ (Family Burden Questionnaire).
Social functioning: return to everyday living for 80% of time.*
Adverse events: any adverse event recorded.
Economic outcomes.
Notes * Powered to be able to identify a difference of ~ 20% between groups for primary outcome with adequate degree
of certainty
BPRS: Brief Psychiatric Rating Scale
CGI: Clinical Global Impression
PANSS: Positive and Negative Syndrome Scale
Table 2. Excluded studies and suggestions for relevant reviews
Excluded study Comparison Existing review Suggested future review titles
Bouchard 2000; Gallhofer
1995; Kogeorgos 1995;
Oral risperidone vs conven-
tional
antipsychotic drugs (haloperi-
dol, fluphenazine, chlorpro-
mazine, trifluoperazine), not
depot risperidone
Risperidone vs typical antipsy-
chotic medication for
schizophrenia (Hunter 2003).
Risperidone vs haloperidol,
risperidone vs fluphenazine,
risperidone vs chlorpromazine,
risperidone vs trifluoperazine
Littrell 1999; Ritchie 1999;
Robinson 2000
Oral risperidone vs atypical an-
tipsychotics (olanzapine), not
depot risperidone
Risperidone vs olanzapine for
schizophrenia (Jayaram 2006).
Macfadden 2008; Simpson
2006
Dose comparison (25 mg vs 50
mg of risperidone depot).
Risperidone dose for
schizophrenia (Li 2009).
This could also generate further
comparisons for this current re-
view
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A P P E N D I C E S
Appendix 1. Previous searches
1.1 Search in 2002
1.1.1 Cochrane Schizophrenia Group’s Register
We searched the Cochrane Schizophrenia Group’s Register (December 2002) using the phrase:
[(risp* or * risp * or 9-OH-risperidone*) and (* depot* or * microsph* or * micro-sp* or * long-acting* or * long act*) in title, abstract,
index terms of REFERENCE] or [(depot and risp*) in interventions of STUDY]
The Schizophrenia Group’s Trials Register is based on regular searches of BIOSIS Inside, CENTRALCINAHL, EMBASE,MEDLINE,
PsycINFO, hand searching of relevant journals and conference proceedings, and searches of several key grey literature sources. A full
description is given in the group’s module.
1.2 Search in 2010
1.2.1 Cochrane Schizophrenia Group’s Register
We searched the register using the phrase:
[((risp* or * risp * or 9-OH-risperidone*) and (* depot* or * microsph* or * micro-sp* or * long-acting* or * long act*) in title, abstract,
index terms of REFERENCE) or ((depot and risp*) in interventions of STUDY)]
This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group’s Module).
1.3 Search in 2012
1.3.1 Electronic searches
1.3.1.1 Cochrane Schizophrenia Group Trials Register (October 2012)
Using the phrase:
[(risp* or * risp * or *9-OH-risperidone*) and (* depot* or * microsph* or * micro-sp* or * long-acting* or * long act*) in title, abstract,
index terms of REFERENCE] or [((*depot* or *long* or *LAI*) and *risp*) in interventions of STUDY]
1.3.1.2 Economic study search of Cochrane Schizophrenia Group Health Economic Database (2013)
For the economic search, we replicated the above strategy in the Cochrane Schizophrenia Group Health Economic Database
(CSzGHED) on 31 January 2014. The database of studies relates to cost-effectiveness of schizophrenia treatments. This database was
constructed from systematic searches of four databases: Health Economic Evaluation Database (HEED), National Health Services
Health Economic Database (NHS EED), Cost-Effectiveness Analysis Registry (CEA) and EconLit as well as Cochrane Registry.
1.3.2 Searching other resources
1.3.2.1 Reference searching
The reviewers inspected references of all identified studies for more studies.
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1.3.2.2 Personal contact
The reviewers attempted to contacted the first author of each study considered for inclusion in the review for more information
regarding unpublished trials or any data available.
1.3.2.3 Drug companies
The reviewers contacted the Janssen-Cilag Limited for further data.
Appendix 2. Previous data collection and analysis
1. Selection of trials
Two reviewers (PH, JD) independently inspected the citations identified from the search. Potentially relevant abstracts were identified
and full papers ordered and reassessed for inclusion and methodological quality. Any disagreement was discussed and reported.
2. Quality assessment
Trials were allocated to three quality categories, as described in the Cochrane Collaboration Handbook (Clarke 2002) by each reviewer,
again, working independently. When disputes arose as to which category a trial was allocated, resolution was attempted by discussion.
When this was not possible, and further information was necessary, data were not entered into the analyses and the study was allocated
to the list of those awaiting assessment. Only trials in Category A or B were included in the review.
3. Data management
3.1 Data extraction
Two reviewers (PH, JD) independently extracted data and, where further clarification was needed, contacted authors of trials to provide
missing data.
3.2 Intention to treat analysis
Data were excluded from studies where more than 50% of participants in any group were lost to follow-up (this did not include the
outcome of ’leaving the study early’). In studies with less than 50% drop-out rate, people leaving early were considered to have had the
negative outcome, except for the event of death. The impact of including studies with high attrition rates (25-50%) was analysed in a
sensitivity analysis for primary outcomes. If inclusion of data from this latter group did result in a substantive change in the estimate
of effect, the data were not added to trials with less attrition, but presented separately.
4. Data analysis
4.1 Binary data
For binary outcomes a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI) was calculated. The number
needed to treat statistic (NNT) was also calculated. If heterogeneity was found (see section 5) a random effects model was used.
4.2 Continuous data
4.2.1 Intention-to-treat analyses versus analyses that only take into account those who completed the study: in the case of continuous
data, it was supposed that in many cases an intention-to-treat analysis would not be available, so an analysis was presented on those
who completed the study.
4.2.2 Rating scales: a wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and
many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. Continuous data from rating
scales were included only if the measuring instrument had been described in a peer-reviewed journal (Marshall 2000), the instrument
was either a self report or completed by an independent rater or relative (not the therapist), and the instrument could be considered a
global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, such data
was tagged as ’prone to bias’.
4.2.3 Normal distribution of data: mental health continuous data are often not normally distributed. Most statistics assume a normal
distribution. To avoid including non-normally distributed data in the statistical analysis, the following criteria are applied to all data
before inclusion:
a. Standard deviations and means were reported or derivable from data in the paper, or were obtainable from the authors.
b. When a scale started from zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean was
unlikely to be an appropriate measure of the centre of the distribution (Altman 1996). Endpoint scores on scales often have a finite
start and end point and this rule can be applied to them.
c. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale) it is
impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale endpoint data, which
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typically cannot have negative values. If endpoint data were not available, reviewers chose to use change data, because the statistics used
in Metaview are rather robust towards skew.
d. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above in (b)
should be modified to take the scale starting point into account. In these cases skew is present if 2SD>(S-Smin), where S is the mean
score and Smin is the minimum score.
4.2.4 Endpoint versus change data: endpoint scale-derived data are finite, ranging from one score to another. Change data are more
problematic and for it the rule described above does not hold. Although most change scores are likely to be skewed, this cannot be
proven so they were presented in MetaView. Where both endpoint and change were available for the same outcome, we presented the
former in preference.
4.2.5 Summary statistic: for continuous outcomes, a weightedmean difference (WMD) between groups was estimated. Again, a random
effects model was used.
4.3 Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as randomisation by clinician or practice) but analysis and pooling of clustered
data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a ’unit of analysis’
error (Divine 1992) - whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated
- causing type I errors (Bland 1997, Gulliford 1999). Secondly, RevMan does not currently support meta-analytic pooling of clustered
dichotomous data, even when these are correctly analysed by the authors of primary studies, since the ’design effect’ (a statistical
correction for clustering) cannot be incorporated.
Where clustering was not accounted for in primary studies, we presented data in a table, with an asterisk (*) symbol to indicate the
presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies,
to seek intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (Gulliford 1999).
Where clustering had been incorporated into the analysis of primary studies, then we presented these data in a table. No further
secondary analysis (including meta-analytic pooling) will be attempted until there is consensus on the best methods of doing so, and
until RevMan, or any other software, allows this. A Cochrane Statistical Methods Workgroup is currently addressing this issue. In the
interim, individual studies were very crudely classified as positive or negative, according to whether a statistically significant result (p<0.
05) was obtained for the outcome in question, using an analytic method that allows for clustering.
5. Test for heterogeneity
A Chi-square test was used, as well as visual inspection of graphs, to investigate the possibility of heterogeneity. A significance level less
than 0.10 was interpreted as evidence of heterogeneity. If heterogeneity was found, the data were re-analysed using a random effects
model to see if this made a substantial difference. If it did, the studies responsible for heterogeneity were not added to the main body
of homogeneous trials, but summated and presented separately and reasons for heterogeneity investigated.
6. Addressing publication bias
Data from all included studies were entered into a funnel graph (trial effect against trial size) in an attempt to investigate the likelihood
of overt publication bias (Egger 1997).
7. Sensitivity analyses
The effect of including studies with high attrition rates was analysed in a sensitivity analysis.
8. General
Where possible, reviewers entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for
depot risperidone.
Appendix 3. Previous description of studies
4. Included studies
Two studies, reported as nine conference presentations and one full paper met the selection criteria and are included.
4.1 Study design
All included studies were randomised and X featured some form of blinding, though the extent of this varied widely.
Chue 2002 involved an eight-week run in period preceding randomisation. In the first two weeks, antipsychotic drugs other than
risperidone were discontinued and oral risperidone introduced. In the next two weeks the risperidone dose was optimised and then
people continued on this dose of oral risperidone for another four weeks before randomisation. Kane 2002* had a two-week run in
period preceding randomisation. The first week was a screening week followed by seven days during which people were started on oral
risperidone and the dose was titrated to 4mg/day.
4.2 Participants
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People entering both studies met the criteria for DSM IV schizophrenia, so for at least six continuous months a participant must have
shown some evidence of schizophrenia, and for at least one month must have shown at least two symptoms of frank psychosis. These
symptoms would include delusions, hallucinations, incoherent speech, disorganised or catatonic behaviour, or flat affect. To meet DSM
IV criteria, the symptoms must be disabling in such a way that social and occupational functioning is impaired; these symptoms should
not be the direct result of a physical disorder or of substance misuse.
For Kane 2002* people who had substance dependence, tardive dyskinesia or a history of neuroleptic malignant syndrome, ECG
abnormalities, suicidal ideas or risk of violent behaviour were excluded. Patients who had a history of unresponsiveness to risperidone
were also excluded.
Chue 2002 also stipulated that participants should have a total PANSS score of at least 50. This, in addition to the fulfilment the DSM
IV criteria, means that people with at least some active symptoms of illness were included. In effect, despite the rigorous entry criteria,
nearly 47% of people entering this study were rated by the authors as ”not ill” or only ”mildly ill” at baseline assessment on the CGI
scale before randomisation. Chue 2002 randomised 640 people. Kane 2002*, however, randomised 400 people who appeared to be
more severely ill. They had a baseline PANSS score in the range of 60-120, with an average of about 80.
In both studies, participants were mainly men (about 70%) with an average age of about 40 years.
4.3 Interventions
Chue 2002 randomised people to an active injection every two weeks and placebo tablets daily, or a placebo injection every two weeks
and active tablets daily. Depending on the optimal stabilisation dose the person was randomised to continue that oral regimen or start
the ’equivalent’ dose of depot. For example, 2mg of oral risperidone per day was taken as being equivalent to 25mg of depot risperidone
every two weeks. It is not clear, however, how the conversion dose was arrived at.
Kane 2002* randomised people to either a placebo injection or 25mg or 50mg or 75mg of depot risperidone every two weeks. People
also received either placebo tablets or 2mg or 4mg or 6mg of oral risperidone respectively for the first three weeks after randomisation.
4.4 Outcomes
4.4.1 Global improvement
Chue 2002 reported global improvement in the form of the percentage of people who were not ill or mildly ill on the Clinical Global
Impression (CGI) scale at the end of the study period. Throughout this study results are reported for oral and depot groups as a whole,
and not for specific dosage groups of depot. Chue 2002 did not report mean or change scores in the abstracts available for this review.
Kane 2002* also used the CGI but reported average change from baseline to endpoint and data were unusable due to the substantial
attrition.
4.4.2 Mental state
Kane 2002* interpreted an improvement of more than 20% in PANSS total score as clinically important. This study also reported
average change at endpoint from baseline in PANSS total, PANSS positive and PANSS negative but again so much data were lost
because people left the study early that the results of the PANSS were unusable. Chue 2002 reported average change scores on PANSS
total at endpoint in both the composite oral and depot groups. Chue 2002 did not seem to stipulate cut off points as ’clinically
important improvement’.
4.4.3 Leaving the study early
Both studies reported numbers discontinuing the study and specific reasons for this, such as adverse events, compliance problems and
insufficient responses.
4.4.4 Adverse effects
Chue 2002 reported overall rates of adverse events in both groups, and the numbers withdrawing from the study as a result of side
effects. No details were given regarding the nature of these adverse events or how they were recorded. The abstracts available for this
review state that body weight was measured and laboratory tests were undertaken. The reports state that there were no differences
between oral and depot groups, but present no numbers. Chue 2002 also used the Extrapyramidal Symptom Rating Scale (ESRS) but,
again, no numerical data were reported. Kane 2002* reported rates of individual adverse events spontaneously reported by participants,
and reported these for all people in the study, not just those who completed the trial. Median ESRS scores were also reported for each
group at baseline and change at endpoint. Pain and swelling at injection sites rated by investigators and patients were also reported.
4.4.5 Outcome measures used in this review
Global functioning. Clinical Global Impression - CGI (Guy 1976)
A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical
improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater
recovery.
Positive and Negative Symptom Scale - PANSS (Kay 1987)
This scale was developed to evaluate the positive, negative and general symptoms in schizophrenia. The PANSS has 30 items, and each
item can be defined on a seven-point scoring system varying from one (absent) to seven (extreme). This scale is divided into three
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subscales for measuring the severity of general psychopathology, positive symptoms (PANSS-P) and negative symptoms (PANSS-N).
A low score indicates lesser severity.
Extrapyramidal Symptom Rating Scale - ESRS (Chouinard 1980)
This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician’s examination for parkinsonism and
dyskinetic movements (eight items) and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement
disorder.
4.4.6 Missing outcomes
There are no data for outcomes beyond three months. Neither are data available on general functioning and change in behaviour. Nor
were there any details on service outcomes, engagement with services, satisfaction with services, quality of life or economic outcomes.
Appendix 4. Previous Chue write up
3. COMPARISON: 2. DEPOT RISPERIDONE vs ORAL RISPERIDONE
Chue 2002 compared depot risperidone against oral risperidone
3.1 Global improvement
The study did not report mean scores on the CGI scale. The trialists did report percentage of people mildly ill or not ill in both the
depot risperidone and oral risperidone groups at the end of the study period, as rated using the CGI (about 57% as read from the
graph, compared to 47% at baseline). Hence 43% must have been moderately ill or severely ill at the end of the study period. There
was no difference between the depot group and the oral group (n=640, RR 1.06 CI 0.92 to 1.22).
3.1.1 Mental state
Chue 2002 reported both average end score and change across time. For endpoint score there was no difference between groups (MD
0.00 CI -2.91 to 2.91), nor was there any difference between depot and oral risperidone for average change in the total PANSS score
(n=541, WMD -0.90 CI -2.84 to 1.04), PANSS positive (WMD -0.30 CI -0.86 to 0.26) and PANSS negative scores (WMD -0.10
CI -0.93 to 0.73).
3.2 Poor compliance
Compliance was measured in several ways. Most people received at least four injections (83.4% in the depot group and 85.6% in
the oral risperidone group, n=640, RR <4 injections or “major protocol violation” 1.16 CI 0.81 to 1.67). There was no difference
between groups in the rate of discontinuation before the end of the 12-week study (n=640, RR 1.27 CI 0.90 to 1.78). Please note that
’compliance’ in this context could apply to protocol violation for many reasons only one of which would be non-compliance with the
study drugs.“
3.3 Adverse effects
Adverse events are reported in order of severity. One death was reported in the oral risperidone group (n=640, RR death 1.04 CI 0.91
to 1.18). Low proportions of people had to withdraw from the study due to adverse events and there were no differences between the
oral and depot preparation (n=640, RR 1.21 CI 0.62 to 2.35). Over half of both groups reported some adverse effects (n=640, RR
1.04 CI 0.91 to 1.18)
Appendix 5. Previous discussion
4. COMPARISON: 1. DEPOT RISPERIDONE vs PLACEBO
4.1 Global improvement
No meaningful conclusions can be drawn as more than 50% of patients did not complete the trial. Hence the authors’ conclusion that
depot risperidone is superior to placebo is based on very limited data. Currently clinicians, recipients of care and researchers do not
know if risperidone depot is any better than placebo in terms of global improvement in the short term.
4.2 Mental state
The main mental state outcome (20% improvement in the PANSS total score) conveys no useful information as half the data are based
on an assumption. From data presented on adverse effects, it is possible to get some data on mental state. Risperidone depot does not
seem to affect symptoms of anxiety or nervousness but it may decrease agitation. There is no evidence that depot risperidone effects
hallucination but the frequency of ’psychosis’ was reduced. We are unsure what this means when both are reported as adverse effects.
Overall the information regarding the effects on mental state of long acting risperidone compared with placebo is poor.
4.3 Leaving the study early.
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The majority of participants did not complete the 12-week study period which makes it difficult to believe that depot risperidone
might improve compliance. The drop out rate was higher in the placebo group but the NNT was six. Six people have to be treated
with risperidone depot to avoid one person being leaving care when compared to the attrition from placebo injection treatment.
4.4 Adverse effects
Only spontaneously reported adverse events in more than 5% of the participants were reported. Adverse effects which were not reported
by the patient, or that were infrequent might have gone unnoticed. Serious adverse effects (those that resulted in death or were life
threatening, required hospitalisation or prolongation of hospitalisation, resulted in persistent or significant disability or incapacity, or
resulted in congenital anomaly or birth defect) were reported in such a way that the reviewers were left in some doubt about safety.
Firstly, overall, these were common (13-23%). Although there was no collective difference between the experimental and control groups
it is feasible that those allocated to placebo needed ’prolongation of hospitalisation’ and those given the depot drug encountered ’life
threatening’ effects. The lack of statistical difference in the ’lumped’ data could mask real and disturbing effects. This review does not
reassure users of long acting risperidone as regards safety.
The adverse effects that were reported clearly tended to suggest that the depot compound did cause some unwanted effects and that
there may be a dose effect. The movement disorder effects were convincing of this. This ’atypical’ drug seems to cause extrapyramidal
effects, hyperkinesis and hypertonia, especially at the higher doses.
This depot may also cause more sleepiness and weight gain than placebo, but, as for all these adverse effects, more data are needed to
confirm this.
5. COMPARISON: 2. DEPOT RISPERIDONE vs ORAL RISPERIDONE
Chue 2002 compared depot risperidone with oral risperidone. The main problem with this study is that it involved well people who
are unlikely to be those for whom depot is very relevant.
5.1 Global improvement
Data were difficult to extract from the conference proceedings and may have to be revised once the full paper is published, but there
seems to be very little difference between the depot and oral forms of risperidone in terms of global improvement. This is encouraging,
suggesting that the depot form is as effective as the oral. People already doing well on oral risperidone will continue to do so with depot
risperidone.
5.2 Mental state
Depot risperidone is similar to oral risperidone in terms of the changes in PANSS scores, thus confirming the impression that there is
little difference between the oral and depot preparations for people who are compliant.
5.3 Poor compliance
One major reason for giving a depot is to aid poor compliance. For this client group, there was no difference between the oral and
depot groups in terms of several ways of measuring compliance. This probably reflects the design of the study where only compliant
people were asked to participate. This greatly reduces the value of the study for generalising to real world circumstances.
5.4 Adverse effects.
Again there is no clear difference between the oral and depot forms of risperidone, although more data may be available in the fully
published paper. However, it should be noted that over half of both groups reported some adverse effects.
COMPARISON: 3. DEPOT RISPERIDONE VS PALIPERIDONE PALMITATE
Summary of main results
Overall completeness and applicability of evidence
3. Limited data
3.1 Loss of data
Schizophrenia is often a chronic illness, which may require medication on a long-term basis. In Kane 2002*, 56% of patients left the
study in the first 12 weeks. We will discuss the differential loss to follow-up below, but it would be difficult to encourage long-term use
of depot risperidone based on the findings of this study. It is likely that this huge loss of patients, greater than would be expected in
clinical practice, may result from the limitations of study design where a rigid protocol is imposed on people who are unwell. When a
similar protocol is implemented on reasonably well people attrition is less (17%, Chue 2002). Clinicians prefer depot for people who
are already having difficulty in complying with treatment. In such a situation clinical common sense indicates that depot preparation
may be more helpful, but pragmatic trials are required to confirm this.
3.2 Missing outcomes
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Risperidone depot is one of the options for the long-term treatment of people with schizophrenia. However, there are no outcomes
rated beyond 12 weeks in the current studies, and much of the three-month data are ’carried forward’ from the true time the person
decided to leave the study. There are hardly any data on general functioning and change in behaviour, and none on service outcomes,
engagement with services, satisfaction with services, quality of life or costs. It would seem important to address these deficiencies.
3.3 Problematic outcomes
More clarity is needed in the reporting of adverse effects. In Kane 2002*, only spontaneously reported adverse events occurring in more
than 5% of patients are recorded. This raises the possibility that some rare but clinically important adverse events may have been under-
reported. In the conference proceedings we have for Chue 2002, no specific adverse effects, except death, are reported. We recognise
that it is a huge task to report every adverse event but unless careful attention is paid to rare adverse events they might go unnoticed.
The Kane 2002* full paper also groups severe adverse effects in an unusual way. It is possible that the lumping together of several ’severe’
effects, some of which may be not as severe as others, could mask real effects of the interventions.
2. Applicability
2.1 Diagnosis
Both the included studies used DSM IV operational criteria to help select participants. The use of these criteria means that participants
are homogenous and that the study subsequently has greater internal validity, but external validity, i.e. applicability to the every day
world of psychiatric care, is likely to be limited.
2.2 Severity of illness
Chue 2002 included only people who were already stabilised on oral risperidone. Even though the inclusion criteria stipulated a PANSS
score of >50, nearly half the participants were described as mildly ill or not ill at all on the CGI scale at baseline. From this study one can
only infer the effects of depot risperidone on stable, reasonably well people. This study does not answer questions as to whether depot
risperidone is helpful for people who are very ill. Kane 2002*, however, includes patients who were experiencing more symptoms, as
observed by the high baseline PANSS total score.
Quality of the evidence
1. Quality of studies
It is disappointing that the reporting of studies was not better. Perhaps to hope that CONSORT requirements (Moher 2001) should
be met in conference proceedings is ambitious, but at least they should be considered when they are published in full. Both studies
appear to be vulnerable to inclusion bias in favour of risperidone depot.
F E E D B A C K
Response from Janssen-Cilag Ltd
Summary
Dear Editor
The purpose of this letter is to provide comment on the recent review of Risperdal Consta long-acting injectable in Schizophrenia.
We appreciate the opportunity to discuss issues with the review’s conclusions and provide insight into possible solutions to any issues
raised.
The content of this discussion will be based on the following key assertions:
- That the review’s conclusions are overly critical of available data;
- That the review’s conclusions regarding reliable evidence are potentially misleading and are based on incomplete information;
Comment on these assertions will be focused on the following specific issues:
1. Application of strict methodological rules to placebo controlled trials in schizophrenia leading to exclusion of any data where patient
drop outs are >50%. This led to exclusion of key data from Kane et al 2002, where overall drop rates were only 56%.
Additional analysis will be provided for consideration, including:
- Mean change in total PANSS - Results (from total patient cohort and risperidone long-acting injectable monotherapy cohort) up to
the Cochrane methodology-defined point where 50% of patients had dropped out (between 6 and 10 weeks and at end-point), show
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statistically significant differences between risperidone long-acting injectable and placebo. These analyses report on the total ’starting’
patient cohort, and separately for the risperidone long-acting injectable ’monotherapy’ subset.
- Population analysis for clinical improvement associated with risperidone long-acting injectable showing a conclusive treatment effect
unrelated to demographic expectations and low NNT values for significant reduction in Total PANSS.
- Additional testing of an ”assumption“ of stability after leaving the study by using last observation carried forward (potential impact
of drop outs) showed no impact on the conclusions of the study related to the relative comparison of risperidone long-acting injectable
to placebo.
2. Identification of specific outcome measures in the review appear to provide potentially misleading or erroneous conclusions.
3. Conclusions based on critique and dismissal of non-inferiority data cause isolation of the effectiveness of risperidone long-acting
injectable from established benefits of risperidone compound.
4. Discussion of the risks associated with categorization of risperidone long-acting injectable as a ”depot“.
Detailed comments
1. Exclusion of Kane et al 2002 due to drop out rates
We acknowledge the transparent nature of Cochrane methodology and the corresponding universal application of the 50% drop out
rate criterion.
Previous Cochrane reviews (1, 2, 3) of atypicals have included studies of shorter duration (e.g. 6-8 weeks). However, concluding that
the Kane study provides a lack of reliable data based on an overall drop out rate of 56% over the longer period of 12 weeks, is overly
critical. Post-hoc analysis shows that, had this study been ended at 6 weeks the criterion would have been satisfied and, the data would
therefore have been included in this review.
To this end, we include in Appendix A the Weighted-mean Difference analyses of mean change in total PANSS from baseline (using
Forrest plots) of the Kane 2002* (4) data at 6 weeks, where drop outs were less than 50% overall, as well as the end-point last observation
carried forward (LOCF) data. Significant effect was seen with both doses at end-point (-8.60 for 25mg/fortnight; -11.20 for 50 mg/
fortnight) and for 50mg/fortnight at 6 weeks (Where n>50%), of -8.30.
We also include these analyses for the sub-population known as ’monotherapy’. This included only those patients who underwent a
PANSS evaluation after 18 days of oral risperidone supplementation and then continued in the study, thus reflecting the effects - from
treatment baseline - of risperidone long-acting injectable alone. Again, both doses were associated with significant effect at end-point
(-11.90 for 25 mg/fortnight and -9.60 for 50mg/fortnight) and significantly for 25mg at 10 weeks (n>50%), being -9.10.
Empirical analysis (Chi-squared test) of percentages of ’responders (showing a 20% or greater improvement in Total PANSS)’ showed a
significant advantage in the risperidone long-acting injectable treatment group at 6 weeks and at end-point for all doses taken together
(Appendix B). Furthermore, for this sample, NNT’s for a 20% or greater drop in Total PANSS versus placebo were 5.6 (+/- 0.17 for
95% confidence) at 6 weeks and 3.3 (+/- 0.10) at End Point. These results clearly indicate a significant difference from the placebo
group.
Additional analyses were conducted to assess the impact from the level of dropouts in the study on conclusions of Kane et al, 2002.
This was an attempt to assess whether the assumption inherent in the regulatory-driven primary LOCF analysis were valid for this trial.
Longitudinal analysis of observed cases were entirely consistent with primary analysis, supporting the overall conclusions. In addition,
analysis further to that in the Study Report for Kane et al (2002), tested assumptions more conservative than for LOCF. By adding an
assumed 10 points in PANSS to the endpoint change from baseline for all drop outs (i.e. endpoint levels for drop outs were assumed
to be 10 points worse at 12 weeks than reported in primary analysis at endpoint), the mean change from baseline for each group was
different as would be expected, but the between group comparisons with placebo were still significant.
Also, conclusions did not change when testing the outcome of achieving at least a 20% improvement in total PANSS, where each drop
out was set to ”No“.
As there were differential drop out rates in each group (itself an outcome measure of benefit included in all Cochrane reviews), based
on the above, the only way it seems that the conclusions would be altered is if we assume the placebo drop outs would have improved at
12 weeks had they stayed in the trial, and the risperidone long-acting injectable patients would have become worse. Concluding a lack
of reliable evidence of clinical benefit of risperidone long-acting injectable based on this assumption, is misleading and overly critical.
Recommendations
We would request that the total PANSS mean change data from Kane et al 2002 (4) be included in the graphs section, also the
population analyses for ’responders’ and reviewed in the results text, highlighting the statistically significant differences in favour of
risperidone long-acting injectable over placebo. Conclusions should also be altered to reflect that there is reliable RCT data supporting
significant benefits of risperidone long-acting injectable for schizophrenia patients.
2. Specific outcome measures
Adverse Events: The review rightly highlights the need for consistency and greater clarity in the reporting of adverse events (Discussion
3.2 ’Problematic outcomes’, p20) and yet draws some analytical conclusions from such spontaneously reported data (Sections 2.4.2,
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p18 and Section 4.4, p21). The validity of and - even more thorough - the reporting of adverse events, and the interpretation of these
reports as clinical outcomes has to be questioned in the absence of standardised techniques for assessing prevalence and severity of these
events.
Trial discontinuation: ’Poor compliance’ implies cessation of taking the medication, which is very different from protocol violation.
In Analysis: 02.04 (’Poor compliance’, p47), the three risk-ratio analyses from the data of Chue et al’s 2002 study, show groups of
patients who for various reasons were non-compliant with the trial and left the study: this does not necessarily mean that they were
non-compliant with the medication and this should be clarified.
3. Dismissal of non-inferiority data and exclusion of benefits already clearly established with risperidone
The results reported for the Chue et al 2002 study (5), critically imply no clear differences between risperidone long-acting injectable
and risperidone oral when taken over 12 weeks, without acknowledging that this trial was designed apriori to investigate the hypothesis
of non-inferiority.
Further, there is no acknowledgement of the inference of benefits to risperidone long-acting injectable supported by the established
safety and effectiveness of risperidone oral in treatment of schizophrenia (which, in turn, is supported by the most recently updated
Cochrane review of risperidone versus typical antipsychotics). We find this inconsistent with the review’s acknowledgement that the
data fromChue et al’s study (2002) established non-inferiority of risperidone long-acting injectable compared to oral risperidone (’Main
Results’, p5) and with the statement - quite correct - that risperidone long-acting injectable ”encapsulates unmodified risperidone“ and
provides ”therapeutic blood levels of the drug..“ (’background’, p7).
Again, the conclusion that there is no reliable evidence to support the claim that risperidone long-acting injectable is beneficial for
people with schizophrenia is misleading and potentially harmful.
Recommendations
That the review should be modified to recognize that, based on a study designed to show non-inferiority, there is clinical equivalence
between risperidone long-acting injectable and daily-administered oral risperidone over 12 weeks of therapy. In addition, is would be
useful to recognize that advice and requirements of regulatory authorities were strictly adhered to in designing the study, and took
into account the delicate ethico-clinical balances involved when designing placebo-controlled trials with this group of severely unwell
patients (a point also self-evident from the placebo drop-out rates).
4. Classification of risperidone long-acting injectable as a depot
Risperidone long-acting injectable is the first atypical long-acting compound available for schizophrenia patients. It contains a micro-
spheres technology with a water-based delivery system, clearly differentiating it from traditional oil-based antipsychotic depot medica-
tions.
Conventional depot medications, due to their long-standing availability, have established dosage and administration techniques.
Labelling risperidone long-acting injectable as ”Depot risperidone“ is misleading and potentially harmful, as physicians may assume
that mode of administration, plasma profile and drug metabolism detriments associated with depot injections apply to risperidone
long-acting injectable. These detriments include ’scarring’ and subcutaneous nodules due to oil-based residual impurities, pain at site
of injection and during the injection, the need to use the painful z-track technique and post-injection seepage of the oily vector. Due
to its advanced microspheres technology and aqueous formulation, these major shortcomings are not seen with Risperdal long-acting
injectable.
It is clear, therefore, that it is desirable at all levels to separate a description of risperidone long-acting injection from that for the older
and problematic depots. Specific concerns are that the confusion caused by this mislabelling could, for example, discourage people
prescribing from using risperidone long-acting injection because of their or their patients’ previous bad experiences with typical depots.
Market research has shown that the term ’depot’ has a negative connotation for many patients for the reasons outlined above, and
because, over time, depots have been reserved clinically for ’the worst of the worst’ -type of patient. The word ’depot’ then, is widely
seen as a pejorative term. Lastly, the mental image generated by the word ’depot’ focuses more with the physical aspects of the older
and less sophisticated oily injection that the intramuscular site from which the drug is released.
Together, these issues lead to an unnecessary and inaccurate stigmatization and potential limitation in use of risperidone long-acting
injection due to the imposition of a convenient but misleading label.
Recommendations
The use of ”depot risperidone“ should be replaced everywhere in the review to risperidone long-acting injectable.
Overall conclusions and recommendations
- Our further analyses of data from the placebo-controlled trial (Kane et al, 2002) demonstrate convincing evidence that risperidone
long-acting injectable is beneficial for people with schizophrenia when compared with those taking injectable placebo, both in the short
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and long-term. The review should acknowledge this and the conclusion (p6) that ”there is no reliable evidence that risperidone long-
acting injectable is beneficial for people with schizophrenia“ should be withdrawn.
- Risperidone long-acting injectable represents a novel and unique delivery of the same active antipsychotic agent as exits in oral
formulations of risperidone. Since this fact, as well as the clinical equivalence of risperidone long-acting injectable and oral risperidone
are acknowledged in the review, by inference it cannot be safely stated that ”there is no reliable evidence that risperidone long-acting
injectable is beneficial for people with schizophrenia“. A further reason that this conclusion should be withdrawn.
- The use of ”depot risperidone“ should be replaced everywhere in the review with ”risperidone long-acting injectable“ since it does
not accurately describe risperidone long-acting injectable and may lead to dangerous clinical confusion.
- Finally, conclusions based on spontaneously reported non-clinical events interpreted as outcomes should be treated with caution, as
should the assumption that trial protocol violation equated to poor compliance with medication.
(1). Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue
1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
(2). Duggan L, FentonM,Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia (Cochrane Review). In: The Cochrane
Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
(3). Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia (Cochrane Review). In: The Cochrane Library,
Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
(4). Cited as: Kane, J. et al, Am J Psychiatry 2003, 160 (6) 1125-32.
(5).Cited as: Chue, P. et al, Schizophrenia Research 2002, 3 (Suppl 1) 174.
Reply
Wewould like to thank the commentators for their comments and for acknowledging the transparent nature of Cochrane methodology.
We would like to discuss the issues raised by them.
1. Exclusion of data from Kane 2002*
We too are concerned with excluding data. We do not, however, agree that loss of 56% of people by 12 weeks should be described as
”only 56%“ and feel this degree of complacency is lamentable. The Agency for Health Care Policy and Research (AHCPR) proposed
criteria for assessing a randomised controlled trial’s quality that included dropout rates suggests that any study of less than three months’
duration with a dropout rate exceeding 10% (15% for study of more than three months) should be considered as flawed to a major
degree (Hadorn 1996).
The commentators correctly point out that other Cochrane reviews have included studies of shorter duration. The designers of Kane
2002* felt that outcomes were meaningful at 12 weeks. We agree. Recalculating now to make the study fit into the less than 50%
attrition category contradicts the protocol of the trial. It is a data-driven exercise.
The level of attrition acceptable to reviewers does differ. Partly this is a function of the participants involved, the interventions and the
outcome. So for the acute treatment of aggression secondary to psychosis outcomes may be measured in hours and almost any loss to
follow-up unacceptable. For longer studies some attrition is deemed acceptable. We thought that the cut off of 50% to be generous.
We are sorry that the commentators do not.
We would like to thank the commentators for their sensitivity analysis around their assumptions. First, it seems problematic to us that
these analysis cause conclusions to be drawn when over half the data are assumed. Second, we are unsure if a 20% improvement is
clinically meaningful and would be more interested in levels of 40% and above. It has been noted in other Cochrane Reviews relevant
to risperidone that the 20% cut off may have little clinical meaning (Hunter 2004).
2. Specific outcome measures
Having been criticized for NOT reporting data, because of large loss to follow-up, we are now criticized for reporting data that are
there and usable. We are glad that commentators agree that greater clarity is needed in reporting of adverse events and that it is not the
best way to interpret clinical outcomes from spontaneously reported data. We hope that the commentators are in a better position to
influence trial design to ensure better reporting in their own trials in the future.
With regard to analysis 02.04, we note the comment that non-compliance does not necessarily mean poor compliance with medication
and have amended this in the text.
Current text reads ”Compliance was measured in several ways. Most people received at least four injections (83.4% in the depot group
and 85.6% in the oral risperidone group, n=640, RR <4 injections or “major protocol violation” 1.16 CI 0.81 to 1.67). There was no
difference between groups in the rate of discontinuation before the end of the 12-week study (n=640, RR 1.27 CI 0.90 to 1.78).“
Amended text reads ”Compliance was measured in several ways. Most people received at least four injections (83.4% in the depot group
and 85.6% in the oral risperidone group, n=640, RR <4 injections or “major protocol violation” 1.16 CI 0.81 to 1.67). There was no
difference between groups in the rate of discontinuation before the end of the 12-week study (n=640, RR 1.27 CI 0.90 to 1.78). Please
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note that ’compliance’ in this context could apply to protocol violation for many reasons only one of which would be non-compliance
with the study drugs.“
3. Dismissal of non-inferiority data and exclusion of benefits already clearly established with risperidone
The commentators are correct to point out that we have not worded the conclusions well. We intended to state that there are no clear
differences between the depot preparation of risperidone and oral risperidone in people whose symptoms are already controlled using
oral risperidone. This does not imply that actively symptomatic patients would benefit from the depot preparation. We have stated in
the conclusion that ”People already stabilised on oral risperidone may continue to maintain benefit if treated with depot risperidone
and avoid the need to take tablets, at least in the short term.“ As we have not been clear enough in the conclusions we have reworded
them. We have also emphasised the possible benefits for people who are non compliant with medications in the real world who are
unlikely to voulnteer for a clinical trial.
Current version of conclusions in the ABSTRACT reads
”There is no reliable data to support the claim that depot risperidone is beneficial for people with schizophrenia. For reasonably well,
stable people it may mean that the need for regular oral doses can be avoided, but adverse affects are not well reported. For more
severely ill people, few benefits are evident although it may increase compliance with injections in comparison with placebo. Use of
depot risperidone, especially at the higher doses, is weakly associated with movement disorders.“
Updated version in response to this comment reads
”For reasonably well, stable people use of the depot formulation may mean that the need for regular doses of oral risperidone can be
avoided, but adverse affects of the depot formulation are not well reported. For such people, depot risperidone may be as effective as
the oral preparation, although data are few. For more severely ill people, few benefits of depot risperidone are evident although it may
increase compliance with injections in comparison with placebo. Use of depot risperidone, especially at the higher doses, is weakly
associated with movement disorders.“
Current version of conclusions in the IMPLICATIONS FOR PRACTICE reads
Implications for practice
For people with schizophrenia
There are only two studies on which to base an informed choice about depot risperidone. Depot risperidone may be more acceptable
than placebo injection but it is hard to know if it is any more effective in controlling the symptoms of schizophrenia. The active drug,
especially higher doses, may be associated with more movement disorders than placebo. People already stabilised on oral risperidone
may continue to maintain benefit if treated with depot risperidone and avoid the need to take tablets, at least in the short term.
For clinicians
There is no reliable data to support the claim that depot risperidone is beneficial to people with schizophrenia. For reasonably well
and stable people it may mean they can avoid taking regular oral doses but adverse affects are not well reported. When given to more
severely ill people, few benefits were demonstrated in the short term, although it may increase compliance with injections compared
with placebo. Use of depot risperidone, especially at the higher doses, is weakly associated with movement disorders.
Updated version in response to this comment reads
For people with schizophrenia
There are only two studies on which to base an informed choice about depot risperidone. Depot risperidone may be more acceptable
than placebo injection but it is hard to know if it is any more effective in controlling the symptoms of schizophrenia. The active drug,
especially higher doses, may be associated with more movement disorders than placebo. People already stabilised on oral risperidone
may continue tomaintain benefit if treated with depot risperidone and avoid the need to take tablets, at least in the short term. In people
who are happy to take oral medication the depot risperidone is approximately equal to oral risperidone as seen within the considerable
limitations of the relevant study. It is possible that the depot formulation, however, can bring a second-generation antipsychotic to
people who do not reliable adhere to treatment. People with schizophrenia who have difficulty adhering to treatment, however, are
unlikely to volunteer for a clinical trial. Such people may gain benifit from the depot risperidone with no increased risk of extrapyramidal
side effects.
For clinicians
For reasonably well and stable people it may mean they can avoid taking regular oral doses but adverse affects are not well reported.
When given to more severely ill people, few benefits were demonstrated in the short term, although it may increase compliance with
injections compared with placebo. Use of depot risperidone, especially at the higher doses, is weakly associated withmovement disorders.
Review of the evidence on the efficacy of depot formulations of first-generation antipsychotics in comparison with oral indicates that
there is only a very modest advantage of depot. There is very little difference between depot and oral in most studies. Patients who
volunteer for research are often cooperative patients who will take their medication particularly if they are seen every few weeks for
ratings, reminding them of the importance of adherence to the medication schedule. The importance of the two risperidone depot
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studies is to indicate that this preparation may be effective within the limitations of themethodology. It is possible that depot risperidone
may have a unique benefit in non-compliant patients but the included studies do not address this issue.
4. We do not agree that the labelling of risperidone long acting injection as depot risperidone is misleading. The difference in the
meaning of depot injection and long acting injection is none for all practicable purpose. The debate is more of semantics. The Oxford
English Dictionary defines the physiological meaning of ’depot’ as ”the site of an accumulation or deposit of a substance (esp. fat) in an
animal body….applied to any substance stored for eventual absorption by the organism, or to an action or process concerned with the
deposition of such a substance.“ (OED 1989) We acknowledge that the risperidone preparation that is the focus of this review is not
deposited in fat. It is, however, clearly comes with the meaning of ”deposited in an animal body and a substance stored for eventual
absorption by the organism.“
The word depot may have negative connotation within psychiatry but it does not take away from the fact depot means a long acting
injectable preparation. For marketing purposes the manufactures may want to use different terms/names to differentiate it from other
drugs, but from a clinical point of view it is a depot preparation which means a long acting injection, whatever may be its technical
differences from the other drugs.
Nowhere in the reports on risperidone injectable preparations it has been claimed that it is not a depot. The term long acting injection has
been used as a synonym for the depot in these reports. For example Chue 2002 states… ”Currently, however, only typical psychotropics
have been available as long acting formulations. Risperidone is the first atypical psychotropic medication available in a long acting
formulation“. Therefore there is no justification to alter the word ”depot“ to ”long acting injection“ throughout the review.
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Last assessed as up-to-date: 28 October 2015.
Date Event Description
25 January 2016 New citation required and conclusions have changed Results of update searches provide more data and evi-
dence.
28 October 2015 New search has been performed Search re-run (October 2015), seven studies added to
Characteristics of excluded studies.
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H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 4, 2003
Date Event Description
17 February 2014 Amended Results of updated search (December 2010, May 2012) added to review, 10 new studies added
to Characteristics of included studies and one study to the Characteristics of studies awaiting
classification pending update of review.
30 October 2008 Amended Converted to new review format.
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